




EASL

Milan, Italy
5–8 June

CONGRESS

2024



List of accepted abstracts

#EASLCongress

easlcongress.eu

Contents

Acute liver failure and drug induced liver injury - Basic.....	2
Acute liver failure and drug induced liver injury - Clinical.....	5
Alcohol-related liver disease and MetALD - Basic.....	9
Alcohol-related liver disease and MetALD - Clinical.....	14
Cirrhosis and its complications: ACLF and Critical illness.....	20
Cirrhosis and its complications: Experimental and pathophysiology.....	25
Cirrhosis and its complications: Other clinical complications except ACLF and critical illness.....	34
Cirrhosis and its complications: Portal Hypertension.....	46
Fibrosis / Stellate cell biology.....	54
Gut microbiota and liver disease / Liver-organ crosstalk.....	58
Hepatocyte biology.....	64
Immune-mediated and cholestatic disease: Clinical aspects.....	66
Immune-mediated and cholestatic: Experimental and pathophysiology.....	78
Liver development and regeneration.....	84
Liver immunology.....	86
Liver transplantation and hepatobiliary surgery - Basic.....	90
Liver transplantation and hepatobiliary surgery - Clinical.....	92
Liver tumours: Clinical aspects except therapy.....	100
Liver tumours: Experimental and pathophysiology.....	108
Liver tumours: Therapy.....	117
MASLD: Clinical aspects except therapy.....	125
MASLD: Diagnostics and non-invasive assessment.....	140
MASLD: Experimental and pathophysiology.....	159
MASLD: Therapy.....	174
Non-invasive assesment of liver disease except MASLD.....	181
Nurses and Allied Health Professionals.....	184
Public Health: Except viral hepatitis.....	187
Public Health: Viral hepatitis.....	194
Rare liver diseases (including paediatric and genetic) - Basic.....	205
Rare liver diseases (including paediatric and genetic) - Clinical.....	208
Viral hepatitis A/E: Clinical aspects.....	216
Viral hepatitis B and D: Clinical aspects.....	217
Viral Hepatitis B and D: Current therapies.....	228
Viral Hepatitis B and D: New therapies, unapproved therapies or strategies.....	232
Viral Hepatitis C: Clinical aspects including follow up after SVR.....	237
Viral hepatitis C: Therapy and resistance.....	242
Viral Hepatitis: Experimental and pathophysiology.....	244

Acute liver failure and drug induced liver injury - Basic

39

Endogenous Annexin A1 has a protective effect on the liver in a diabetic mouse model

Poster presentation

Presenter: Diego Dias dos Santos

602

Multi-omics uncovers spatial remodelling of the hepatic lipidome in acute liver injury

Poster presentation

Presenter: Aleksandra Gruevska

624

IL-1B exacerbates acute-on-chronic liver failure by promoting neutrophil extracellular traps formation via IL1R1/MyD88/TBK1 axis

Poster presentation

Presenter: Liang PENG

627

The TAK1- β -catenin signaling is essential for inducing chaperone-mediated autophagy and M2 macrophage polarization in acetaminophen-induced liver injury

Poster presentation

Presenter: Tao Yang

691

Mechanical stress of acute portal hypertension aggravates PA-HSOS by damaging gut-vascular barrier targeting NR4A3/PV1

Poster presentation

Presenter: han zhang

795

Obeticholic acid promotes the hepatic ductular reaction via macrophage-mediated Relb-TNFSF14 signaling in cholestasis

Poster presentation

Presenter: Jie Wang

798

Obeticholic acid promotes the hepatic ductular reaction via hepatocyte-mediated HMGB1 by disrupting autophagosome-lysosome fusion in cholestasis

Poster presentation

Presenter: Jie Wang

1020

Sibiriline, an inhibitor of regulated necrosis, protects mice against Acetaminophen-induced liver injury, alone or in combination with N-acetyl-cysteine

Poster presentation

Presenter: Mélanie Simoes Eugenio

1142

DDX3X regulates the functional transition of endoplasmic reticulum stress in the pathogenesis of liver failure

Poster presentation

Presenter: Ling Xu

1423

NGFR inhibition by TAT-Pep5 protects mice from acetaminophen-induced liver injury

Poster presentation

Presenter: Laura Kitto

1502

APAP induced liver damage is prevented by activation of PPAR-gamma and PPAR-alpha

Poster presentation

Presenter: Paul Gomez-Jauregui

1523

Hepatocyte TAF15 promotes APAP-induced acute liver injury via activating NF- κ B to induce PANoptosis

Poster presentation

Presenter: si zhao

1653

Clusterin deficiency exacerbates cholestatic liver disease through ER stress and NLRP3 inflammasome activation

Poster presentation

Presenter: Hye-Young Seo

1689

A therapeutic strategy to target CD47 using SIRP alpha expressed extracellular vesicles derived from engineered mesenchymal stem cells to promote liver regeneration following severe injury

Poster presentation

Presenter: Seohyun Kim

1823

SEMA6B triggers macrophage mediated systemic inflammation in acute-on-chronic liver failure

Poster presentation

Presenter: Jun Li

1856

Specific metabolomic and bile acid profiles and their relationship with gut microbiota composition in patients with drug-induced liver injury

Oral presentation

Presenter: Sara Román-Sagüillo

1884

HYX1-derived exosomal let-7c-5p protects against acute liver failure by inhibiting SLC11A2-mediated ferroptosis

Poster presentation

Presenter: Yu Chen

2071

Serum proteomics can help identify new prognostic biomarkers in adults with acute liver failure

Poster presentation

Presenter: Katharina Remih

2231

DNA differential methylation as a potential drug-induced liver injury biomarker and genome-wide DNA methylation functional analysis

Poster presentation

Presenter: Marina Villanueva

2398

Adipose-derived mesenchymal stem cells ameliorate APAP-induced liver injury via REDD1-ULK1-FUNDC1 axis-mediated mitophagy

Poster presentation

Presenter: Yelei Cen

2460

Plasma lipidomics and fungal peptide-based community analysis identifies signatures of severity and early mortality in acute liver failure

Poster presentation

Presenter: Neha Sharma

2484

Plasma multi-omic reveals dysregulated gut arbitrated increase in bacterial peptides and metabolites predictive of poor outcomes in acute liver failure

Poster presentation

Presenter: Sushmita Pandey

2620

MiRNA/mRNA network topology in acute-on-chronic liver failure identified miR-503-5p as a regulatory hub of lymphocytes activation through antigen-presentation suppression

Poster presentation

Presenter: Jun Li

2719

Clinical and molecular features of immune-mediated and drug-induced liver injury

Poster presentation

Presenter: Thais Leonel

2895

Visualisation of intrahepatic activation of coagulation and its contribution to disease progression in mice with acetaminophen-induced acute liver injury

Poster presentation

Presenter: Fien von Meijenfeldt

2899

Up-regulation of hyaluronan synthase 2 in hepatocytes contributes to oxaliplatin-induced portal hypertension

Poster presentation

Presenter: Ling Wu

2950

3D bioengineered liver for the study of acute and chronic hepatic damage

Oral presentation

Presenter: Ainhoa Ferret Miñana

2986

Advancing in drug-induced liver injury models development: high content screening in cell-based models derived from skin tissues

Poster presentation

Presenter: Antonio Segovia-Zafra

3072

An exploration of plasma neurofilament protein as a marker of neuronal damage in acute liver failure

Poster presentation

Presenter: Marilena Stamouli

Acute liver failure and drug induced liver injury - Clinical

512

Frequency and clinical features of tamoxifen-induced liver injury

Poster presentation

Presenter: Masayuki Ueno

529

Cerebral oedema at autopsy in acute liver failure: relationship to clinical features and changes over time

Oral presentation

Presenter: William Bernal

549

Establishing a predictive nomogram for 21-day transplant-free survival in drug-induced liver failure

Poster presentation

Presenter: Mengyu Tao

641

Early diagnosis and treatment with Terlipressin for adults with hepatorenal syndrome improves clinical outcomes and reduces healthcare resource utilization

Poster presentation

Presenter: Juan F. Gallegos-Orozco

665

Efficacy of magnesium isoglycyrrhizinate in patients with immune checkpoint inhibitor-related hepatotoxicity

Poster presentation

Presenter: Yang Zhi

735

Monocytes/macrophages imbalance in chronic drug-induced liver injury: potential candidates for disease pathogenesis

Poster presentation

Presenter: Zhengsheng Zou

751

Depressed TFAM promotes acetaminophen-induced hepatotoxicity regulated by DDX3X-PGC1 α -NRF2 signaling pathway

Poster presentation

Presenter: Sisi Chen

769

Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury

Poster presentation
Presenter: Lina Hountondji

872

Impact of hepatic steatosis on risk of acute liver injury among people with chronic hepatitis B and SARS-CoV-2 infection

Poster presentation
Presenter: Matthew Shing Hin Chung

1083

Clinical and HLA associations of fluoroquinolone induced liver injury: results from the drug induced liver injury network (DILIN)

Poster presentation
Presenter: Jawad Ahmad

1124

RECAM-J 2023 – validation of RECAM and development of the Japanese version for the diagnosis of DILI

Poster presentation
Presenter: Atsushi Tanaka

1180

Assessment of liver fibrosis in patients taking Methotrexate: long-term outcomes and changes in measurements over time

Poster presentation
Presenter: Ewan H Forrest

1186

Polyreactive immunoglobulin G is elevated in autoimmune hepatitis and drug-induced autoimmune-like hepatitis compared to self-limiting drug-induced liver injury

Oral presentation
Presenter: Bastian Engel

1359

Incidence and outcomes of drug-induced liver injury in a large primary care urban area

Poster presentation
Presenter: Anna Pocerull

1413

Therapeutic plasma exchange in Amanitin associated acute liver failure – results from an interim analysis of the Amanita-PEX study

Poster presentation
Presenter: Bahar Nalbant

1416

Immune-mediated liver injury induced by PD-1/PD-L1 checkpoint inhibitors is different from idiosyncratic drug-induced liver injury

Poster presentation

Presenter: Yan Wang

1740

Personalized prediction of spontaneous recovery in acute liver failure listed for liver transplantation

Poster presentation

Presenter: Xun Zhao

1858

A nationwide, multi-center, prospective study of drug-induced liver injury in mainland China

Poster presentation

Presenter: Mengmeng Zhang

1874

β -adrenergic drive impairs small intestinal gut-vascular barrier (GVB): mechanism involved in gut-vascular-barrier dysfunction in acute-on-chronic liver failure (ACLF)

Poster presentation

Presenter: Marco Felber

2040

Efficacy of magnesium isoglycyrrhizinate as add-on therapy to glucocorticoids in immune checkpoint inhibitor-related hepatotoxicity

Poster presentation

Presenter: Yinuo Dong

2080

Histopathological findings in liver biopsies of patients affected by multiple sclerosis undergoing disease-modifying therapies and pulse methylprednisolone

Poster presentation

Presenter: Federica Pedica

2167

High volume plasma exchange may improve transplant-free survival in patients with severe paracetamol-induced acute liver failure: a case control study

Poster presentation

Presenter: Sébastien L'Hermite

2417

Evaluating the life-saving potential of liver transplantation for acute-on-chronic liver failure with circulatory failure: an observational cohort study

Poster presentation

Presenter: Jun Li

2476

Pathological dynamics and clinical implications of hepatitis in cancer patients undergoing immune checkpoint inhibitor

Poster presentation

Presenter: Ryo Izai

2487

Longitudinal single-cell transcriptomics analyses reveal distinct peripheral immune characteristics linked to ACLF progression

Poster presentation

Presenter: Jun Li

2943

Urinary amatoxin concentration as an early predictor for liver toxicity in patients with amanita spp poisoning

Oral presentation

Presenter: Enric Reverter

3236

The combination of s-adenosylmethionine with Bifidobacterium infantis 35624 inhibits oxidative stress as a risk factor for cytostatic-induced liver injury

Poster presentation

Presenter: Igor Skrypnik

3314

Anticancer drugs are the first cause of drug-induced liver injury in the REFHEPS network

Poster presentation

Presenter: Lucy Meunier

Alcohol-related liver disease and MetALD - Basic

256

Dissecting metabolic dysfunction-associated steatotic liver disease with increased alcohol intake (MetALD): clinical and molecular insights and classification

Poster presentation

Presenter: Jun Liu

355

Minibioreactor arrays (MBRAs) to model microbiome response to tryptophan and alcohol in the context of alcohol-associated liver disease (ALD)

Poster presentation

Presenter: Wanchao Hu

357

Exploring the AhR molecular pathways to improve gut microbiota and liver injury in alcohol-associated liver disease

Poster presentation

Presenter: Wanchao Hu

530

Alcohol-related hepatitis is associated with a distinctive pattern of disordered bile acid metabolism and reduced bile acid transporter expression

Poster presentation

Presenter: Luke D Tyson

648

Plasma cell-free mtDNA is released in alcohol-associated liver disease and correlates with liver injury

Poster presentation

Presenter: Maram Alenzi

673

Complement protein signatures in patients with alcohol-associated hepatitis

Poster presentation

Presenter: Laura Nagy

674

Incretin-based therapies reduce alcohol intake in lean and obese hamster models of chronic alcohol consumption

Oral presentation

Presenter: Francois Briand

702

Improvement in alcohol-associated hepatitis is characterized by reduction of RNA modification processes

Poster presentation

Presenter: Alastair M Kilpatrick

731

The humoral profile of immunoglobulins specific for microbiota antigens stratifies the severity of patients affected by alcohol-related liver disease and predicts their 90-d mortality

Poster presentation

Presenter: Antonella Putignano

791

Single-nucleus RNA sequencing of the liver identifies predictive markers to corticosteroid treatment in patients with severe alcohol-related hepatitis

Poster presentation

Presenter: Lukas Van Melkebeke

937

Deep lipidomic analysis of plasma classifies lipid species capable of segregating septic-shock and predictive of early mortality in severe alcoholic hepatitis (SAH)

Poster presentation

Presenter: Gaurav Tripathi

1106

Exosomal miRNA Profiles in MASLD: from steatohepatitis to hepatocellular carcinoma progression

Poster presentation

Presenter: Huiping Zhou

1302

Functional characterization of intrahepatic CD8+ T lymphocytes in patients with severe alcohol-associated hepatitis

Poster presentation

Presenter: Luca Maccioni

1313

Farnesoid X receptor agonist INT-787 exhibits high intestinal localization

Poster presentation

Presenter: Jennifer Burkey

1320

Farnesoid X receptor agonist INT-787 protects human liver organoids from alcohol-induced injury

Poster presentation

Presenter: Francesca De Franco

1431

Novel mechanism of golgiphagy in hepatocytes and the protective impact of hydroxychloroquine on alcohol-induced liver damage and steatosis

Poster presentation

Presenter: Armen Petrosyan

1664

Mouse models of MetALD and metabolic dysfunction-associated steatohepatitis elicit similar patterns of liver injury
Poster presentation
Presenter: Naomi Lange

1669
Identification of alcoholic associated hepatitis-related genes and mesenchymal stem cell treatment target genes by meta analysis
Poster presentation
Presenter: Moon Young Kim

1709
Establishment of a mouse model of severe alcoholic hepatitis and study on the material basis of traditional chinese medicine rhubarb in the treatment of severe alcoholic hepatitis
Poster presentation
Presenter: Min Liu

1812
Cellular senescence is reduced following alcohol cessation in severe alcohol-associated hepatitis
Oral presentation
Presenter: Daniel Rodrigo-Torres

2124
The pan-cyclophilin inhibitor renofilstat exhibits therapeutic anti-fibrotic effects in human relevant models of alcohol-related liver disease via extracellular matrix remodelling
Poster presentation
Presenter: Una Rastovic

2276
Supplementation of the amino acid L-arginine attenuates the onset of alcohol-related liver diseases
Poster presentation
Presenter: Anja Baumann

2481
Growth differentiation factor 15 and adrenergic receptor beta 2 modulate free fatty acid release by inducing foamy macrophage in adipose tissue under chronic alcohol consumption
Poster presentation
Presenter: Min Jeong Kim

2576
HSD17B13 loss-of-function splice variant delays onset of incident steatotic liver disease and suggests slower progression in established liver disease

Poster presentation
Presenter: Audrey Chu

2589

Abstinence induces site-specific metabolomic alterations in resolution from alcohol-related liver disease

Poster presentation
Presenter: Nupur Sharma

2777

Needle biopsy-derived liver organoids enable alcohol-associated liver disease modelling and drug response

Poster presentation
Presenter: Silvia Ariño

2792

Integrated plasma multi-omics analysis classifies key mycobiome, microbiome and metabolome changes linked to development of poor outcome in severe alcoholic hepatitis

Poster presentation
Presenter: Gaurav Tripathi

2807

Hepatocyte response to metabolic stress in alcoholic fatty liver leads to sublethal cell toxicity through the perturbation of protein translation-elongation machinery

Poster presentation
Presenter: Takeshi Saito

2846

Differential apoptotic and non-apoptotic cell death profiles in alcohol associated liver disease and their prognostic impact on acute-on-chronic liver failure

Poster presentation
Presenter: Pratibha Garg

2867

Single-cell RNA sequencing analysis in alcohol-related liver disease identifies specific cell subpopulations characterized by an inflammatory profile in alcohol-associated hepatitis

Oral presentation
Presenter: Jordi Gratacós-Ginès

2874

Multiomics landscape of alcohol detoxification and the role of PNPLA3 genotype

Poster presentation
Presenter: Anna Karl

3081

The new nomenclature of steatotic liver disease identifies different risk trajectories for liver-related complications

Poster presentation

Presenter: Bocquillon Adrien

3105

Protein source differentially alters the outcome of fecal microbiota transplant in mouse model of alcohol-related liver disease

Poster presentation

Presenter: Shvetank Sharma

3247

Portal neutrophils exhibit an activated phenotype in alcohol-related liver disease

Poster presentation

Presenter: Sara Reinartz Groba

Alcohol-related liver disease and MetALD - Clinical

269

Transplantation for alcoholic liver disease: impact of on-site substance use disorder treatment on outcome

Poster presentation

Presenter: Shehzad Niazi

383

Updated definition of healthy alanine aminotransferase levels in a metabolically and histologically normal population

Poster presentation

Presenter: Jonggi Choi

453

Metadoxine improves alcohol abstinence and is related to a lower risk of decompensation in cirrhosis at a median five-year follow-up: propensity score matching analysis

Poster presentation

Presenter: Fatima Higuera-de-la-Tijera

508

Long-term trends in the prevalence of alcohol-related cirrhosis among national U.S. veterans affairs data and territory wide Hong Kong data – an east-west perspective

Poster presentation

Presenter: Robert Wong

526

Long-term risk of alcohol-related liver disease after community-based treatment for alcohol use disorder: a nationwide register based cohort study from Denmark

Poster presentation

Presenter: Line Molzen

676

Phosphatidylethanol complements urinary and scalp hair ethyl glucuronide for the detection of different levels of alcohol use in patients with alcohol-related cirrhosis: establishing a 3-days-3 weeks-3 months alcohol use profile

Oral presentation

Presenter: Benedict Vanlerberghe

773

Role of neutrophil lymphocyte ratio in transition of alcoholic cirrhosis with acute decompensation to unstable decompensated cirrhosis

Poster presentation

Presenter: Yuyong Jiang

774

Serum proteomic analyses reveal elevated HGF and IL-8 in patients with alcohol-related hepatitis compared to decompensated alcohol-related cirrhosis and can differentiate patients with AH at risk of infection from those at risk of acute kidney injury

Poster presentation

Presenter: Luke D Tyson

786

Substituting FIB-4 with LiverPRO as an initial test for detecting advanced fibrosis leads to a 6-fold reduction in false positive results

Poster presentation

Presenter: Katrine Lindvig

828

Preliminary results of a phase I study of SZN-043, a novel R-Spondin mimetic, in healthy volunteers and subjects with liver cirrhosis

Poster presentation

Presenter: Edward J. Gane

894

Vitamin D deficiency is associated with advanced liver fibrosis and Type 2 diabetes mellitus in alcohol use disorder

Poster presentation

Presenter: Paola Zuluaga

909

Emergence of co-morbidities in alcohol-related hepatitis over time: insights from the WALDO cohort

Poster presentation

Presenter: Douglas Corrigan

949

FIB-4 score as a predictor of mortality outcomes in individuals with metabolic dysfunction-associated steatotic liver disease with moderate alcohol consumption: a nationwide cohort study

Poster presentation

Presenter: Majd Aboona

1089

Bariatric surgery is a major independent factor of disease progression in cirrhotic patients with alcohol-related liver disease

Poster presentation

Presenter: Louis Onghena

1096

Portal hypertension in alcohol-related hepatitis: natural history and prognostic value

Poster presentation

Presenter: Karim Gebara

1102

Liver-related complications are the fastest growing cause of mortality from alcohol consumption: results from the global burden of disease 2019 study

Poster presentation

Presenter: Benedix Sim

1103

Clinical characteristics, surveillance, treatment allocation and outcomes of alcohol-related hepatocellular carcinoma: meta-analysis of 37 studies and 66,559 patients

Poster presentation

Presenter: Daniel Tung

1234

Screening of compensated alcohol-related liver disease: efficacy of a holistic approach (hepatology visit, brief intervention and non-invasive test) on alcohol abstinence and relapses

Poster presentation

Presenter: Ares Villagrasa

1261

Association between serum homocysteine levels and advanced hepatic fibrosis in alcohol-related liver disease: a cross-sectional study

Poster presentation
Presenter: Hui Yang

1369

Early liver transplantation for severe alcohol-related hepatitis: long-term data of the french-belgian controlled study (QuickTrans)

Oral presentation

Presenter: Alexandre Louvet

1452

Coinfection with viral hepatitis increases the short-term but not the long-term risks of hepatocellular carcinoma and hepatic events in adults with alcohol-related cirrhosis

Poster presentation

Presenter: Vicki Wing-Ki HUI

1538

Diet modifies the association between alcohol intake and alcohol-related liver disease: a prospective study of individual patient data from the UK Biobank

Poster presentation

Presenter: Ewan H Forrest

1785

Assessing LSM thresholds to identify clinically relevant SLD in individuals with excessive alcohol intake and absence of steatosis

Poster presentation

Presenter: Mette lehmman andersen

1792

Subtypes of steatotic liver disease have differing clinical outcomes

Poster presentation

Presenter: Katrina Pekarska

1914

Diagnostic performance of noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) with increased alcohol intake (MetALD) in a primary care setting

Poster presentation

Presenter: JOO HYUN OH

1916

Dietary habits and ultra-processed food consumption in steatotic liver diseases: differences among etiologies and impact on liver histology

Poster presentation

Presenter: Salomé Declerck

1922

Prevalence and characteristics of MASLD with greater alcohol consumption (MetALD) in the general population

Poster presentation

Presenter: JOO HYUN OH

1926

Incorporation of cholestasis into prognostic models improves predictive outcome in alcohol-related liver disease: a retrospective multicenter study

Poster presentation

Presenter: Mohsan Subhani

2085

Hepatorenal syndrome markedly impacts prognosis of patients with alcohol-associated hepatitis. Results from the spanish registry of alcohol-associated liver disease (REHALC)

Poster presentation

Presenter: Jordi Gratacós-Ginès

2285

Assessing efficacy and safety of baclofen in the management of alcohol dependence among patients with alcoholic liver disease

Poster presentation

Presenter: Berta López-Sáez

2378

Fibrosis stage progression in alcohol-related liver disease evaluated by repeated biopsies

Poster presentation

Presenter: Ellen Lyngbeck Jensen

2410

Natural history of varices in patients with severe alcohol-associated hepatitis

Poster presentation

Presenter: SHARATH S

2442

Recidivism and post-transplant outcomes in patients with alcohol-associated liver disease

Poster presentation

Presenter: Suaka Kagbo-Kue

2443

Reduced Pannexin-1 and IL-33 in liver tissue are associated with lesser neutrophilic satellitosis and a higher rate of infections in severe alcoholic hepatitis patients

Poster presentation

Presenter: Chhagan Bihari

2626

Annual decompensation and death in patients with intermediate severity of alcohol-related liver fibrosis

Poster presentation

Presenter: Sara Hauskov

2726

The interaction between metabolic syndrome and alcohol consumption after an episode of alcohol-associated hepatitis is associated with increased mortality: results from de spanish registry of alcohol-associated liver disease (REHALC)

Poster presentation

Presenter: Jordi Gratacós-Ginès

2797

There is a need to improve retention of people with alcohol-related liver disease in clinical trials: a systematic review and meta-analysis of retention rates in interventional trials

Poster presentation

Presenter: Paula Boeira

3004

Impact of corticosteroid treatment and clinical risk factors in patients with alcohol-associated hepatitis and clinically significant portal hypertension

Poster presentation

Presenter: Petra Dinjar Kujundžić

3180

Semaglutide can reduce alcohol use in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Vladislav Fomin

3185

The prognostic value of the hepatic venous pressure gradient in severe alcohol-related hepatitis

Poster presentation

Presenter: Andreea Livia Bumbu

3209

Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH/MASH serial liver biopsy study

Poster presentation

Presenter: Vlad Ratziu

3299

Sarcopenia, frailty and growth hormone-insulin like growth factor axis among decompensated and alcohol-associated hepatitis patients

Poster presentation

Presenter: Aishani Wadhawan

3305

Screening for alcohol related liver disease in acute hospital admissions

Poster presentation

Presenter: Jessica Lovatt

3309

Is it worth staining for hepatic glucocorticoid receptors in alcohol related hepatitis?

Poster presentation

Presenter: Mina Ignat

Cirrhosis and its complications: ACLF and Critical illness

7

Safety and efficacy of liver hemodialysis in managing hepatic dysfunction: a systematic review and meta-analysis

Poster presentation

Presenter: Eyad Gadour

10

Effect of terlipressin on patients with hepatorenal syndrome, alcohol-associated hepatitis, and acute-on-chronic liver failure grade 0–2

Poster presentation

Presenter: Kevin Moore

271

Predictors of acute-on-chronic liver failure (ACLF) and mortality in ambulatory cirrhotic patients

Poster presentation

Presenter: Maamoun Basheer

444

Incidence and prognostic value of zinc and selenium deficiency in cirrhosis

Poster presentation

Presenter: Nina Dominik

542

Soluble PD-L1 levels as predictors of ACLF in decompensated cirrhosis: findings from two independent cohorts

Poster presentation

Presenter: Adrià Juanola

785

Impact of underlying portal hypertension and systemic inflammation on acute-on-chronic liver failure (ACLF) severity and outcome

Poster presentation

Presenter: Vlad Taru

941

Herpesvirus viremia – cause or consequence of ACLF? Higher prevalence of cytomegalovirus, Epstein–Barr virus and herpes simplex virus viremia in patients with acute-on-chronic liver failure

Poster presentation

Presenter: Jannik Sonnenberg

959

Machine learning algorithms predict survival in patients with cirrhosis hospitalized due to infections based on routine features obtained within 24 hours of admission

Poster presentation

Presenter: Shoham Dabbah

1053

Lower inpatient mortality and second infections in inpatients with cirrhosis managed between 2021-22 than between 2011-13 in prospective North American cohorts

Poster presentation

Presenter: Jasmohan Bajaj

1131

Prognostic value of nutritional index in patients with decompensated cirrhosis: a single-center cohort study

Poster presentation

Presenter: Heechul Nam

1172

Differential impact of proton pump inhibitors, statins, and non-selective beta-blockers on survival in different stages of chronic liver disease

Poster presentation

Presenter: Wenyi Gu

1409

Proton pump inhibitors does not impact on the severity and mortality of the acute-on-chronic liver failure: andalusian multicentric prospective study

Poster presentation

Presenter: María Carmen García-Gavilán

1412

Dynamics of systemic inflammation after TIPS implantation and their impact on acute-on-chronic liver failure and liver-related death

Poster presentation

Presenter: Andrea Kornfehl

1415

Portal vein thrombosis increases short-term mortality independent of liver disease severity score among hospitalized patients of decompensated cirrhosis - result from CLEARED consortium

Poster presentation

Presenter: Ashok Kumar Choudhury

1463

Extra-hepatic organ failure in ACLF patients is associated with poor survival and limited curative therapy - results from AARC cohort

Poster presentation

Presenter: Ashok Kumar Choudhury

1795

Predictors of clinical response to empirical antibiotic therapy in patients with cirrhosis and bacterial infections: results from a resource-constrained setting

Poster presentation

Presenter: Chitta Ranjan Khatua

2051

Pre-transplant work-up for acute-on-chronic liver failure patients in intensive care units, a nationwide french survey

Poster presentation

Presenter: Claire BELLEC

2091

Spleen stiffness measurement as a promising non-invasive marker of mortality in chronic liver disease inpatients with jaundice

Poster presentation

Presenter: Jiankang Song

2204

Urinary biomarkers of tubular and glomerular damage predict renal recovery in patients with hepatorenal syndrome-acute kidney injury

Poster presentation

Presenter: Salvatore Piano

2212

Enrolling patients in ACLF trials – the need to increase ACLF awareness (DHELIVER trial)

Poster presentation

Presenter: Dominique Thabut

2461

Extended validation of proteomics and machine learning guided biomarker discovery and pathway perturbations in infection-related acute-on-chronic liver failure

Poster presentation

Presenter: Nipun Verma

2498

Evaluation of the scoring systems dedicated to liver transplantation in acute-on-chronic liver failure (ACLF) in an international multicenter cohort

Poster presentation

Presenter: Sébastien L'Hermite

2537

Blood and peritoneal metabolomics suggest VS-01 actively captures metabolites associated with acute-on-chronic liver failure

Poster presentation

Presenter: Berenice Alard

2569

Therapeutic plasma-exchange improves short-term survival in patients with ACLF admitted to intensive care unit with organ failures - a multinational AARC data analysis

Poster presentation

Presenter: Rakhi Maiwall

2606

Real-world practice patterns on the use of terlipressin in patients with cirrhosis and acute kidney injury - results from the ICA-GLOBAL AKI study

Oral presentation

Presenter: Ann Thu Ma

2784

A clinical decision support tool to identify predictors of decompensation, acute-on-chronic liver failure and mortality in liver cirrhosis from the multi-center SingHealth chronic liver disease registry (SoLiDaRity-DAM)

Poster presentation
Presenter: Jason Pik Eu Chang

2928
Longitudinal salivary metagenomics in acute-on-chronic liver failure patients
Poster presentation
Presenter: Mathieu Almeida

2979
Supplemental low-dose hydrocortisone in cirrhotic patients with septic shock: a double-blind, randomised, placebo-controlled, multicentre trial; the SCotCH study
Poster presentation
Presenter: Philippe Meersseman

2982
A placebo controlled, randomized, double blinded trial to evaluate the use of Tolvaptan for correction of hyponatremia in liver cirrhosis patients
Oral presentation
Presenter: Arun Valsan

3128
Distinguishing clinical profiles in acute-on-chronic liver failure: a comparative analysis of alcohol-related hepatitis versus infection precipitated acute-on-chronic liver failure
Poster presentation
Presenter: Annarein Kerbert

3152
The predictive role of immunoglobulins indicative of gut barrier dysfunction in a prospective patient cohort with cirrhosis and acute decompensation
Poster presentation
Presenter: David Tornai

3170
Bilirubin monoglucuronides play an important role in the pathophysiology of acute-on-chronic liver failure
Poster presentation
Presenter: Nahum Méndez-Sánchez

3174
Predicting with the "POAD" score the course of acute kidney injury in acute-on-chronic liver failure: a metabolomics approach
Poster presentation
Presenter: Rakhi Maiwall

3202

Acute kidney injury (AKI) severity in critically-ill patients with decompensated liver cirrhosis and acute-on-chronic liver failure (ACLF)

Poster presentation

Presenter: Lena Wolters

3217

Therapeutic plasma exchange improves organ function and potentially increases short-term survival in ACLF-3 patients who do not respond to standard medical treatment: a single centre propensity score-matched retrospective study

Poster presentation

Presenter: Jonas Schumacher

3266

Serum bile acids determine AKI progression and terlipressin non-response in patients with acute-on-chronic liver failure with acute kidney injury

Poster presentation

Presenter: Rakhi Maiwall

3346

Dynamic assessment of lactate and AARC-Laclear score could determine survival in acute-on-chronic liver failure with septic shock admitted to the intensive care unit: a prospective cohort study [NCT06116305]

Poster presentation

Presenter: Vishnu Girish

Cirrhosis and its complications: Experimental and pathophysiology

262

Role of apoptosis in B-cell compartment retraction during decompensation of cirrhosis and acute-on-chronic liver failure

Poster presentation

Presenter: Lorena Paule

267

Exploring the potential of human serum albumin to reprogram B cell function

Poster presentation

Presenter: Berta Romero-Grimaldo

313

Modulation of portal and hepatic venous flow leads to fibrotic liver changes and can be prevented through anticoagulation

Poster presentation

Presenter: Beat Moeckli

330

Glucagon-like peptide-1 receptor agonist, semaglutide attenuates liver cirrhosis-related skeletal muscle atrophy in diabetic mice

Poster presentation

Presenter: Kosuke Kaji

338

Carvedilol decreases hepatic vascular resistance in cirrhosis by deactivating hepatic stellate cells (HSC) and improving liver sinusoidal endothelial cells (LSEC) dysfunction, resulting in decreased liver fibrosis and improved nitric oxide release

Poster presentation

Presenter: Yeldos Nulan

365

Multifactorial modulation of the endothelial transcription factor ERG in chronic liver disease

Poster presentation

Presenter: Eric Felli

416

Administration of xyloglucan alone or in combination with norfloxacin improves intestinal barrier homeostasis in cirrhotic rats with ascites

Poster presentation

Presenter: Ramon Bartolí

501

Assessment of plasma VCAM-1 levels in pediatric portal hypertension and its relationship with disease severity

Poster presentation

Presenter: Huihong Yu

503

Red blood cell distribution width-to-platelet ratio estimates the 3-year risk of decompensation in patients with metabolic dysfunction-associated steatotic liver disease-related cirrhosis

Poster presentation

Presenter: Mario Romeo

571

Targeted breath biopsy® profiling of induced biomarkers unveils a metabolic adaptation in cirrhosis toward alcohol production

Poster presentation

Presenter: Giuseppe Ferrandino

601

Enhancing infection diagnostics and antimicrobial resistance detection in cirrhosis: a clinical metagenomics approach for blood culture assessment

Poster presentation

Presenter: Merianne Mohamad

660

Characterising the hemodynamic and pro-inflammatory profile of a CCl4/LPS-induced acute-on-chronic liver failure (ACLF) rat model

Poster presentation

Presenter: Vlad Taru

678

Hyperammonemia-induced mitochondrial dysfunction is abrogated by targeting toll-like receptor 4

Poster presentation

Presenter: Supachaya Sriphoosanaphan

697

Endothelial-to-mesenchymal transition: a targetable mechanism involved in portal vein thrombosis in cirrhosis

Oral presentation

Presenter: Aina Anton

747

Transplanted acellular liver scaffold is not affected by the cirrhotic liver remaining a healthy template for cell growth

Poster presentation

Presenter: Marlon Dias

806

Loss of heterogeneity and CD4+ T-cell differentiation in patients with alcohol-related cirrhosis

Poster presentation

Presenter: Paola Zuluaga

824

Increased procoagulant activity of tissue factor-expressing microvesicles in patients with liver cirrhosis

Poster presentation

Presenter: Adonis Protopapas

928

The linoleic acid-derived leukotoxin 9,10-DiHOME drives immunosuppression in patients with acute-on-chronic liver failure

Oral presentation

Presenter: Bryan J. Contreras

964

The soluble guanylate cyclase pathway is dysregulated in rodent models of cirrhosis and portal hypertension

Poster presentation

Presenter: Thomas Sorz-Nechay

1006

Plasma proteomics uncovers progression markers of acute-on-chronic liver failure

Poster presentation

Presenter: Florian Rosenberger

1024

Extensive characterization of new biomarkers associated with infection and outcome of decompensation of cirrhosis using high throughput metabolomics, lipidomics and cytokinomics

Poster presentation

Presenter: Cristina López-Vicario

1159

Nitazoxanide directly protects from stress-induced cell death to alleviate liver damage in preclinical models of acute-on-chronic liver failure

Poster presentation

Presenter: Marie Bobowski-Gerard

1213

Effects of albumin treatment on cell death markers in patients with decompensated cirrhosis and in acute-on-chronic liver failure

Poster presentation

Presenter: Estefania Alcaraz

1225

Investigating the role of specialized intestinal macrophages in preserving gut-vascular barrier integrity during experimental cirrhosis

Oral presentation

Presenter: Lena Smets

1226

The role of endothelial FoxO1 pathway in decompensated liver cirrhosis and acute-on-chronic liver failure

Poster presentation

Presenter: Fabian Schachteli

1284

Developing a discovery platform for engineered macrophage cell therapies for end stage liver disease

Poster presentation

Presenter: Lara Campana

1353

Mitoquinol intervention ameliorates cirrhosis associated hematopoietic imbalance and improves innate immune function

Poster presentation

Presenter: Deepanshu Maheshwari

1500

The association of hepatocyte large extracellular vesicles with plasma biomarkers levels improve prediction of mortality in patients with cirrhosis

Poster presentation

Presenter: Audrey Payancé

1616

Female mice with cirrhosis are more prone to acute and chronic effects of psilocybin exposure without tolerance compared to male mice

Poster presentation

Presenter: Jasmohan Bajaj

1639

Differential regulation of soluble guanylate cyclase signaling during liver fibrosis regression

Poster presentation

Presenter: Thomas Sorz-Nechay

1822

Plasma extracellular vesicles improve prediction of 90 day mortality in patients with acute decompensation of cirrhosis

Poster presentation

Presenter: Shantha Valainathan

1866

Exploring the immunomodulatory potential of TLR7/8 agonism in decompensated cirrhosis

Poster presentation

Presenter: Dimitrios Patseas

1890

Type-I interferon shapes peritoneal immunity in cirrhosis and drives caspase-5-mediated progranulin release during spontaneous bacterial peritonitis

Poster presentation

Presenter: Michael Rooney

1924

Effect of long-term treatment with Simvastatin and Rifaximin in mitochondrial and proinflammatory pathways in patients with decompensated cirrhosis. A single-cell RNA seq analysis in PBMCs

Poster presentation

Presenter: Adrià Juanola

1991

Exploring the role of short chain fatty acids in skeletal muscle atrophy within end stage liver disease

Poster presentation

Presenter: Sophie Allen

2082

Evaluation of statins as a new therapy to alleviate hepatic encephalopathy in cirrhotic mice

Poster presentation

Presenter: Subas Aroob

2186

Multi-compartment metabolomics for stratifying cirrhotic patients with acute decompensation

Poster presentation

Presenter: Christophe Junot

2501

In vivo experiments and network pharmacology to explore the effect and mechanism of JiGuCao capsule in treating liver cirrhosis

Poster presentation

Presenter: Shihao Zheng

2523

Targeting the histamine receptor 2 for HCC chemoprevention

Oral presentation

Presenter: Emilie Crouchet

2591

Galectin 9 predicts clinical outcome and regulates immune dysfunction in acute-on-chronic liver failure

Poster presentation

Presenter: Antonio Riva

2601

Low-density lipoprotein can predict hospital readmissions and outcomes following acute decompensation of cirrhosis

Poster presentation

Presenter: Kohilan Gananandan

2605

Cell-free DNA dynamics in advanced cirrhosis: unravelling the role of nuclear and mitochondrial DNA in inflammation, coagulation dysfunction and short-term mortality

Poster presentation

Presenter: Marilena Stamouli

2607

Food antigen-specific antibodies contribute to hypergammaglobulinemia in patients with decompensated liver cirrhosis

Poster presentation

Presenter: Lara Kelsch

2646

Primary biliary cholangitis increases the risk of hepatocellular carcinoma: results from Mendelian randomization analysis and bioinformatics analysis

Poster presentation

Presenter: Yikai Wang

2665

Alterations in plasma neuronal and glial proteins in varying severities of cirrhosis and differing grades of hepatic encephalopathy

Poster presentation

Presenter: Marilena Stamouli

2711

Pharmacological inhibition of high mobility group box 1 ameliorate sepsis induced hepatic micro vascular dysfunction and portal hypertension in non-cirrhotic and cirrhotic animals

Poster presentation

Presenter: Vaibhav Tiwari

2775

Increased gut urease activity contributes to hyperammonemia and is a potential biomarker of disease severity in cirrhosis

Poster presentation
Presenter: Deepika Jakhar

2793

Histological, molecular, and neuromotor alterations of the liver-brain axis in an aged model of experimental cirrhosis
Poster presentation
Presenter: Oriol Juanola

2800

Activated cytotoxic T-cells in mesenteric lymph nodes limit systemic bacterial dissemination, inflammation, and disease progression in chronic liver injury
Poster presentation
Presenter: Pinky Juneja

2827

Albumin infusion in decompensated cirrhotic patients with ascites induced decreasing serum active form of vitamin D, 1,25 dihydroxy vitamin D, an opposite effect on promoting systemic inflammatory cytokines reduction
Poster presentation
Presenter: Thitaporn Roongrawee

2834

Liver cirrhosis and epithelial damage – The gut-liver axis in spontaneous bacterial peritonitis and its modulation by p53
Poster presentation
Presenter: Celina Macek

2891

Isolation and immortalization of human endothelial cells from the portal vein
Poster presentation
Presenter: Aina Anton

2903

High shear stress induced PIEZO1 activation promotes cytoskeleton remodelling and a nuclear deformation develops pro-thrombotic microenvironment and contributes to portal hypertension
Poster presentation
Presenter: Rajni Yadav

2988

Exercise alters immune cell senescence and inflammation in cirrhosis patients with sarcopenia
Poster presentation

Presenter: Preeti Negi

2994

Circulating lipids are associated with mortality in acute-on-chronic liver failure

Poster presentation

Presenter: Pragyan Acharya

3005

APASL-ACLF without previous decompensation is rare but immunological distinct from ACLF with previous decompensation in a european cohort

Poster presentation

Presenter: Mona-May Langer

3007

Final results from the italian real-world experience on lusutrombopag treatment in cirrhotic patients with severe thrombocytopenia: insights from the reality study

Poster presentation

Presenter: Paolo Gallo

3051

Nicotinamide riboside supplementation improves bacterial clearance and mitigates fibrosis in animal model of cirrhosis

Poster presentation

Presenter: Nidhi Nautiyal

3079

Long-term albumin infusion reduces the mortality of cirrhosis and ACLF animal models by modulating the gut-liver axis and hepatic TLR4 signalling

Oral presentation

Presenter: Alexandra Phillips

3115

Systemic albumin administration improves the gut microbiome and intestinal permeability in animal models of cirrhosis and ACLF

Poster presentation

Presenter: Alexandra Phillips

3163

Hyperuricemia leads to early cognitive dysfunction and neuronal cell injury in bile-duct ligated rats

Poster presentation

Presenter: Sydnée L'écuyer

3224

Biglycan as a biomarker in acute-on-chronic liver failure (ACLF)

Poster presentation

Presenter: Martin Schulz

3238

Bone morphogenic protein 9 (BMP9): a novel therapeutic agent for the prevention of extrahepatic organ failure in acute-on-chronic liver failure (ACLF)

Poster presentation

Presenter: Alexandra Phillips

3295

Hepatic inflammation-senescence-regeneration gene expression during recovery from ACLF and the effect of granulocyte-colony stimulating factor (G-CSF), toll-like receptor-4 (TAK-242) inhibition and their combination (G-TAK)

Poster presentation

Presenter: MohammadMahdi Saeidinejad

Cirrhosis and its complications: Other clinical complications except ACLF and critical illness

189

Effect of adipose-related parameters on survival in patients with cirrhosis: a systematic review and meta-analysis

Poster presentation

Presenter: Xinxing Tantai

327

Decompensated cirrhosis is associated with disruption of nuclear positioning in skeletal muscle and selective atrophy of type II myofibers

Poster presentation

Presenter: Aldo J Montano-Loza

335

Superior prognostic accuracy of the LiverPRO score versus FIB-4 in predicting liver-related events in a cohort of 457,152 individuals

Poster presentation

Presenter: Katrine Lindvig

504

Prevalence of dysgeusia in patients with advanced chronic liver disease, relationship with the liver-disease progression status, and impact on malnutrition-sarcopenia-frailty

Poster presentation

Presenter: Marina Cipullo

515

Spontaneous bacterial empyema is a rare yet life-threatening complication in patients with hepatic hydrothorax

Poster presentation

Presenter: Grace Lai-Hung Wong

535

Acute kidney injury and infections as the main determinants of outcome in hospitalised patients with liver cirrhosis: a retrospective cohort from a tertiary hospital

Poster presentation

Presenter: Adonis Protopapas

582

Untargeted serum metabolomic profiles remain stable over time in large multi-center cohort of >700 outpatients with cirrhosis

Poster presentation

Presenter: Jasmohan Bajaj

632

Differences between urgent and elective major surgery in patients with advanced chronic liver disease and discriminatory capacity of the VOCAL-Penn

Poster presentation

Presenter: Lidia Canillas

646

Evaluating the influence of human albumin infusions on the MELD and MELD-Na scores in patients hospitalized with an acute decompensation of cirrhosis: an ATTIRE trial analysis

Poster presentation

Presenter: Nikolaj Torp

651

Thematic trial: phase 2 dose-ranging randomized clinical trial of capsular or enema fecal microbiota transplant to prevent hepatic encephalopathy in cirrhosis already on Rifaximin and Lactulose

Oral presentation

Presenter: Jasmohan Bajaj

684

The relationship between abnormal body composition by computed tomography imaging and long-term mortality in patients with cirrhosis

Poster presentation

Presenter: Rui Huang

685

Independent association of loss of skeletal muscle mass with long-term liver-related mortality in cirrhotic patients

Poster presentation

Presenter: Jiarui Zheng

699

Measuring the burden and impact of comorbidity in cirrhosis: insights from clinical database analysis

Poster presentation

Presenter: Lynsey Corless

718

Anthropometric muscle mass indicators are effective in diagnosing muscle mass loss but are unable to diagnose myosteatosis, thus failing to identify all patients with sarcopenia in liver cirrhosis

Poster presentation

Presenter: Alexandra Alexopoulou

721

The lower, the worse? Impact of PHES results on the risk of overt hepatic encephalopathy in patients with minimal hepatic encephalopathy

Poster presentation

Presenter: Christian Labenz

775

Aspirin reduces risk of ascites and encephalopathy in cirrhotic patients without increasing the risk of gastrointestinal bleeding

Poster presentation

Presenter: Roie Tzadok

789

Von Willebrand factor is associated with portal vein thrombosis in patients with liver cirrhosis

Poster presentation

Presenter: Yuzheng Zhuge

908

Construction and validation of a nomogram prediction model for predicting cirrhosis-related deaths based on severe sarcopenia and clinical serological indicators

Poster presentation

Presenter: Hong Yu

938

Silver-coating of tunneled peritoneal drainage system is associated with a lower incidence of spontaneous bacterial peritonitis and device explanation

Poster presentation

Presenter: Sarah Lisa Schütte

991

Terlipressin therapy is associated with increased risk of colonization with multidrug-resistant bacteria in patients with decompensated cirrhosis

Poster presentation

Presenter: Marcus Mücke

1014

Diagnostic scoring system for diagnosis of covert hepatic encephalopathy in child-pugh class a cirrhosis patients

Poster presentation

Presenter: Masanori Fukushima

1109

Patterns & predictors of postacute discharge location other than home in a global cohort of 3,678 patients hospitalized with cirrhosis

Poster presentation

Presenter: Wai-Kay Seto

1139

Cirrhotic liver transplant candidates with portosystemic shunts benefit from low dietary soluble fiber consumption

Poster presentation

Presenter: Simona Parisse

1193

Decreasing incidence of cirrhosis due to hepatitis C following the treatment as prevention for hepatitis C nationwide elimination campaign

Poster presentation

Presenter: Einar S. Björnsson

1219

Validating and expanding Baveno VII criteria of recompensation in patients with decompensated cirrhosis

Oral presentation

Presenter: Marta Tonon

1343

Wide variations in proton pump inhibitor use in hospitalized patients with cirrhosis in a worldwide cohort shows little impact on clinically significant outcomes

Poster presentation
Presenter: Jasmohan Bajaj

1345
Diagnostic potential of speech artificial intelligence analysis in minimal hepatic encephalopathy
Oral presentation
Presenter: Jakub Gazda

1352
Tissue factor pathway inhibitor and serum amyloid A-4 protein are promising to predict occurrence of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
Poster presentation
Presenter: Huan Tong

1372
Proton pump inhibitors are not associated with an increased risk of hepatic encephalopathy
Poster presentation
Presenter: Simon Johannes Gairing

1404
Clot wave analysis parameters are associated with the severity of liver cirrhosis
Poster presentation
Presenter: Kessarin Thanapirom

1406
Outcomes of minimal ascites in patients with etiologically controlled liver cirrhosis
Poster presentation
Presenter: Haiyu Wang

1424
Infections and outcomes in patients hospitalized with an acute decompensation of cirrhosis: insights from the ATTIRE trial
Poster presentation
Presenter: Nikolaj Torp

1521
Folic acid prescription is associated with a lower mortality and hospital readmission in patients with decompensated alcohol-related liver cirrhosis
Poster presentation
Presenter: Laura Buttler

1537

Impact of diabetes mellitus on results in the animal naming test in patients with and without liver cirrhosis

Poster presentation

Presenter: Eva Maria Schleicher

1539

Alfapump implantation significantly improved quality of life and showed similar safety outcomes compared to a contemporaneously enrolled refractory ascites cohort

Poster presentation

Presenter: Jasmohan Bajaj

1562

Impact of Farnesoid X receptor polymorphisms on prognosis in hepatocellular carcinoma

Poster presentation

Presenter: Talha Ozudogru

1564

Outcomes of thromboelastography guided versus routine empirical or on-demand platelet transfusion in patients with liver cirrhosis and severe thrombocytopenia undergoing high-risk invasive percutaneous and vascular procedures: an open-label, randomized co

Poster presentation

Presenter: Sagnik Biswas

1565

Risk of serious infection in patients with chronic liver disease: a nationwide population-based cohort study

Poster presentation

Presenter: Won Sohn

1568

Differential diagnosis of covert hepatic encephalopathy in a cohort of outpatients with chronic liver disease

Poster presentation

Presenter: Lyès Kheloufi

1579

Private verbal fluency test (PVFT): a quick-to-use cognitive tool for the screening of covert hepatic encephalopathy

Poster presentation

Presenter: Lyès Kheloufi

1596

Predictors of clinical trajectories in patients surviving an acute decompensation of cirrhosis

Poster presentation

Presenter: Carmine Gambino

1599

Differences in the clinical phenotype of decompensated liver cirrhosis between MASLD, MetALD and ALD patients

Poster presentation

Presenter: Laura Buttler

1628

Comparison in epidemiology and outcomes of bacterial infections in patients with cirrhosis between university hospitals with and without liver transplant

Oral presentation

Presenter: Clàudia Torras

1631

Six years long-lasting clinical benefits of previous short-term resistance training in cirrhosis – follow-up after a clinical randomized trial

Poster presentation

Presenter: Luise Aamann

1755

Long-term albumin administration in outpatients with decompensated cirrhosis and diabetes mellitus: post-hoc analysis of the ANSWER trial database

Poster presentation

Presenter: Giulia Iannone

1762

Usefulness of liver volume assessment for simple screening of covert hepatic encephalopathy

Poster presentation

Presenter: Masanori Fukushima

1909

Cerebral diffusion tensor imaging in patients with liver diseases admitted for evaluation of neurological symptoms

Poster presentation

Presenter: Nicolas Weiss

1913

Global epidemiology of acute kidney injury in hospitalized patients with cirrhosis: the ICA-GLOBAL AKI study

Poster presentation

Presenter: Kavish Patidar

1995

Impact of underlying etiology of liver cirrhosis on tests for diagnosing minimal hepatic encephalopathy

Poster presentation

Presenter: Julius Egge

1999

Physical frailty diagnosed by short physical performance battery test is an independent poor prognostic factor of 360-day mortality in patients with liver cirrhosis

Poster presentation

Presenter: Alexandra Alexopoulou

2043

Safety and tolerability of long-term albumin treatment in patients with decompensated cirrhosis

Poster presentation

Presenter: Javier Fernández

2053

Rectus femoris cross sectional area predicts 90-day readmission in patients hospitalized for an acute decompensation of cirrhosis

Poster presentation

Presenter: Roberta Gagliardi

2084

Hypodynamic cardiocirculatory status measured at echocardiography is associated with one-month mortality in patients admitted for acute decompensation of liver cirrhosis

Poster presentation

Presenter: Alexandru Victor Dragan

2104

Safety and effectiveness of anticoagulation in patients with cirrhosis listed for liver transplantation: a single center observational study

Poster presentation

Presenter: Riccardo Caccia

2141

Comparison of clinical outcomes among patients with refractory ascites and implantation of either Alfapump®, tunneled peritoneal drainage system or transjugular intrahepatic portosystemic shunt

Poster presentation

Presenter: Sarah Lisa Schütte

2145

Predictors of ascites resolution in patients with cirrhosis receiving long-term albumin treatment. Results from a real-world study in Italy (Real-ANSWER)

Poster presentation

Presenter: Enrico Pompili

2194

The efficacy of Glucagon-like Peptide-1 receptor agonists in patients with compensated cirrhosis and obesity

Poster presentation

Presenter: Yee Hui Yeo

2200

Clinical impact of acute kidney disease in patients with decompensated cirrhosis: insights from a prospective observational study on renal dysfunction

Poster presentation

Presenter: Alberto Calleri

2209

Lisinopril is associated with reduced hepatocellular carcinoma and mortality risk in patients with MASLD-related compensated cirrhosis: a multicenter, nationwide propensity score matching analysis

Poster presentation

Presenter: Yee Hui Yeo

2222

Complications following percutaneous liver biopsy: results of a nationwide database

Poster presentation

Presenter: Christiana Graf

2243

Development and validation of a prognostic model (AMMON-AD) to define risk of overt hepatic encephalopathy in cirrhosis patients with acute decompensation

Poster presentation

Presenter: María Pilar Ballester

2263

Role of HLA DR+ CD4+ T cell %T cell in mediating the effect of Lactobacillus delbrueckii on liver cirrhosis

Poster presentation

Presenter: Xuanchen Liu

2280

New concept of cirrhosis recompensation in clinical practice: it's key time

Poster presentation

Presenter: Inês Rodrigues

2309

End of life care in advanced chronic liver disease: results from a national audit of practice in the United Kingdom

Poster presentation

Presenter: Daniel Maggs

2312

Development of a screening tool for covert hepatic encephalopathy through automated speech signal analysis in patients with chronic liver diseases and/or portosystemic shunts

Poster presentation

Presenter: Apolline Leproux

2322

Rifaximin reduces healthcare utilization but not overall costs in patients with cirrhosis and recurrent episodes of hepatic encephalopathy: a retrospective efficacy study

Poster presentation

Presenter: Diederick van Doorn

2421

Risk factors for hepatocellular carcinoma in cirrhosis: a comprehensive analysis from a decade-long study

Poster presentation

Presenter: Zhenhuan Cao

2554

Change in frailty status with nutritional therapy in patients with cirrhosis – a randomized controlled trial

Poster presentation

Presenter: Sudhir Maharshi

2610

Impact of bacterial infections on kidney function and survival in patients with decompensated cirrhosis and acute kidney injury worldwide – analysis of the ICA-GLOBAL AKI study

Poster presentation

Presenter: Adrià Juanola

2709

Development of global leadership initiative on malnutrition-dictated nomograms to predict long-term mortality among hospitalized cirrhosis with external validation cohort

Poster presentation

Presenter: Chao Sun

2857

Entecavir can significantly improve the prognosis of patients with first decompensated hepatitis B cirrhosis
Poster presentation
Presenter: Rui Ding

2864

Thyroid and adrenal dysfunction is associated with negative mid-term prognosis in decompensated cirrhosis
Poster presentation
Presenter: Laura Iliescu

2882

Impact of micronutrient deficiencies on the mortality of patients with cirrhosis admitted for acute decompensation
Poster presentation
Presenter: Ariadna Altadill

2890

Smoking cessation correlates with rapid decrease of inflammatory markers in patients with decompensated cirrhosis
Poster presentation
Presenter: Letitia Toma

2995

Upper extremity skeletal muscle index to assess sarcopenia in patients with cirrhosis
Poster presentation
Presenter: Anna Ostrovskaya

3034

Male sex is associated with worse outcomes in primary biliary cholangitis
Poster presentation
Presenter: Nirbaanjot Walia

3052

Feasibility of bedside ultrasonography of rectus femoris muscle for sarcopenia diagnosis in liver cirrhosis
Poster presentation
Presenter: Sara De Monte

3074

Recompensation after TIPS reduces the risk of hepatocellular carcinoma and death in patients with decompensated cirrhosis
Poster presentation

Presenter: Jose Sanchez-Serrano

3075

Rifaximin monotherapy has significantly reduced the risk of overt hepatic encephalopathy recurrence versus lactulose monotherapy in patients with cirrhosis and a history of previous episode(s): a post hoc analysis of randomized trials

Poster presentation

Presenter: Jasmohan Bajaj

3103

Screening and assessing Sarcopenia in liver cirrhosis: feasibility and implications for clinical outcomes

Poster presentation

Presenter: Philipp Altmann

3116

Unveiling the role of GH-IGF1 axis in decompensated cirrhosis: implications for sarcopenia, frailty, decompensations, and mortality

Poster presentation

Presenter: Parminder Kaur

3156

The impact of acute kidney injury in cirrhosis: a meta-analysis of 5,202,232 patients

Poster presentation

Presenter: Vasileios Lekakis

3173

Rapid infection diagnostics in liver disease– evaluation of a multiplex PCR platform to improve infection and antimicrobial resistance detection

Poster presentation

Presenter: Veena Ramachandran

3206

The respiratory assessment of cirrhotic patients: six-minute walk test is an independent predictor of mortality in cirrhosis

Poster presentation

Presenter: Onur Keskin

3285

Validation of an easy-to-use malnutrition screening in cirrhosis to predict outcome

Poster presentation

Presenter: Stefan Fürst

3293

Pre- and post-test diagnostic concordance rates of TJLB for suspected liver and blood diseases

Poster presentation

Presenter: Asako Nogami

3329

Bleeding risk after endoscopic polypectomy in patients with cirrhosis

Poster presentation

Presenter: Christoph Schramm

3339

A multi-center randomized controlled study of primary prevention of esophageal variceal bleeding in cirrhotic patients treated with HVPG-guided therapy or standard heart rate-guided therapy: an interim analysis of the PORTHOS trial

Poster presentation

Presenter: Annelotte Broekhoven

3369

Prognostic significance of HDL-associated apolipoproteins in patients with decompensated cirrhosis and spontaneous bacterial peritonitis

Poster presentation

Presenter: Mohamad Murad

Cirrhosis and its complications: Portal Hypertension

8

Patients with hepatorenal syndrome and lower baseline mean arterial pressure derive significant survival benefit from treatment with terlipressin

Poster presentation

Presenter: Paul Yien Kwo

53

Soluble urokinase plasminogen activator receptor (suPAR) levels predict survival in patients with portal hypertension undergoing TIPS

Poster presentation

Presenter: Sven H Loosen

56

Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension. A randomized, double-blind clinical trial

Poster presentation

Presenter: Valeria Perez-Campuzano

96

A machine learning algorithm generated using routine parameters could avoid unnecessary taps to exclude SBP in a national VA cohort with internal and external validation

Oral presentation

Presenter: Jasmohan Bajaj

101

Mild overt hepatic encephalopathy (HE) – more than meets the eye

Poster presentation

Presenter: Chiara Mangini

314

Point-of-care ultrasound of the inferior vena cava for intravascular volume assessment in patients with cirrhosis during intravenous albumin infusion

Poster presentation

Presenter: Daniel Segna

398

Evaluation of Baveno VII criteria and other non-invasive tests for clinically significant portal hypertension in chronic hepatitis D

Poster presentation

Presenter: Mathias Jachs

399

Spleen stiffness measurement by transient elastography at 100Hz refines the non-invasive diagnosis of clinically significant portal hypertension in compensated advanced chronic liver disease – final results of a european multicenter study

Oral presentation

Presenter: Mathias Jachs

415

Assessment of portal hypertension risk by liver and spleen stiffness using real-time 2D-shear wave elastography – the prospective AiXplore study

Poster presentation

Presenter: David Bauer

439

Ongoing alcohol use after TIPS implantation is associated with increased rates of ACLF and liver related death among individuals with alcohol related ACLD

Poster presentation

Presenter: Caroline Schwarz

447

Residual minimal ascites 3 months after TIPS implantation indicates risk of further decompensation and death

Poster presentation
Presenter: Lukas Hartl

522

Effect of rifaximin in severe cirrhotic patients with ascites: a double-blind randomized placebo-controlled phase 3 trial

Oral presentation

Presenter: Thierry Thévenot

573

The modified child-turcotte-pugh score based on plasma ammonia to predict survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt: a multicenter validation

Poster presentation

Presenter: Feng Zhang

598

Comparison of endoscopic variceal ligation and endoscopic cyanoacrylate injection for the treatment of acute variceal bleeding from the cardia to the lesser curvature of the stomach

Poster presentation

Presenter: Yu-Fu Chen

655

Prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt by live combined Bifidobacterium and Lactobacillus tablets: a randomized controlled trial

Poster presentation

Presenter: Ying Li

745

Whole blood thrombin generation improves the understanding of cirrhotic coagulopathy and predicts clinical outcomes in patients with cirrhosis: a prospective cohort study

Poster presentation

Presenter: Alberto Zanetto

756

Safety and Efficacy of the Natriuretic Peptide Ularitide in Refractory Cirrhotic Ascites: Interim Analysis of a Randomized Controlled Trial

Poster presentation

Presenter: Rasmus Gantzel

823

Preclinical and clinical evaluation of PHIN-214, a vasoactive peptide

Poster presentation

Presenter: Gerardo Castillo

851

Frequency of chronic liver disease after chemotherapy for gastrointestinal tumors

Poster presentation

Presenter: Paulo Bittencourt

899

Clinical Value of 4D Flow MRI in Assessing Varices Needing Treatment in Cirrhotic Patients with Portal Hypertension: A Prospective Study

Poster presentation

Presenter: Qian Zhang

913

Effects of zibotentan and dapagliflozin on patients with compensated cirrhosis: a randomized double-blind placebo controlled exploratory pilot study

Poster presentation

Presenter: Juan Carlos García-Pagán

920

Circulating fibronectin levels are linked to endothelial dysfunction, fibrogenesis, and portal hypertension in advanced chronic liver disease

Poster presentation

Presenter: Benedikt Simbrunner

921

Biomarkers of extracellular matrix remodelling are linked to portal hypertension and disease progression in patients with stable advanced chronic liver disease

Poster presentation

Presenter: Benedikt Simbrunner

987

Argon plasma coagulation or endoscopic band ligation for gastric antral vascular ectasia: a randomized comparative analysis

Poster presentation

Presenter: Ashok Jhajharia

1060

Accuracy of spleen stiffness measurement for the diagnosis of high-risk esophageal varices in patients with advanced chronic liver disease: a systematic review and individual patient data meta-analysis

Poster presentation

Presenter: Elton Dajti

1130

Trial of the establishment of shear wave elastography measurement methods for improvement of versatility

Poster presentation

Presenter: Hidemi Unozawa

1145

The Toulouse algorithm identifies patients with an increased risk of cardiac decompensation only in patients with TIPS for refractory ascites

Poster presentation

Presenter: Emma Vanderschueren

1258

Role of serum Mac-2 binding protein glycosylation isomer in identifying patients with chronic liver diseases at risk for portal hypertension-related complications

Poster presentation

Presenter: Kessarin Thanapirom

1290

A Phase 2 study of OCE-205, a novel, selective vasopressin receptor mixed agonist-antagonist: positive proof-of-concept established in subjects with cirrhosis and hepatorenal syndromeacute kidney injury (HRS-AKI)

Poster presentation

Presenter: Florence Wong

1319

The presence of NOD2 risk variants is associated to a higher incidence of first decompensation in patients with cirrhosis and varices

Poster presentation

Presenter: Henrik Karbanek

1397

Lower levels of Insulin-like growth factor 1 are independently associated with unfavorable prognosis in patients with advanced chronic liver disease

Poster presentation

Presenter: Michael Schwarz

1402

Prospective 5-year follow-up study of spleen stiffness measurement with a spleen-dedicated module (SSM@100Hz) for predicting hepatic decompensation in cACLD: competitive risk analysis

Poster presentation

Presenter: Luigi Colecchia

1427

Sustainable endoscopy in hepatology: quantifying the effect of applying BAVENO VII guidelines on the endoscopic carbon footprint; a multi-centred regional assessment
Poster presentation
Presenter: Dylan Angel

1542
Impact of albumin dosing on the need for terlipressin therapy and prognosis in patients with liver cirrhosis
Poster presentation
Presenter: Eva Maria Schleicher

1659
Morphological changes in esophageal varices in patients with HCV related cirrhosis who achieved sustained virological response by direct-acting antivirals
Poster presentation
Presenter: Chikako Nagao

1660
Heartbeats and Platelets: unveiling the symphony of heart failure and congestive hepatopathy
Poster presentation
Presenter: Anas Zaher

1697
Prognostic factor which can predict esophageal varices aggravation after plug-assisted retrograde transvenous obliteration (PARTO)
Poster presentation
Presenter: Chan Jin Yang

1744
Assessment of sarcopenia improves the prediction of post-TIPS mortality in older adult patients with cirrhosis
Oral presentation
Presenter: Dario Saltini

1832
Assessment of the diagnostic accuracy of cell count on spontaneous bacterial peritonitis
Poster presentation
Presenter: Prebasha Moodley

1853
Spleen-dedicated stiffness measurement higher than 50 kPa is sufficient to diagnose clinically significant portal hypertension in cACLD individuals
Poster presentation
Presenter: Xiaofeng Zhang

1897

Splenic stiffness using spleen-dedicated 100 Hz transient elastography compared with the Baveno criteria to predict high risk esophageal varices in cirrhosis

Poster presentation

Presenter: Harsh Jain

2003

Pre-emptive TIPS should not be contra indicated in high-risk patients with acute variceal bleeding and alcohol hepatitis

Poster presentation

Presenter: Marika Rudler

2037

Three-dimensional transjugular intrahepatic portosystemic shunt geometry predicts shunt dysfunction in decompensated liver cirrhosis

Poster presentation

Presenter: Markus Kimmann

2048

Changes in mean arterial pressure are inadequate to guide treatment with terlipressin and albumin in patients with hepatorenal syndrome – acute kidney injury

Poster presentation

Presenter: Valeria Calvino

2219

Addition of simvastatin to carvedilol improves survival in patients with decompensated cirrhosis after variceal bleed. A randomised controlled trial

Oral presentation

Presenter: Randeep Rana

2250

Evaluating the correlation between portal pressure, collagen proportional area, and α -smooth muscle actin in patients with portal hypertension due to MASH cirrhosis

Poster presentation

Presenter: Pol Boudes

2277

Evaluation of portal hemodynamics after etiological factor removal and persistence of varices in patients with an HVPG <10mmHg and NITs within the grey zone

Poster presentation

Presenter: Pol Olivas Alberch

2491

End-procedural complete hemodynamic response may not be essential for the clinical success of tips in patients with cirrhosis

Poster presentation

Presenter: Davide Roccarina

2509

The safety and technical success of endoscopic ultrasound-guided portal pressure gradient measurement: a systematic review and meta-analysis

Poster presentation

Presenter: Yousaf Zafar

2553

Paired assessment of the hepatic venous pressure gradient with the push-wedge versus balloon-occlusion technique: impact of intrahepatic collaterals

Poster presentation

Presenter: Naomi Gestels

2577

Neutrophil extracellular traps are not linked to the development of decompensation, ACLF, or death in clinically stable patients with advanced chronic liver disease

Poster presentation

Presenter: Lorenz Balcar

2590

Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) predicts acute-on-chronic liver failure in patients with acute decompensation

Poster presentation

Presenter: Lorenz Balcar

2809

Multivariable models for prediction of decompensation in compensated advanced chronic liver disease often lack external validation and measures of calibration

Poster presentation

Presenter: Ian Rowe

2814

Lower post-transjugular intrahepatic portosystemic shunt overt hepatic encephalopathy and mortality in patients with hepatic venous communication

Poster presentation

Presenter: Li Ma

2872

Long-term therapy with intravenous human albumin increase survival in patients with decompensated cirrhosis and refractory ascites

Poster presentation
Presenter: Antonino Lombardo

2893
Association between alleviation of portal vein thrombosis and mortality rate in cirrhotic patients: a prospective cohort study
Poster presentation
Presenter: Xiaoquan Huang

2940
Hemodynamic alterations and survival outcomes in cirrhotic patients with cirrhotic cardiomyopathy undergoing transjugular intrahepatic portosystemic shunt
Poster presentation
Presenter: Yaozu Liu

3012
Improvement of liver frailty, hand grip strength and mid-upper arm circumference in cirrhotic patients after TIPS insertion
Poster presentation
Presenter: Martin Kabelitz

3119
Association between pre-operative TIPS and post-operative mortality in a veterans affairs cohort
Poster presentation
Presenter: Nadim Mahmud

3213
Efficacy and safety of carvedilol in cirrhosis patients with uncomplicated ascites without high-risk esophageal varices - a randomized controlled trial [NCT05057572]
Oral presentation
Presenter: Rahul khajuria

3334
Heart failure outcomes following transjugular intrahepatic portosystemic shunts
Poster presentation
Presenter: Jemima Finkel

Fibrosis / Stellate cell biology

45
SOX9 is influential in type 2 immune mediated liver fibrosis

Poster presentation

Presenter: Kim Su

117

DA-1241, a GPR119 agonist, combined with Semaglutide synergistically improved liver fibrosis in mice with CCl₄-induced liver fibrosis

Poster presentation

Presenter: Il Hoon Jung

160

The effect of the novel selective and orally bioavailable CXCR7 modulator in carbon tetrachloride (CCl₄)-induced liver fibrosis using mouse model

Poster presentation

Presenter: Yunhee Kim

380

--Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101

Poster presentation

Presenter: Raanan Greenman

520

Activation of the GABA_A receptor counteracts hepatic steatosis and fibrosis: a novel first-in-class approach for MASH therapy

Poster presentation

Presenter: Elisabeth Rohbeck

686

Temporal and spatial development of cholestasis induced liver injury

Poster presentation

Presenter: Jonas Øgaard

864

The hepatoprotective role of ECM1: inhibition of mediators of latent TGF- β 1 activation and implications for anti-fibrotic treatment strategies in chronic liver disease

Poster presentation

Presenter: Steven Dooley

1231

Proteomics analysis of liver fibrosis reveals Fibulin-3 as a new regulator of hepatic stellate cells

Poster presentation

Presenter: Célia THOMAS

1517

Elevated expressions of NTCP on NK cells from liver fibrosis of metabolic dysfunction-associated steatohepatitis patients are associated with increased bile acid uptake that impaired their function via STAT signaling pathway

Oral presentation

Presenter: Ahmad Salhab

1605

Circulating matricellular fibrosis markers TSP2, IGFBP7, TSP4 and M2-macrophage marker CD163 as predictors of fibrosis and outcome in people with primary sclerosing cholangitis

Poster presentation

Presenter: Ludwig J. Horst

1627

Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast targets TGF-beta inhibition to specific cell types in human liver explant tissue with biliary fibrosis

Poster presentation

Presenter: Johanna Schaub

1705

Single cell resolution of hepatic heterogeneity in liver fibrosis progression and regression

Poster presentation

Presenter: Le Thi Thanh Thuy

1733

Roles of intrahepatic IgA on the fibroblast activation in livers with steatotic liver diseases

Poster presentation

Presenter: Jae-Sung Yoo

1753

Pioglitazone ameliorates fibrotic niche of HBV transgenic mice by restoring NK cell function and inhibiting macrophage activation

Poster presentation

Presenter: Huanyu Xiang

1835

New insight of liver fibrosis: altered chromatin accessibility in hepatic stellate cells

Poster presentation

Presenter: Tingting Jia

2075

Aging-associated liver sinusoidal endothelial cell dysfunction is involved in the progression of diet-induced liver steatosis and fibrosis

Poster presentation

Presenter: Qingqing Dai

2482

Retinoids induce restorative monocyte-derived macrophage by scavenging oxidative stress in liver fibrosis

Oral presentation

Presenter: Kyurae Kim

2598

Study of hepatic stellate cell activation and extracellular matrix remodelling mechanisms in distinct stages in liver fibrosis progression and aetiology using patient-derived primary human hepatic stellate cells

Poster presentation

Presenter: Lai Wei

2602

Exploring novel targets in hepatic stellate cell activation: interference with the mitochondrial function as part of the antifibrogenic effect of Rilpivirine

Poster presentation

Presenter: Ana Benedicto

2698

Liver fibrosis in NLRP3^{tm1Hhf/J} knockout mice suffering from apical periodontitis

Poster presentation

Presenter: Cristiane Cantiga

2701

Cell communication network in diseased livers reveals lymphotoxin beta as a potential inducer of hepatic stellate cell activation

Poster presentation

Presenter: Stefaan Verhulst

2721

Inhibition of hyaluronic acid synthesis by hyaluronan synthase 2 targeting siRNA downregulates expression of chemokine (C-X-C motif) ligand 16 and suppresses liver fibrosis in mice

Poster presentation

Presenter: Noreen Halimani

2724

Magnetic levitation culture: a step towards quiescent hepatic stellate cell in vitro models

Poster presentation

Presenter: Nataliya Rohr-Udilova

2755

Evaluation of liver fibrosis: reproducibility of transient elastography

Poster presentation

Presenter: Cyrine Ben Mehrez

2851

The improvement of Bortezomib on cirrhosis and its potential mechanism

Poster presentation

Presenter: Ling Wu

2970

Characterization of in vivo mouse models of regressive fibrosis and resolving portal hypertension

Poster presentation

Presenter: Katharina Bonitz

2996

MCPIP1 RNase inhibits liver fibrosis by targeting TGF- β 1 mRNA

Poster presentation

Presenter: Jerzy Kotlinowski

3026

Delivery of antimiR-155 using lipid nanoparticles ameliorate liver fibrosis by alleviating macrophage-driven liver inflammation

Poster presentation

Presenter: Vishal Tuli

3166

Single-cell atlas reveals conserved HSC activation process and therapeutic opportunities

Poster presentation

Presenter: Vincent Merens

Gut microbiota and liver disease / Liver-organ crosstalk

184

Identifying patterns of steatotic liver disease severity: a multi-omic analysis of 834 distinct omics features from healthy to end-stage liver disease in 854 individuals

Oral presentation

Presenter: Johanne Kragh Hansen

207

Unveiling the myth and truth of “Yellow Soup” in managing acute liver injury

Poster presentation

Presenter: Sen-Yung Hsieh

281

Comparative analysis of the gut-liver axis in preclinical models of decompensated cirrhosis

Poster presentation

Presenter: Elisa Castillo

448

Tissue-specific roles of Farnesoid X Receptor in gut-liver axis and influence on progressive cholestatic liver injury

Poster presentation

Presenter: Lina Ludwigs

462

Gut Akkermansia improves liver injury in D-penicillamine treated copper exposure model

Poster presentation

Presenter: Yimin Zhang

472

Metabolic dysfunction-associated steatotic liver disease and gut microbiota

Poster presentation

Presenter: Vitalii Petryna

494

KYNA induced by short-term fasting through gut microbiota remodelling ameliorates hepatic ischemia/reperfusion injury via activating AhR-YAP signalling in mice

Poster presentation

Presenter: Xiaolong Chen

591

Hepatic steatosis in young adults is associated with altered intestinal microbiology

Poster presentation

Presenter: Yasmina Tashkent

619

Faecal microbiota transplantation in patients with cirrhosis, reduces antimicrobial resistance and enteric pathogen carriage, and enhances intestinal barrier function, associated with bacteriophage remodelling

Oral presentation

Presenter: Lindsey Edwards

625

N-acetyl-phenylalanine, a new metabolite derived from the intestinal microbiota participating in hepatic steatosis by altering ER-mitochondria communication

Oral presentation
Presenter: Cyrielle Caussy

743
Evidence of gut microbiome differences in post-menopausal females with metabolic dysfunction-associated liver disease compared to pre-menopausal females and males
Poster presentation
Presenter: Laura Martinez-Gili

876
Protein-educated fecal cell-free transplant enhances remission better than protein-educated fecal microbiota transfer in alcohol-related liver disease
Poster presentation
Presenter: Ashi Mittal

926
The double-edged sword of bariatric surgery: extending the excluded limb can trigger bacterial translocation, liver inflammation and death
Poster presentation
Presenter: Louis Onghena

994
Amelioration of metabolic dysfunction-associated steatohepatitis by *Lactobacillus delbrueckii* subsp. *lactis* CKDB001 restoring gut microbiota.
Poster presentation
Presenter: Hyunchae Joung

1016
Association of HLA alleles with Oral Microbiome in Liver Cirrhosis patients
Poster presentation
Presenter: Rosmy Babu

1046
Isolation and characterization of extracellular vesicles in faecal matter: implications for future biomarker discovery
Poster presentation
Presenter: Hector Leal-Lassalle

1128
Gut microbiota promotes macrophage M1 polarization in hepatic sinusoidal obstruction syndrome via regulating intestinal barrier function mediated by butyrate
Poster presentation
Presenter: si zhao

1132

Butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis

Poster presentation

Presenter: Rui Wang

1165

Oatmeal a day does not keep the doctor away: the impact of the combination of inulin and exercise on MASLD amelioration and gut-liver crosstalk

Poster presentation

Presenter: Artemiy Kovynev

1221

Linking gut microbiome enterotypes and dysbiosis to liver disease severity and prognosis

Oral presentation

Presenter: Marisa Isabell Keller

1240

Lean and non-lean non-alcoholic fatty liver disease patients differ significantly with regard to gut microbiota expression: results of an observational study

Poster presentation

Presenter: Prajna Anirvan

1297

Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism

Poster presentation

Presenter: Laura Beretta

1648

The narcolepsy drug sodium oxybate improves metabolism in developing and existing obesity

Poster presentation

Presenter: Sen Zhang

1828

Unravelling bacterial metabolites using high-resolution magic angle spinning nuclear magnetic resonance spectroscopy in intact hepatocellular carcinoma liver tissue

Poster presentation

Presenter: Wendy Fernandes

1903

Transplantation of fecal microbiota derived from idiosyncratic drug-induced liver injured patients caused by amoxicillin-clavulanate determines a specific bile acid profile in germ-free mice

Poster presentation
Presenter: Sara Román-Sagüillo

1907
Variation of the human microbiome across multiple body sites and temporal dynamics in different stages of decompensated cirrhosis
Oral presentation
Presenter: Wenyi Gu

1919
MiR122 expression regulates liver immune tolerance and microenvironment
Poster presentation
Presenter: Maytal Gefen

2013
Sulphated progesterone metabolites undergo apical sodium bile acid transporter-mediated enterohepatic recycling and stimulate glucagon-like peptide 1 and peptide YY release
Poster presentation
Presenter: Alice Mitchell

2173
Rifaximin-alpha acts through increased abundance of Lactobacillus spp. in murine models of chronic liver disease
Poster presentation
Presenter: Maximilian Joseph Brol

2178
Toll-like receptor 2 signaling cascades are a trigger of aging-associated liver decline in mice
Poster presentation
Presenter: Annette Brandt

2191
Investigating gut microbial biomarkers for early detection of sarcopenia in individuals at various stages of alcohol-related liver disease
Poster presentation
Presenter: Haripriya Gupta

2475
Urobilinogen promotes leaky gut by impacting intestinal integrity in a three-dimension intestinal organoid model system
Poster presentation
Presenter: Manisha Yadav

2516

Aging promotes liver injury: studies on C57Bl/6 mice

Poster presentation

Presenter: Kusum Kharbanda

2632

Restoration of mucosa-associated invariant T (MAIT) cell function and metabolism in cirrhosis with rifaximin-a

Poster presentation

Presenter: Thomas Tranah

2682

Inhibition of miR-21 improves muscle activity in experimental metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: André Simão

2731

Multi-omics study of chronic liver diseases with rifaximin treatment

Poster presentation

Presenter: Yingjie Ai

2734

Phages targeting Enterococcus B bacteria associated with increased short-term mortality and proven bacterial infection in patients with decompensated liver cirrhosis and ACLF

Poster presentation

Presenter: Lore Van Espen

2758

Criss-cross fecal microbiota transplant identifies hepatic steroid biosynthesis and linoleic acid metabolism linked with liver injury and dysbiosis in rat

Poster presentation

Presenter: Manisha Yadav

2788

Hepatocellular carcinoma risk associated with circulating metabolites of gut microbiome origin assessed by targeted mining of high-resolution untargeted metabolomics data

Poster presentation

Presenter: Mazda Jenab

2794

Effect of various edible exosomes in restoring gut homeostasis and hepatic metabolic axis: a comparative study

Poster presentation

Presenter: P. Debishree Subudhi

2845

Protein-modulated microbiota for fecal transplantation improves metabolic functions in alcohol-related liver disease model

Poster presentation

Presenter: Nishu .

2853

Gut dysbiosis-induced humoral dysregulation in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Hong Sheng Cheng

2984

Gender-dependent HCC development in X/MYC mouse model

Poster presentation

Presenter: Vincenzo Alfano

3122

Nitrogen recycling by the gut microbiome in sarcopenia

Poster presentation

Presenter: Rosa Haller

3366

Crosstalk between liver spheroids and pancreatic islets in the anterior chamber of the eye promotes growth and vascularization

Poster presentation

Presenter: Noah Moruzzi

Hepatocyte biology

191

Novel regulatory mechanisms of the transforming growth factor β signaling pathway by the histone Methyltransferase G9a.

Poster presentation

Presenter: Borja Castello

854

Establishing a Liver-on-Chip using tissue-resident progenitor cells from adult human liver

Poster presentation

Presenter: Defu Kong

1029

A rule-based multiscale model of hepatic stellate cell plasticity: critical role of the inactivation loop in fibrosis progression

Oral presentation

Presenter: Matthieu Bougueon

1207

EGF/STAT1 signals to maintain ECM1 expression in hepatic homeostasis are disrupted by IFN γ /NRF2 in chronic liver disease

Poster presentation

Presenter: Yujia Li

1675

Dickkopf-1 inhibitor treated with sorafenib inhibited Wnt/PI3K/Akt pathway in hepatocellular carcinoma

Poster presentation

Presenter: Seung Up Kim

1847

Relevance of hepatic estrogen receptor alpha in liver metabolic adaptation during pregnancy

Poster presentation

Presenter: Arianna Dolce

1862

Remodelling of hepatocyte cholesterol metabolism mediates colorectal liver metastasis

Oral presentation

Presenter: Ane Nieva-Zuluaga

2296

Oxidative stress and metabolic reprogramming of hepatocytes forming liver cell rosettes in patients with primary sclerosing cholangitis

Oral presentation

Presenter: Carlotta Mayer

2488

Role of hepatocyte-intrinsic humoral factors in establishing bioscaffold that regulates the fate determination of primary hepatocytes

Poster presentation

Presenter: Takeshi Saito

2511

Taurine supplementation plays hepato-protective role against steatosis in mouse hepatocytes

Poster presentation

Presenter: Pavitra Kumar

2762

Induced pluripotent stem cell-derived hepatocytes revisited: improved liver functionality compared to liver cancer cell lines and a better model for pre-clinical large-scale therapeutic screening and drug safety

Poster presentation

Presenter: Nikolaos Nikolaou

2971

KLB depletion fosters stem-like properties and epithelial-mesenchymal transition plasticity in HepG2 cells

Poster presentation

Presenter: Nadia Panera

Immune-mediated and cholestatic disease: Clinical aspects

171

Real-world study of reasons for non-utilization of second-line treatment in patients with primary biliary cholangitis

Poster presentation

Presenter: Seema T. Meloni

309

Chronic pruritus presents with similar clinical features in metabolic and cholestatic liver diseases

Poster presentation

Presenter: Miriam M. Düll

310

The skin microbiome diversity differs in regard to age and gender but not presence of pruritus in patients with hepatobiliary diseases

Poster presentation

Presenter: Miriam M. Düll

324

Patient-reported insights on current care practices for primary biliary cholangitis, quality of life and self-management: results of the german PBC online survey

Poster presentation

Presenter: Diane Langenbacher

325

Results from a phase 2a trial with the CD80 antagonist RhuDex as a second line treatment for primary biliary cholangitis

Poster presentation

Presenter: Gideon Hirschfield

405

Second-line treatment in recurrent primary biliary cholangitis after liver transplantation: an international multicentre study

Poster presentation

Presenter: Nadir Abbas

450

External validation of the international autoimmune hepatitis group response criteria in a multicentric real-world cohort

Poster presentation

Presenter: Lorenz Grossar

458

Patient-reported outcomes in primary sclerosing cholangitis: an australian multicentre cohort perspective

Poster presentation

Presenter: Natassia Tan

459

Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis

Poster presentation

Presenter: Minghui Li

532

The epidemiological and prognostic burden of autoimmune liver disease: results of a nationwide population-based study over the past decade

Poster presentation

Presenter: Christophe Corpechot

540

Short- and medium-term effects of hypnosis and psychoeducational interventions on fatigue associated with primary biliary cholangitis: a randomized controlled trial

Poster presentation

Presenter: Christophe Corpechot

562

Understanding the experience of people living with primary biliary cholangitis (PBC): further development of an experience map

Poster presentation

Presenter: Alexander Artyomenko

700

Ulcerative colitis-associated anti-integrin α V β 6 antibodies are highly prevalent in primary sclerosing cholangitis

Poster presentation

Presenter: Moritz Leppkes

767

Deep learning discriminates autoimmune hepatitis and primary biliary cholangitis

Oral presentation

Presenter: Alessio Gerussi

777

Investigating ACOX2 deficiency as an underlying cause of recurrent hypertransaminasemia in the Spanish population: an epidemiological study

Poster presentation

Presenter: Marta Alonso-Peña

836

A randomized phase II proof-of-concept study of beta-lapachone in patients with primary sclerosing cholangitis

Poster presentation

Presenter: Woo Hyun Paik

1009

Quantitative magnetic resonance cholangiopancreatography provides additional prognostic value in prediction of transplant-free survival in primary sclerosing cholangitis

Poster presentation

Presenter: Tim Middelburg

1030

Population pharmacokinetics of elafibranor in healthy participants and patients with liver diseases: A pooled analysis of 17 clinical studies

Poster presentation

Presenter: Dimitar Tonev

1059

The course of radiological features and liver stiffness measurement during long-term treatment with fibrates and UDCA in patients with Primary Sclerosing Cholangitis

Poster presentation

Presenter: Elisa Catanzaro

1062

Increasing prevalence of primary biliary cholangitis in The Netherlands

Poster presentation

Presenter: Rozanne C. de Veer

1065

The male-to-female ratio among patients with primary biliary cholangitis depends on age

Poster presentation

Presenter: Ellen Werner

1067

Key questions that patients with primary biliary cholangitis should ask their physician -Delphi method-

Poster presentation

Presenter: Ellen Werner

1070

Predicting post-partum flare in Autoimmune Hepatitis- who is at risk?

Poster presentation

Presenter: Charlotte Sewell

1074

Prospective validation of the prognostic value of liver stiffness assessed by Fibroscan in primary sclerosing cholangitis: final results of the FICUS study

Oral presentation

Presenter: Olivier Chazouillères

1107

Urgent call to action: people living with primary sclerosing cholangitis-inflammatory bowel disease (PSC-IBD) lose 10 years of life compared to those with IBD alone

Poster presentation

Presenter: Kristel Leung

1164

Familial risk of biliary tract cancer and colorectal cancer in patients with primary sclerosing cholangitis

Poster presentation

Presenter: Erik von Seth

1200

Sleep disturbance due to pruritus is associated with anxiety, depression, and worse quality of life: evidence for management of pruritus and sleep in chronic liver disease

Poster presentation
Presenter: Anna Halliday

1203
Assessment of the pharmacokinetic drug-drug interaction potential of elafibranor with atorvastatin in healthy adult male participants: an open-label phase I trial
Poster presentation
Presenter: Richard Allan

1206
Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE® trial
Oral presentation
Presenter: Mark Sonderup

1222
Prophylaxis for tuberculosis and pneumocystis jirovecii does not seem necessary in patients with autoimmune hepatitis treated with corticosteroid therapy: spanish multicentre study
Poster presentation
Presenter: ALVARO DIAZ-GONZALEZ

1230
Assessing the safety, tolerability and efficacy of rituximab in patients with difficult-to-treat autoimmune hepatitis: results from a tertiary UK liver unit
Poster presentation
Presenter: Abhishek Gairola

1260
Diabetes mellitus (DM) is associated with worse outcomes in patients with primary biliary cholangitis (PBC) regardless of the presence of liver steatosis: results from the ColHai registry
Poster presentation
Presenter: María Del Barrio Azaceta

1278
Time to initiation of the second-line therapy obeticholic acid in patients with primary biliary cholangitis
Poster presentation
Presenter: Sonal Kumar

1294
Incidence of fungal and other opportunistic infections in patients with autoimmune hepatitis: a spanish multicentre study
Poster presentation
Presenter: ALVARO DIAZ-GONZALEZ

1317

Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid

Poster presentation

Presenter: Antonio De Vincentis

1354

Diagnostic and therapeutic trends in primary biliary cholangitis: insights from the european reference network registry (R-LIVER)

Poster presentation

Presenter: Alessio Gerussi

1380

Single-cell RNA sequencing of autoimmune hepatitis identifies pathogenic marker MIF and reveals distinctions between CD8-Tc-PDCD1 cells in autoimmunity and cancer

Poster presentation

Presenter: Chao Cai

1386

Acute liver injury with autoimmune features following SARS-CoV-2 vaccination in an ERN/IAIHG cohort: autoimmune hepatitis versus drug-induced autoimmune-like hepatitis

Poster presentation

Presenter: Benedetta Terziroli Beretta-Piccoli

1398

Optimization of treatment in patients with primary biliary cholangitis: Gamma-glutamyl transferase levels as an early prognostic marker for ursodeoxycholic acid response. Results from the ColHai registry

Poster presentation

Presenter: Flor M Fernandez-Gordón Sánchez

1446

Clinical benefits with maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study

Poster presentation

Presenter: Douglas B. Mogul

1448

Maralixibat improves growth in patients with progressive familial intrahepatic cholestasis: data from the MARCH/MARCH-ON trials

Poster presentation

Presenter: Regino P. Gonzalez-Peralta

1645

Seladelpar treatment increases fatty acid beta-oxidation and serum carnitine levels in patients with primary biliary cholangitis consistent with increased expression of the carnitine transporter OCTN2 and the mitochondrial carnitine shuttle

Poster presentation

Presenter: Yun-Jung Choi

1666

Improvements in serum bile acid levels are associated with improvements in key markers of liver health after maralixibat treatment in children with progressive familial intrahepatic cholestasis: data from the MARCH/MARCH-ON trials

Poster presentation

Presenter: Lorenzo D'Antiga

1848

Small duct primary sclerosing cholangitis is not associated with a heightened risk of colorectal cancer compared to inflammatory bowel disease alone

Poster presentation

Presenter: Sarah Al-Shakhshir

1870

Fatigue is not influenced by chronotype and is reported to be mainly muscular in patients with primary biliary cholangitis

Poster presentation

Presenter: Erica Nicola Lynch

1941

Quantitative assessment of anti-mitochondrial antibodies in primary biliary cholangitis: a cross-sectional analysis

Poster presentation

Presenter: Lorenzo Canova

1947

Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in primary biliary cholangitis

Poster presentation

Presenter: Giulia Francesca Manfredi

1949

Optimizing thiopurine therapy in autoimmune hepatitis (AIH): a multi-center study on monitoring metabolite profiles and co-therapy with allopurinol

Poster presentation

Presenter: Jan Philipp Weltzsch

1967

The role of transient elastography and enhanced liver fibrosis score in IgG4-hepato-pancreato-biliary related disease

Poster presentation

Presenter: Rodrigo Motta

2027

Factors associated with the real-world biochemical response to fibrate therapy in primary biliary cholangitis

Poster presentation

Presenter: Maria C. van Hooff

2035

Alkaline phosphatase levels at 6 months as a predictor of response to ursodeoxycholic acid at 1 year in patients with primary biliary cholangitis

Poster presentation

Presenter: Carmen Sendra

2083

Novel machine learning algorithm for risk prediction of cholangiocarcinoma in primary sclerosing cholangitis

Poster presentation

Presenter: Ewa Wunsch

2092

Improvement in lipid profiles with elafibranor treatment in primary biliary cholangitis during the phase III ELATIVE® trial

Poster presentation

Presenter: Marlyn J. Mayo

2138

Sex, ethnicity and clinical outcomes in autoimmune hepatitis: results from a large multicenter longitudinal cohort

Poster presentation

Presenter: Aldo J Montano-Loza

2146

Radiomics for prognostication in primary sclerosing cholangitis: a proof-of-concept using GLRLM run entropy

Poster presentation

Presenter: Laura Cristoferi

2176

The impact of ursodeoxycholic acid on biochemistry of patients with primary biliary cholangitis in a nationwide cohort
Poster presentation
Presenter: Ellen Werner

2195

Liver stiffness measurement by vibration-controlled transient elastography predicts adverse clinical outcomes in autoimmune hepatitis: results from a large multicenter longitudinal study
Oral presentation
Presenter: Aldo J Montano-Loza

2196

A prospective study on the causes of notable elevation of alanine aminotransferase (ALT) as well as elevation of both ALT and alkaline phosphatase (ALP) with special emphasis on drug-induced liver injury (DILI)
Poster presentation
Presenter: Sigurdur S. Sigurdarson

2202

Metabolomic signature by ¹H-NMR spectroscopy discriminates autoimmune hepatitis from other liver diseases
Poster presentation
Presenter: Kalliopi Zachou

2218

Paris II criteria are better than Poise to predict liver-related complications after second line therapy in patients with primary biliary cholangitis
Poster presentation
Presenter: Helena Hernández-Èvole

2240

Metabolomic signature in autoimmune hepatitis discriminates disease activity and predicts response to treatment
Poster presentation
Presenter: Kalliopi Zachou

2244

Pruritus in primary biliary cholangitis: exploring the itch phenomenon and its progression
Poster presentation
Presenter: Marcin Krawczyk

2283

Long term risk assessment of patients with primary sclerosing cholangitis using clinical prognosis models
Poster presentation
Presenter: Matei Manda

2336
Presence of cholestasis and its impact on survival in patients with COVID-19 associated acute respiratory distress syndrome
Poster presentation
Presenter: Mathias Schneeweiss-Gleixner

2341
Long-term variability of pruritus in primary sclerosing cholangitis and implications for future clinical trial design
Poster presentation
Presenter: Nasir Hussain

2347
Immunosuppressive treatment facilitates hepatic recompensation in patients with decompensated cirrhosis due to autoimmune hepatitis – a pilot study
Poster presentation
Presenter: Benedikt Hofer

2396
Risk of extrahepatic malignancies in patients with autoimmune hepatitis: a nationwide cohort study
Poster presentation
Presenter: Sung Won CHUNG

2426
Appraising gain of an extended 2-year placebo-controlled trial in primary biliary cholangitis: challenges for evaluating clinical outcomes
Poster presentation
Presenter: Bettina E. Hansen

2471
Landscape of gall bladder cancers in India: a 25 years experience at a tertiary care cancer centre
Poster presentation
Presenter: RUPAL TRIPATHI

2496
Evaluation of four chatbots in autoimmune liver disease: a comparative analysis
Poster presentation

Presenter: Jimmy Daza

2535

Ursodeoxycholic acid treatment for primary sclerosing cholangitis

Poster presentation

Presenter: Bregje Mol

2574

Liver steatosis assessed by controlled attenuation parameter in patients with primary biliary cholangitis

Poster presentation

Presenter: Carlo Saitta

2593

Non-invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis based on the cholestasis degree

Poster presentation

Presenter: Ciro Celsa

2614

Hepatic sarcoidosis diagnosis and management: an italian multicenter study

Poster presentation

Presenter: Cristina Della Corte

2673

Specific glycomic profiles can identify patients at risk of poor transplant-free survival in primary biliary cholangitis

Poster presentation

Presenter: Nicky Somers

2810

Harnessing synergy of 'triple' anti-cholestatic therapy in patients with primary biliary cholangitis

Poster presentation

Presenter: Guilherme Cançado

2906

Hydroxychloroquine as an adjuvant drug to immunosuppressive treatment to achieve histological remission in autoimmune hepatitis

Poster presentation

Presenter: Andreia Evangelista

2944

Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated liver cirrhosis in the open-label, long-term ASSURE safety study: interim results

Oral presentation

Presenter: Stuart C Gordon

2948

Rifaximin helps reduce cholestasis in patients with primary biliary cholangitis and increased fecal calprotectin

Poster presentation

Presenter: Laura Iliescu

3024

Recurrence of primary sclerosing cholangitis after living donor liver transplantation: experience from turkish registry

Poster presentation

Presenter: Gupse Adali

3029

Effects of HLA-G in primary biliary cholangitis: a study on a genetic isolate population

Poster presentation

Presenter: Michela Miglianti

3092

Lack of association between persistently raised serum transaminase levels and hepatic steatosis/steatohepatitis in autoimmune hepatitis (AIH)

Poster presentation

Presenter: Sarah Flatley

3132

Clinical outcome in patients with autoimmune hepatitis and its variant with primary sclerosing cholangitis

Poster presentation

Presenter: Karolina Wronka

3133

Second line therapy in patients with primary biliary cholangitis and inadequate response to UDCA: are we choosing the right target population for clinical trials?

Poster presentation

Presenter: Alejandra Villamil

3218

Prospective european reference network registry (R-LIVER) supports improvement in bone disease care delivery at local level for patients with autoimmune liver diseases and enables detailed description of risk elements

Poster presentation
Presenter: Boglarka Bozso

3230
Obeticholic acid normalizes inflammatory biomarkers in patients with primary biliary cholangitis
Poster presentation
Presenter: David E. Jones

3243
Risk of primary sclerosing cholangitis is increased among patients with gastritis – a nationwide cohort study
Poster presentation
Presenter: Lina Lindström

3288
Time to complete biochemical response and disease progression in autoimmune hepatitis
Oral presentation
Presenter: Martine A.M.C. Baven-Pronk

3290
Liver fibrosis in adolescents and young adults with autoimmune hepatitis: magnetic resonance elastography, transient elastography and liver fibrosis changes during transition of care
Poster presentation
Presenter: Maciej Janik

3306
Portal hypertension and its prognostic implications in patients with autoimmune hepatitis
Poster presentation
Presenter: Lukas Burghart

Immune-mediated and cholestatic: Experimental and pathophysiology

100
Claudin-1 is a mediator and therapeutic target of biliary fibrosis by modulating liver progenitor cell fate and signaling
Oral presentation
Presenter: Fabio Del Zompo

379

Itg-Cre/DTA mice develop the autoimmune biliary disease that serologically and pathogenically models human primary biliary cholangitis
Poster presentation
Presenter: Jiaqi Zhang

644
Advancements in liver biopsy analysis: convolutional neural networks for portal tract segmentation
Poster presentation
Presenter: Giorgio Cazzaniga

687
Molecular analysis of checkpoint inhibitor-induced liver injury
Poster presentation
Presenter: Sarp Uzun

811
SRT-015: Novel therapeutic for cholestatic liver diseases
Poster presentation
Presenter: Kathleen Elias

830
Assessment of PPARdelta target engagement in mouse liver assessed by single nuclei sequencing following a single oral dose of seladelpar.
Poster presentation
Presenter: Edward Cable

882
Plasmatic expression of miR122-5p and miR21-5p predicts relapse of autoimmune hepatitis after treatment withdrawal
Poster presentation
Presenter: Pinelopi Arvaniti

1032
Machine learning-driven identification of serum protein signature for primary sclerosing cholangitis and enhanced liver fibrosis score
Poster presentation
Presenter: Tom Snir

1135
Site-specific maturation dynamics of type 2 conventional dendritic cells connect with gamma delta T17 effector differentiation in cholestatic liver disease
Oral presentation
Presenter: Stefan Thomann

1286

Functional relevance of CD44 for hepatocyte proliferation in diet-induced liver injury models

Poster presentation

Presenter: Sophia Bernatik

1504

Immunokinetics of CD4⁺ T cells in primary sclerosing cholangitis by functional transcriptome analysis. Immunokinetics of CD4⁺ T cells in primary sclerosing cholangitis by functional transcriptome analysis

Poster presentation

Presenter: Naoya Kato

1509

Inhibition of bile acid conjugation improves DDC-induced cholestatic liver injury in mice with a humanized bile acid pool

Poster presentation

Presenter: Claudia Fuchs

1945

Primary biliary cholangitis symptoms are reduced in liver specific Mcpip1 knock-out mice after treatment with probiotic lactobacillus rharmentosus

Poster presentation

Presenter: Katarzyna Trzos

1962

Spatial characteristics of cell compartments in primary sclerosing cholangitis

Poster presentation

Presenter: Markus S. Jördens

1997

Single-cell profiling of intrahepatic T cells uncovers expanded Th17/MAIT cells with overlapping gene expression in primary sclerosing cholangitis

Oral presentation

Presenter: Lisa R. V. Brynjulfsen

2133

Aramchol, a stearyl-CoA desaturase inhibitor, attenuates the TGF β -stimulated fibroinflammatory signals by cholangiocytes in primary sclerosing cholangitis

Poster presentation

Presenter: Sayed Aseem

2136

TAZ and YAP play an interdependent role in biliary development and adaptation to cholestasis

Poster presentation
Presenter: Adelya Gabdulkhakova

2193

The role of interleukin-8 in primary sclerosing cholangitis-associated immune cell dysregulation

Poster presentation
Presenter: Lander Heyerick

2253

Galectin-3 and prohibitin 1 are autoantigens in IgG4-related cholangitis without clear-cut protective effects against toxic bile acids

Poster presentation
Presenter: David Trampert

2290

Impaired muscle metabolism during exercise is associated with elevated IL-6 in PBC patients with fatigue: is this a new therapeutic target?

Poster presentation
Presenter: Aaron Wetten

2344

The deletion of PTP1B protects against liver biliary damage by shifting immune cell recruitment and enhancing oval cell proliferation

Poster presentation
Presenter: Silvia Calero Pérez

2359

Single-cell RNA sequencing identifies the fundamental role of intrahepatic CD8+ T cells in the pathogenesis of autoimmune hepatitis

Poster presentation
Presenter: Ignasi Olivas

2400

PPAR-delta activation with seladelpar regulates cholangiocyte inflammation

Poster presentation
Presenter: Xia Wu

2462

Long-term, real-world outcomes under obeticholic acid treatment in primary biliary cholangitis: a nationwide multicentre study

Poster presentation
Presenter: Nadir Abbas

2639

Mitochondrial integrity and auto(mito)phagy are disrupted in experimental models of primary biliary cholangitis, contributing to disease pathogenesis

Poster presentation

Presenter: Irune Lasa-Elosegi

2654

Studying cholangiocyte properties and functions using a bile duct on a chip

Poster presentation

Presenter: Henry Hoyle

2676

A DNA methylation signature associated with inflammation is found in primary sclerosing cholangitis and IgG4-related cholangitis

Poster presentation

Presenter: Rodrigo Motta

2700

Generation and utilisation of an advanced iPSC-derived hepatocyte model for cholestasis modelling

Poster presentation

Presenter: Elena Garitta

2728

Metabolic reprogramming induced by pravastatin prevents polycystic liver disease progression improving mitochondrial bioenergetics in cystic cholangiocytes

Oral presentation

Presenter: Enara Markaide

2761

WTAP deficiency in mice hepatocyte induces cholestatic liver diseases by modulating nuclear receptor FXR

Poster presentation

Presenter: Chuanhui Peng

2813

Lysophosphatidic acid (LPA)-receptors, a group of established itch receptors, show elevated agonism during cholestasis and are likely to contribute to cholestasis-associated itch

Poster presentation

Presenter: Frank Wolters

2839

Interleukin-2 mediated regulatory T cell expansion is associated with dual outcomes of ductular reaction and liver fibrosis

Poster presentation
Presenter: Man Chun Wong

2964
Impaired hepatic sympathetic neuronal communication intensifies hepatic inflammation, fibrosis and metabolic dysregulation, exacerbating liver injury
Poster presentation
Presenter: Saddam H Bhat

3001
Moderate overexpression of c-Met in hepatocytes decreases cholestatic liver injury
Poster presentation
Presenter: Aránzazu Sánchez

3094
Mice lacking the NO receptor develop primary sclerosing cholangitis
Poster presentation
Presenter: Muhammad Ashfaq-Khan

3112
Induction of proliferative state and reduction of liver fibrosis by N-Acetyl-L-Cysteine in Mdr2^{-/-} mice: a mechanistic insight through spatial transcriptomics
Poster presentation
Presenter: Adi Har-Zahav

3189
Human leukocyte antigen-DRB1 expression in cholangiocytes of 'early' primary sclerosing cholangitis
Poster presentation
Presenter: Ynto de Boer

3200
Establishing a cholangioid library for biliary niche-on-a-chip multicellular models for the study of liver disease-associated ductular reaction
Poster presentation
Presenter: Tian Lan

3319
Targeting neutrophil injury-pathways and fibrogenesis in non-parenchymal immune tissue-like liver organoids generated from human induced pluripotent stem cells
Poster presentation
Presenter: Susanna Quach

Liver development and regeneration

182

Hepatic loss of the endosomal sorting complex Retromer delays postnatal liver maturation and increases hepatocellular proliferation

Poster presentation

Presenter: Markus Gregorio Barbosa

223

Small nucleolar RNA expression and their prognostic values in non-viral hepatocellular carcinoma

Poster presentation

Presenter: Venkata Ramana Mallela

492

β -arrestin2 promotes cytoskeleton polymerization through RhoA-Diaph2 signaling to activate YAP to mediate liver regeneration after hepatectomy in mice

Poster presentation

Presenter: Xiaolong Chen

782

New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: a human and experimental study

Poster presentation

Presenter: Matías A Avila

996

Expression and regulation of HNF4 α isoforms in liver development and disease

Oral presentation

Presenter: Paulina Zydowicz-Machtel

1179

Lysosomal protease contributes to hepatocyte proliferation during liver regeneration after partial hepatectomy

Poster presentation

Presenter: Julia Cacho-Pujol

1181

Metabolic needs dictate the regenerative capacity of the liver

Poster presentation

Presenter: Sara Guerra

1263

Collagen-integrin signaling re-establishes bile duct morphogenesis and promotes adult ductular regeneration

Oral presentation

Presenter: Alexander Walker

1775

The role of endothelial cells in the ductular reaction-driven regeneration

Oral presentation

Presenter: Rita Manco

1798

Trained immunity contributes to immunomodulatory plasticity of human bone marrow mesenchymal stem cells

Poster presentation

Presenter: Jun Li

1881

Regulatory role of host cell factor 1 in metabolic control and epigenomic integrity

Poster presentation

Presenter: Debashruti Bhattacharya

2490

Development of in vitro human organoid models for metabolic dysfunction-associated liver disease (MASLD)

Poster presentation

Presenter: Pooja Bhadoria

3043

TGR5 deficiency reduces angiocrine factor expression in liver sinusoidal endothelial cells and hepatocyte proliferation after partial hepatectomy

Oral presentation

Presenter: Impreet Kaur

3046

Liver lymphatic endothelial cells regulate hepatic progenitor cells via lymphangiocrine factors in pathological liver regeneration

Oral presentation

Presenter: Aarti Sharma

3061

Regenerative matrix-based hydrogels repair hepatocellular damage and promote cellular proliferation in pre-clinical models of acute liver injury

Poster presentation

Presenter: Ashwini Vasudevan

3221

Developmental gene regulatory networks driving human liver disease cell states identified by single cell multi-modal data integration

Oral presentation

Presenter: Karen Piper Hanley

Liver immunology

137

Testosterone modulates T cells in healthy individuals and women with autoimmune liver disease

Poster presentation

Presenter: Nico Will

497

Altered immune responses and PD-L1 levels in children with portal hypertension

Poster presentation

Presenter: Tengfei Si

626

Macrophage Dvl2-HSF1 axis regulates STING-mediated innate immunity and hepatocyte death in liver ischemia and reperfusion injury

Poster presentation

Presenter: Tao Yang

659

Distinct soluble and cellular immunological signatures in various entities of hepatitis flares

Poster presentation

Presenter: Roni Souleiman

715

Features of regulatory T cells in primary biliary cholangitis

Oral presentation

Presenter: Naomi Richardson

723

The anti-tumour effector function of mucosal-associated invariant T cells against hepatocellular carcinoma is impaired by fatty acids and aberrant lipid metabolism

Oral presentation

Presenter: Sebastian Deschler

825

Sustained macrophage alterations during injury regression beget increased susceptibility to infections

Poster presentation

Presenter: Moritz Peiseler

870

TIGIT+Tregs maintain tolerance in autoimmune hepatitis via CTLA-4 dependent suppressive mechanism

Poster presentation

Presenter: Amber Bozward

910

Elevated IL18R+CD8+T cells in Autoimmune Hepatitis patients are associated with a worse therapy response

Poster presentation

Presenter: Katharina Yankouskaya

918

Liver immunity index: predicting immune control of chronic hepatitis B from circulating CD8 T cells

Poster presentation

Presenter: Hannah Wintersteller

1233

High-dimensional spectral flow cytometry defines changes in circulating immune cell composition and responsiveness in patients with cirrhosis-associated immune dysfunction

Poster presentation

Presenter: Malgorzata Grzelka

1729

Mendelian randomization strengthens the crosstalk of immune traits with primary biliary cirrhosis and primary sclerosing cholangitis

Poster presentation

Presenter: Jing Xu

1872

Differential phenotypes of $\gamma\delta$ T cells in hepatitis E virus infection: implications for disease pathogenesis

Poster presentation

Presenter: Erich Freyer

1934

Study on the role of natural killer cells in chronic hepatitis B patients treated with intermittent interferon therapy
Poster presentation
Presenter: Xiaoyue Bi

1998
Neutrophil-derived miRNA-223 modulates peritoneal immunity in patients with cirrhosis during spontaneous bacterial peritonitis
Poster presentation
Presenter: Mick Frissen

2042
The role of the immune checkpoint TIGIT in CD4+ T cell dysfunction in patients with decompensated cirrhosis
Poster presentation
Presenter: Joseph Delo

2327
Oncogenic beta-catenin is using CD155 as a molecular actor to corrupt immunosurveillance of cold HCC
Poster presentation
Presenter: Joana Gonçalves Araujo

2437
Melatonin attenuates LPS-induced acute liver injury by reducing the formation of macrophage extracellular traps through upregulated sirtuin 4 expression
Poster presentation
Presenter: Jun Zheng

2454
Variations in dynamic T cell response are associated with the HCC recurrence treated with anti-PD-1 immunotherapy after interventional therapy
Poster presentation
Presenter: Yonghong Zhang

2493
Macrophage-derived IL-15 imprints peritoneal tissue-resident memory T cells during spontaneous bacterial peritonitis in patients with cirrhosis
Poster presentation
Presenter: Oluwatomi Ibidapo-Obe

2679

Deciphering the immunological dynamics of flares following nucleos(t)ide analogue (NA) cessation in HBeAg negative chronic hepatitis B in a large, longitudinal, phase II multi-centred clinical trial (NUC-B study)
Poster presentation
Presenter: Sandra Phillips

2716
CD8+ effector T cells expressing low levels of CD127 upregulate GPR56 expression and reside in the hepatic autoimmune and inflammatory microenvironment
Poster presentation
Presenter: Rémi Fiancette

2795
Th2 cell activation in chronic liver disease is driven by local IL-33 and contributes to IL-13 dependent fibrogenesis
Poster presentation
Presenter: Johanna Reißing

2848
Loss of fibronectin contribute to poor maturation of monocyte to resolving macrophages in acute and chronic liver injury
Poster presentation
Presenter: Sandeep Kumar

2868
Global and Kupffer cell specific Nlrp3 inflammsome in-/activation greatly affects the inflammatory and metabolic progression of alcohol-related liver disease
Poster presentation
Presenter: Lukas Geisler

2885
Cellular immunity changes induced by COVID-19 vaccines in patients with chronic liver disease
Poster presentation
Presenter: Carolina Palma

3006
The surface antigens of circulating small extracellular vesicles, as non-invasive markers of the immune mechanisms involved in liver diseases according to etiology
Poster presentation
Presenter: Albert Guinart-Cuadra

3013

F-actin in autoimmune liver diseases: a comprehensive evaluation of diagnostic potential using a newly-developed autoimmune liver line immunoassay

Poster presentation

Presenter: Christos Liaskos

3240

CD4+T cells license Kupffer cells to revert the CD8+T cell dysfunction induced by hepatocellular priming

Oral presentation

Presenter: Valentina Venzin

Liver transplantation and hepatobiliary surgery - Basic

138

MRI-serum based score accurately identifies liver transplant patients without rejection avoiding need for liver biopsy: a multisite european study

Oral presentation

Presenter: Elizabeth Shumbayawonda

284

Continuous hemodiafiltration prevents sinusoidal endothelial failure during extended ex situ normothermic perfusion of porcine livers

Poster presentation

Presenter: Jordi Vengohechea Llorens

339

Molecular phenotype of chronic antibody-mediated rejection in liver transplant biopsies

Oral presentation

Presenter: Alejandro Campos-Murguía

356

Liver transplantation due to biliary tract dysplasia in primary sclerosing cholangitis

Oral presentation

Presenter: Sigurd Breder

640

Myeloid Mas-dependent macrophage efferocytosis maintains immune homeostasis in the ischemia-stressed mouse and human livers

Poster presentation

Presenter: Shuai Chen

900

CYTOMEGALOVIRUS SPECIFIC POLYFUNCTIONAL T-CELLS CONTROL CMV REACTIVATION,
AFTER LIVER TRANSPLANTATION

Poster presentation

Presenter: Victoria Aguilera Sancho

1549

JNK signaling activates autophagy of CD8+T cells to promote acute rejection after liver transplantation in rats via regulating BECN1/BCL-2 interaction

Poster presentation

Presenter: Xiaowen Wang

1612

Kinetics of immune dysfunction in liver transplanted patients and impact on clinical outcome

Oral presentation

Presenter: Fanny Lebossé

2530

Functions and molecular mechanisms of metformin in ameliorating ischemia-reperfusion injury of steatosis liver by inhibiting ferroptosis

Poster presentation

Presenter: Rong Li

2642

Prognosticating hepatocellular carcinoma before and after liver transplantation with HepatoPredict

Poster presentation

Presenter: Joana Cardoso

2663

Adipose-derived stem cell therapy enhances liver regeneration in echinococcus multilocularis infected mice through activation of the wnt/beta-catenin/nestin signaling axis

Poster presentation

Presenter: Renyong Lin

2680

Long-term post-transplant emergence of metabolic syndrome is associated with gut microbial metabolites in urinary metabolomics

Poster presentation

Presenter: I. Jane Cox

2735

Circulating thrombospondin-2 as a novel, highly predictive serum marker of liver fibrosis progression post liver transplant

Poster presentation

Presenter: sudha rani myneni

3130

Livers undergoing extended ex situ normothermic machine perfusion develop Glutathione- and Methionine-cycle alterations that reverse following transplantation

Poster presentation

Presenter: Aida Vaquero-Rey

3138

Adipose tissue as a predictor of morbidity and mortality in patients listed for liver transplantation

Poster presentation

Presenter: Maxence Lepour

3147

De novo malignancies after liver transplantation: a twenty years long-single center experience

Poster presentation

Presenter: Stefano Fonte

Liver transplantation and hepatobiliary surgery - Clinical

113

Post-colectomy liver transplant recipients have higher rates of chronic kidney disease at 1-year

Poster presentation

Presenter: Victoria Kronsten

176

A visual classification scale of biliary anastomotic strictures with per-oral cholangioscopy predicts outcomes in liver transplant recipients

Poster presentation

Presenter: Andres Cardenas

240

Is there a need to screen for ischemic heart disease in liver transplant candidates without coronary calcification on routine chest CT?

Poster presentation

Presenter: Susan Fischer

347

Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients

Oral presentation
Presenter: Margaret C. Liu

402
The gender-equity model for liver allocation built on artificial intelligence (GEMA-AI) improves outcome predictions among liver transplant candidates
Oral presentation
Presenter: Manuel Rodríguez-Perálvarez

403
Validation of the gender-equity model for liver allocation (GEMA) in a nationwide cohort of liver transplant candidates in Spain
Poster presentation
Presenter: Manuel Rodríguez-Perálvarez

511
Liver transplantation in cystic fibrosis: the evolving landscape in the United Kingdom
Poster presentation
Presenter: Georgeina L Jarman

527
Impact of distance from liver transplant centre on outcomes following liver transplantation - an Australian single centre study
Poster presentation
Presenter: Simone Chin

647
Aging with a liver graft: analysis of very long-term survivors after liver transplantation
Poster presentation
Presenter: Paolo De Simone

816
Evolution of pre liver transplant cardiovascular risk factors and cardiac work-up: impact on post-transplant events
Poster presentation
Presenter: Margherita Saracco

847
Risk stratification of emergent living donor liver transplantation from a nationwide survey of the Republic of Korea
Poster presentation
Presenter: Jongman Kim

945

Retrospective population study of liver transplantation in Iceland – An update

Poster presentation

Presenter: Bjarki Leó Snorrason

992

Impact of lymphadenectomy for patients with clinically node-negative intrahepatic cholangiocarcinoma: a retrospective cohort study

Poster presentation

Presenter: Meng Sha

1005

Assessing sex differences in access to liver transplantation in Italy: a real-world nationwide study

Poster presentation

Presenter: Chiara Becchetti

1091

Bariatric surgery post-liver transplantation: a Belgian nationwide study

Poster presentation

Presenter: Louis Onghena

1098

Significance of routinely measured direct alcohol markers in long-term care after liver transplantation

Poster presentation

Presenter: Julia M. Grottenthaler

1136

Liver stiffness is associated with the results of long-term protocol biopsies in liver transplant patients recipients

Poster presentation

Presenter: Pauline Bozon-Rivière

1173

Socioeconomic deprivation is associated with worse outcomes after adult liver transplantation

Poster presentation

Presenter: Paolo De Simone

1237

Impact of recipient sex on long-term survival after liver transplantation in patients with high MELD

Poster presentation

Presenter: Laia Aceituno

1265

Long-term mortality and risk factors associated with mortality after liver transplantation in the modern era

Poster presentation

Presenter: Magdalena Meszaros

1351

Liver transplantation for biliary tract cancer in primary sclerosing cholangitis

Poster presentation

Presenter: Christina Villard

1381

Real-world evidence of magnesium isoglycyrrhizinate for perioperative protection against hepatic injury in patients undergoing hepatectomy

Poster presentation

Presenter: Changzhen Shang

1388

The relationship between spleen stiffness and portal hypertension liver transplant patients

Poster presentation

Presenter: Kanan Nuriyev

1394

Induction therapy using rabbit anti-thymoglobulin and IVIG for hyperimmunized liver transplant recipients

Poster presentation

Presenter: Nada EL-domiaty

1399

Impact of MELD 3.0 on waitlist outcomes of metabolic dysfunction-associated steatohepatitis cirrhosis among liver transplant waitlist registrants

Poster presentation

Presenter: Margaret Teng

1418

Sequential normothermic regional and end-ischemic ex-situ machine perfusion allows the safe use of very old DCD donors in liver transplantation (DCDNet trial)

Poster presentation

Presenter: Caterina Martinelli

1468

Liver transplantation in patients with autoimmune hepatitis: a large single-center study

Poster presentation

Presenter: Mohssen Nassiri-Toosi

1496

Increased prevalence of metabolic-alcohol liver disease in Europe and of metabolic dysfunction-associated steatotic liver disease in the Americas. Results of the global IMPROVEMENT study.

Poster presentation

Presenter: Luca Miele

1623

Model for end-stage liver disease score-based liver allocation is associated with reduced survival in low donation countries – a comparative analysis between Germany and the USA

Poster presentation

Presenter: Leke Wiering

1634

Everolimus and de novo malignancies after liver transplantation in a nationwide french cohort study: an emulated target trial

Poster presentation

Presenter: Ilias Kounis

1638

Everolimus and hepatocellular carcinoma recurrence post liver transplantation: insights from an emulated target trial

Poster presentation

Presenter: Ilias Kounis

1939

The clinical relevance of prior bariatric surgery in alcohol-related liver disease in a nationwide belgian liver transplant population

Poster presentation

Presenter: Sander Lefere

1960

Liver transplantation for steatotic liver disease: AC, AH, MASLD, and MetALD

Poster presentation

Presenter: Gene Im

1989

A HDL-based prognostic model performs better than MELD in chronic liver failure

Poster presentation

Presenter: Rudolf E. Stauber

2090

Assessment of the role of liver transplantation with or without combined kidney transplantation in polycystic liver or liver and kidney disease

Poster presentation

Presenter: Claire Francoz

2121

Long-term survival (≥ 20 years) after liver transplantation in Italy: a single center retrospective experience

Poster presentation

Presenter: Maria Francesca Donato

2182

Impact of ISO score on oncological outcomes and survival in HCC patients candidate for liver transplantation

Poster presentation

Presenter: Elisa Pinto

2236

Comparing outcomes in patients with portal vein thrombosis undergoing deceased-donor versus living-donor liver transplantation: insights from a major North American center

Poster presentation

Presenter: Zhihao Li

2248

Screening for asymptomatic coronary artery disease in liver transplant recipients: is it time to replace stress echocardiography with coronary CT angiography in selected patients?

Poster presentation

Presenter: Chiara Manuli

2278

Three- vs. six-monthly measurement of phosphatidylethanol (PEth) in the detection of alcohol use relapse after liver transplantation (RAULT) for alcohol-associated liver disease (ALD)

Poster presentation

Presenter: Lubomir Skladany

2310

Women are also disadvantaged in accessing transplant outside the United States: analysis of the spanish liver transplantation registry

Poster presentation

Presenter: Marina Berenguer

2352

Elaboration of a one-year mortality score for first elective liver transplantation recipients over 60 years based on the results of the french national cohort between 2007 and 2017

Poster presentation
Presenter: Marianne Latournerie

2372

Poor radiological – histopathological concordance in patients transplanted for hepatocellular carcinoma: a single centre experience
Poster presentation
Presenter: Mzamo Mbelle

2377

Artificial intelligence and liver transplantation: post-transplantation chronic kidney disease prediction
Poster presentation
Presenter: Veronique Loustaud-Ratti

2414

QuantIFERON monitor as an immune function assay predictive of clinical events in liver transplant recipients: a validation study
Poster presentation
Presenter: Tess McClure

2435

Racial disparities in the receipt of liver transplantation among african american patients with hepatocellular carcinoma in the United States: a systematic review
Poster presentation
Presenter: Nabil El Hage Chehade

2456

Outcome of simultaneous heart and liver transplants with HCC: analysis of US national database
Poster presentation
Presenter: Prasun Jalal

2513

Post-recurrence survival after liver transplantation for hepatocellular carcinoma: outcomes of an "orphan" disease
Poster presentation
Presenter: Marianna Maspero

2549

Immune checkpoint inhibitors after liver transplantation: the key role of immunosuppression management
Poster presentation
Presenter: Eleonora De Martin

2830

The yield of routine post-operative doppler ultrasound to detect early post-liver transplantation vascular complications

Poster presentation

Presenter: Iulia Minciuna

2873

Development of a model to preoperatively predict the risk of microvascular invasion for hepatocellular carcinoma patients undergoing liver transplantation

Poster presentation

Presenter: Quirino Lai

2880

Acute-on-chronic liver failure in severe acute alcoholic hepatitis: impact on management, prognostication, and urgency of liver transplantation

Poster presentation

Presenter: Giovanni Perricone

2915

“Early” vs “standard” liver transplantation in patients with severe alcoholic hepatitis

Poster presentation

Presenter: Raffaella Viganò

3058

Needle tract seeding of hepatocellular carcinoma after liver transplantation: a single center experience

Poster presentation

Presenter: Chiara Sicuro

3125

The survival benefit of liver transplantation for metabolic dysfunction associated steatotic liver disease: an Italian liver transplant registry study

Poster presentation

Presenter: Alessandro Vitale

3164

Liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma following neoadjuvant treatment with chemotherapy and radioembolization

Poster presentation

Presenter: Baptiste Giguet

3225

Evaluation of 18FDG-PET/CT for prediction of waitlist dropout and post transplantation recurrence in patients listed for hepato-cellular carcinoma

Poster presentation

Presenter: Catherine Lamarque

3269

Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival in an international multicentre cohort

Poster presentation

Presenter: Vincenzo Ronca

3281

Recipient donor sex constellation differences in outcome after liver transplantation for hepatocellular carcinoma – an ELTR study

Poster presentation

Presenter: Christian Magyar

3291

Detection of conventional adenomas and serrated lesions during repetitive colonoscopies after orthotopic liver transplantation

Poster presentation

Presenter: Christoph Schramm

Liver tumours: Clinical aspects except therapy

97

Lower frequency of PNPLA3 in african populations and divergent associations with hepatocellular carcinoma

Poster presentation

Presenter: Perapa Chotiprasidhi

354

Improved handling of BCLC 2022 update in the management of hepatocellular carcinoma in clinical practice

Poster presentation

Presenter: Eleonora Alimenti

390

Metformin as a protective factor against hepatocellular carcinoma in chronic hepatitis C patients achieving sustained virologic response: a long-term follow-up study

Poster presentation

Presenter: Henar Calvo

391

A modified Charlson comorbidity index to improve management of patients with hepatocellular carcinoma: a step towards precision medicine

Poster presentation

Presenter: Eleonora Alimenti

409

Utility of the GAAD algorithm in the screening of hepatocellular carcinoma in a prospective cohort of at-risk patients: preliminary results

Poster presentation

Presenter: Emily Larrea

454

Evaluation of the prognostic importance of Gustave Roussy immune score in hepatocellular carcinoma patients

Poster presentation

Presenter: Hatice Gülgün Fırat

569

Development of a preference elicitation tool for treatment choice in unresectable, early/intermediate stage HCC

Poster presentation

Presenter: Andrew Moon

610

The inflammatory state of tumor peripheral liver tissue affects hepatocellular carcinoma progression and prognosis

Poster presentation

Presenter: Zheyu Zhou

705

The impact of etiology on patterns of progression of advanced HCC

Poster presentation

Presenter: Bernardo Stefanini

760

Changes in the landscape of hepatocellular carcinoma – experience of a single tertiary center

Poster presentation

Presenter: Pompilia Radu

860

ASAP score may predict HCC recurrence after complete radiological response to locoregional treatments.

Poster presentation
Presenter: Lorenzo Canova

881

Incomplete thermal ablation plus programmed cell death protein 1 monoclonal antibodies increase the incidence of hyperprogressive disease in hepatocellular carcinoma.

Poster presentation
Presenter: Yuzhe Cao

955

Ethnic and racial disparities in the initial presentation of hepatocellular carcinoma: real-world data from a single non-academic hepatology clinic with a large diverse population in Los Angeles County

Poster presentation
Presenter: Isabella Martinez

967

The risk of hepatic decompensation in patients after the treatment for steatotic liver disease-related hepatocellular carcinoma

Poster presentation
Presenter: Tatsuya Minami

968

Real-World Data of Hepatocellular Carcinoma from 9 Asia-Pacific Countries (The INSIGHT Cohort): Overall Survival associated with choice of first therapy, number of lines of treatment and distance to hospital

Poster presentation
Presenter: Yu Ki Sim

1052

High SAFE scores stratify high risks of hepatocellular carcinoma in patients with chronic liver diseases

Poster presentation
Presenter: Tung-Hung Su

1068

Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Oral presentation
Presenter: Ciro Celsa

1079

The impact of tumor budding on tumor biology in patients with hepatocellular carcinoma
Poster presentation

Presenter: Osman Firat Duran

1147

Machine learning for risk stratification of hepatocellular carcinoma

Poster presentation

Presenter: Jan Clusmann

1204

Trends and evolution of hepatocellular carcinoma due to etiological shift from 2005 to 2020 in Germany: nationwide population-based study

Poster presentation

Presenter: Josune Cabello Calleja

1307

Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis

Poster presentation

Presenter: Laura Beretta

1344

Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: the prospective multicentric PET HCC01 study

Oral presentation

Presenter: Jean Charles Nault

1370

Impact of centre type on treatment and survival outcomes in hepatocellular carcinoma (HCC)

Poster presentation

Presenter: John Creamer

1374

Lesions hyper- to isointense to the surrounding liver in the hepatobiliary phase of gadoxetic acid enhanced MRI

Poster presentation

Presenter: Alicia Furumaya

1389

Development and validation of the CABLE score to estimate individual prognosis of patients with hepatocellular carcinoma treated with 1L atezolizumab and bevacizumab

Oral presentation

Presenter: Simon Johannes Gairing

1401

Competitive risk analysis of spleen stiffness measurement with a spleen-dedicated module (SSM@100Hz) for predicting de-novo HCC occurrence in cACLD patients: a prospective 5-year follow-up study

Poster presentation

Presenter: Federico Ravaioli

1443

Comparison of magnetic resonance imaging (MRI) characteristics of hepatocellular carcinoma (HCC) based underlying liver disease

Poster presentation

Presenter: Hyungjin Rhee

1453

Predicting non-responsive hepatocellular carcinoma to atezolizumab-bevacizumab therapy: a clinical and imaging-based scoring system

Poster presentation

Presenter: Jaeseung Shin

1571

Application of machine learning model-3P to predict portal hypertension in patients with hepatocellular carcinoma

Poster presentation

Presenter: Arianna Bertazzoni

1630

Intrahepatic cholangiocarcinoma: characteristics and outcomes of patients with or without underlying liver disease

Poster presentation

Presenter: Giulia Tesini

1647

A risk prediction model for hepatocellular carcinoma in general population without traditional risk factors for liver disease

Poster presentation

Presenter: Byeong Geun Song

1670

External beam radiotherapy promotes contralateral liver regeneration in primary liver cancer

Poster presentation

Presenter: Shizhong Yang

1677

Patterns and predictors of acute care utilization after liver-directed therapy for hepatocellular carcinoma

Poster presentation
Presenter: Andrew Moon

1751
Assessing the relationship between human plasma metabolites and hepatocellular carcinoma: a two-sample Mendelian randomization analysis
Poster presentation
Presenter: Xi Wei

1764
Impacts of COVID on HCC care cascade recommendation concordance: maintained surveillance rates and improved linkage to care
Poster presentation
Presenter: Joan Ericka Flores

1766
Cholangiocarcinoma across England: evidence of regional, socioeconomic, and temporal variations in incidence, survival, routes to diagnosis and treatment
Poster presentation
Presenter: Shahid Khan

1830
In the era of effective antiviral therapy, cured hepatitis C remains a main cause of HCC
Poster presentation
Presenter: Elena Vargas-Accarino

1843
The impact of competing risk bias in prognostic models for hepatocellular carcinoma in patients with cirrhosis
Poster presentation
Presenter: Laura Burke

1966
Conventional and machine-learning based risk score on survival for patients with hepatocellular carcinoma
Poster presentation
Presenter: CHUN-TING HO

2175
Active HCV or HBV infection does not impact on clinical outcomes in patients with hepatocellular carcinoma
Poster presentation
Presenter: Arianna Bertazzoni

2201

GALAD score is effective for HCC surveillance among high-risk patients

Oral presentation

Presenter: Grishma Hirode

2223

Risk of hepatocellular carcinoma and death among cirrhotics who carry genetic variants of epidermal growth factor, Adiponutrin and 17 β -Hydroxysteroid Dehydrogenase-13: a long-term cohort study

Poster presentation

Presenter: Carla De Benedittis

2230

Role of CD27 on IgD+ CD24+ B cell in mediating the effect of Lactobacillaceae on bile duct carcinoma

Poster presentation

Presenter: Xuanchen Liu

2303

Serum ammonia at the diagnosis of hepatocellular carcinoma predicts a higher risk of mortality

Poster presentation

Presenter: Pietro Guerra

2338

Validation and improvement of the IMbrave050 criteria for high-risk of HCC-recurrence as an indication to adjuvant treatment: results from a 4-year retrospective competitive-risk study

Poster presentation

Presenter: Federico Ravaioli

2358

External validation of hepatocellular carcinoma risk calculators following hepatitis C treatment in a large US cohort

Poster presentation

Presenter: Andrew Moon

2395

The differentiation of the effects of race and income status on predicting five-year survival rates for hepatocellular carcinoma. A descriptive analysis of the surveillance epidemiology and end results database

Poster presentation

Presenter: Samuel Kim

2515

Artificial intelligence for classifying liver lesions in contrast-enhanced ultrasound

Poster presentation

Presenter: Tobias Paul Seraphin

2558

Association between alpha-fetoprotein elevation and recurrence during postoperative surveillance in patients with achieved normalized alpha-fetoprotein after curative resection for hepatocellular carcinoma

Poster presentation

Presenter: Jeong Ah Hwang

2603

Study on the impact of specific HCC histotypes on patients prognosis

Poster presentation

Presenter: Monica Bernasconi

2681

Time-trends in cholangiocarcinoma mortality – a danish nationwide cohort study

Poster presentation

Presenter: Morten Daniel Jensen

2691

Different patterns of care and survival outcomes in transplant-centre managed patients with early-stage HCC – real-world data from an australian multicentre cohort study

Poster presentation

Presenter: Jonathan Abdelmalak

2773

Comparative performance of GAAD and ASAP scores in predicting early-stage hepatocellular carcinoma

Poster presentation

Presenter: Chongkonrat Maneenil

2896

The CRAFTY score to predict hepatocellular carcinoma disease control rate at month 12 in patients undergoing transarterial chemoembolization

Poster presentation

Presenter: Rhea Veelken

2905

Spleen stiffness measurement accurately predicts clinically significant portal hypertension in patients with hepatocellular carcinoma

Poster presentation

Presenter: Razvan Rababoc

3009

Comparative performance of GAAD and ASAP scores for predicting hepatocellular carcinoma in MASLD and other etiologies

Poster presentation

Presenter: Chongkonrat Maneenil

3041

Revolutionizing post-surgical outcome predictions: non-invasive tests and AI for hepatocellular carcinoma patients

Poster presentation

Presenter: Iuliana Nenu

3121

Bile extracellular vesicles hold protein biomarkers for the early diagnosis of cholangiocarcinoma in individuals with primary sclerosing cholangitis

Oral presentation

Presenter: Ainhoa Lapitz

3270

Hepatocellular carcinoma surveillance in an european tertiary hospital. Where are we failing?

Poster presentation

Presenter: Francisco Capinha

3357

Definite characterization of well-differentiated hepatocellular lesions on biopsy: a 20-year retrospective institutional analysis in the United States of diagnostic challenging cases with long term follow-up

Poster presentation

Presenter: Swachi Jain

Liver tumours: Experimental and pathophysiology

111

Urinary microbiome-based metagenomic signature for the noninvasive diagnosis of hepatocellular carcinoma

Poster presentation

Presenter: Eun Ju Cho

206

A metastasis-resident B cell subset serves as tumoricidal effectors with checkpoint-expressing in colorectal cancer liver metastasis

Poster presentation

Presenter: Yujie Bao

401

Anti-MFAP-5 siRNA loaded polycarbonate nanohydrogels for anti-stromal therapy in hepatocellular carcinoma

Poster presentation

Presenter: Paul Schneider

498

Low-density neutrophils display transcriptome profiles similar to the polymorphonuclear myeloid-derived suppressor cells and predict survival and recurrence in hepatocellular carcinoma patients

Poster presentation

Presenter: Chien-Hao Huang

519

Loss of Toll-like receptor 9 protects from hepatocellular carcinoma in murine models of chronic liver disease

Poster presentation

Presenter: Hannes Hatten

531

NADPH oxidase 1 inhibition as therapeutic strategy in hepatocellular carcinoma: insights from human-relevant models

Poster presentation

Presenter: Zenzi De Vos

575

Outcome of targeting ATR in high replication stress murine HCC

Poster presentation

Presenter: Jing Fang

690

The oncogenic m6A demethylase FTO promotes tumorigenesis and immune escape by upregulating GPNMB in hepatocellular carcinoma

Poster presentation

Presenter: Vanilla Xin Zhang

696

CHKA, a potential target marker for early-stage metabolic dysfunction associated steatotic liver disease induced hepatocellular carcinoma with low fibrosis level: analysis by metabolomic and transcriptomic

Poster presentation

Presenter: Jihan SUN

732

Implications and therapeutic potential of neddylation for pediatric liver cancer: hepatoblastoma

Poster presentation

Presenter: Leidy Estefanía Zapata-Pavas

768

Enhancing the response of cholangiocarcinoma to chemotherapy by inhibiting MRP3-mediated drug export

Poster presentation

Presenter: Rocio Macias

978

ERAL1 down-regulates NADH: ubiquinone oxidoreductase core subunit V1 through N6-methyladenosine reader Insulin like growth factor 2 mRNA binding protein 2 to inhibit mitochondrial adenosine triphosphate synthesis and metastasis in hepatoma cells

Poster presentation

Presenter: Li Zhou

1049

Restoring retinoic acid receptor-related orphan receptor alpha reduces intrahepatic cholangiocarcinoma proliferation and modulates cancer-associated fibroblasts

Poster presentation

Presenter: Laura Sererols Viñas

1119

Intratumoural microbiome alterations predict postoperative recurrence and mortality in hepatocellular carcinoma after hepatic resection

Poster presentation

Presenter: Saisai Zhang

1174

Aminoacyl-tRNA synthetases characterization and clinical potential in aggressive hepatocellular carcinoma

Poster presentation

Presenter: Natalia Hermán-Sánchez

1196

Fatty acids accumulate in intrahepatic cholangiocarcinoma-derived tissue and sera

Poster presentation

Presenter: Stefania Mantovani

1251

Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Poster presentation

Presenter: Sarah Cappuyns

1270

Identifying unique cell states in early liver oncogenesis with transcription coupled repair

Poster presentation

Presenter: Elizabeth Carmichael

1277

Caspases compromise SLU7 and UPF1 stability and nonsense-mediated RNA decay activity during hepatocarcinogenesis

Poster presentation

Presenter: Carla Rojo

1378

Novel genetic loci for hepatocellular carcinoma identified through genome-wide association study meta-analysis from 909,722 individuals

Poster presentation

Presenter: Jake Mann

1713

Effect of the metabotropic glutamate receptor 3 on liver cell survival: a potential biomarker in hepatocarcinoma

Poster presentation

Presenter: Isabel Méndez

1717

Promoter DNA demethylation restores CYGB expression and attenuates hepatocellular carcinoma progression

Poster presentation

Presenter: Hoang Hai

1746

New 3D chimeric model to study hepatic stellate cell activation during primary liver cancer

Poster presentation

Presenter: Alba Herrero

1754

Role of the splicing factor PCBP2 in cholangiocarcinoma malignancy and chemoresistance

Poster presentation

Presenter: Candela Cives-Losada

1758

Gut microbiome signature is distinct in cirrhosis with HCC compared to cirrhosis without HCC and controls in a southeast asian cohort and is linked with gut permeability and metabolite biomarkers

Poster presentation

Presenter: Thananya Jinato

1800

Platelet-derived extracellular vesicles (PEVs) as a potential biomarker for hepatocellular carcinoma (HCC)

Poster presentation

Presenter: Ángela Rojas

1854

Immune checkpoint profiles on circulating extracellular vesicles predict response to immunotherapy in hepatocellular carcinoma

Oral presentation

Presenter: Ramsha Masood

1859

Metabolic dysfunction associated steatohepatitis derived HCC model mouse for immunoncology

Poster presentation

Presenter: Taishi Hashiguchi

1928

Liver cancer in ovo models for preclinical testing

Poster presentation

Presenter: Zuzana Macek Jilkova

1957

CLEC14A regulates neutrophil recruitment across liver endothelial cells and correlates with a neutrophil signature in hepatocellular carcinoma

Poster presentation

Presenter: Shishir Shetty

1986

Claudin-1 is a driver for cholangiocarcinoma by modulating cancer cell plasticity and fate

Oral presentation

Presenter: Zeina Nehme

1990

Histological and molecular characterization of GAN diet-induced obese mouse model of advanced fibrosing MASH with progression to HCC

Poster presentation

Presenter: Michael Feigh

2023

NKT cells play a protective role against MASH-derived HCC, particularly in female Balb/c mice

Poster presentation

Presenter: Carlos Cuño-Gómez

2032

Mitochondrial metabolism is disrupted by ciprofloxacin preventing cholangiocarcinoma cell proliferation

Poster presentation

Presenter: Mikel Ruiz de Gauna

2079

Impact of proliferative and metabolic reprogramming by the lysine-specific demethylase 1 in hepatocellular carcinoma

Poster presentation

Presenter: Jie Wang

2101

The role of OSM/OSMR β axis in shaping the immune-microenvironment favouring MASLD-related HCC immune evasion

Poster presentation

Presenter: Beatrice Foglia

2169

CRISPR metabolic screen identifies UXS1 as a driver of hepatocellular carcinoma progression via regulating hippo signaling pathway

Poster presentation

Presenter: Haoying Ke

2247

Cabozantinib induces mtDNA-dependent cytotoxicity through cGas-STING signaling in experimental hepatocellular carcinoma

Poster presentation

Presenter: Patricia Rider

2311

Efficacy of WNTinib, a novel selective therapeutic for CTNNB1 mutant tumors, in preclinical models of hepatoblastoma

Poster presentation

Presenter: Ugne Balaseviciute

2326

Spatial single-cell profiling and network analysis reveal the immune architecture of hepatocellular carcinoma associated with immune checkpoint inhibitor therapy outcome

Oral presentation

Presenter: Henrike Salié

2424

ACSL4 affects the invasion and metastasis of hepatocellular carcinoma by regulating the activation of arachidonic acid

Poster presentation

Presenter: Yusufukadier Maimaitinijati

2583

Multi-dimensional profiling of hepatoblastomas and patient-derived tumor organoids uncovers tumor subpopulations with divergent WNT activation profiles and drug sensitivities

Poster presentation

Presenter: Weng Chuan Peng

2584

Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma

Poster presentation

Presenter: Mirco CASTOLDI

2618

Targeting inflammasome activation by sorafenib/regorafenib as strategy to enhance efficacy in hepatocellular carcinoma therapy

Poster presentation

Presenter: Anna Tutusaus

2621

TOX3 inhibits the progression of HCC through Jag1/Notch2 pathway

Poster presentation

Presenter: Shaoping She

2625

Aurora kinase A and programmed death-ligand 1: expression dynamics in hepatocellular carcinoma development and the regulatory role of the kinase in immune checkpoint modulation

Poster presentation

Presenter: Luca Grisetti

2628

Prediction of TERT promoter mutations using MALDI imaging and artificial intelligence in small hepatocellular nodules in cirrhosis

Poster presentation

Presenter: Helene Cazier

2640

Functional role of CD44+ cancer stem cells in intrahepatic cholangiocarcinoma

Oral presentation

Presenter: Paula Cantalops Vilà

2696

Single-cell sequencing reveals differential efficacy of targeted therapy combined with immunotherapy in patients with hepatocellular carcinoma

Poster presentation

Presenter: Boxiang Zhang

2712

Immunosuppressive CD73 is upregulated on tumour endothelium and may limit effective immune infiltrate in hepatocellular carcinoma

Poster presentation

Presenter: Rosemary Faulkes

2714

Phosphoinositide 3-kinase delta promotes plasticity and development of the microenvironment in cholangiocarcinoma

Poster presentation

Presenter: Nassima BENZOUAIR

2781

Tumor cell lines and patient derived xenograft models of intrahepatic cholangiocarcinoma maintain histology, transcription profiles and driver mutations of primary tumor but lose human stroma

Poster presentation

Presenter: Denise Schlösser

2806

KDM2A chromatin regulator constrains senescence program and immunoresponse in liver cancer

Poster presentation

Presenter: Elisa Morganti

2855

Engineering NK cell immunotherapy to optimise liver homing and T cell regulation

Poster presentation
Presenter: Mariana Diniz

2878

Metformin boosts the sensitivity of hepatocellular carcinoma to sorafenib via reshaping the tumor microenvironment metabolism

Poster presentation
Presenter: Juan Gao

2917

Characterization of the intratumoral immune microenvironment of hepatocellular carcinoma before selective intrahepatic radiation therapy (SIRT) and study of its prognostic value on response to treatment

Poster presentation
Presenter: Maria Stella Franzè

2937

The fetal insulin receptor isoform stimulates liver carcinogenesis through non-cell autonomous mechanisms

Poster presentation
Presenter: Fanny Leandre

3015

Analysis of HBV DNA integration in patients with intrahepatic cholangiocarcinomas and overt or occult HBV infection

Poster presentation
Presenter: Daniele Lombardo

3054

Counterfactual explanations for histopathology slides of hepatocellular carcinoma and cholangiocarcinoma enhance the understanding of artificial intelligence models

Poster presentation
Presenter: Laura Žigutytė

3060

Mannose receptor (CD206) as a therapeutical target in the liver metastatic microenvironment of colorectal cancer

Poster presentation
Presenter: Ines Alonso

3104

CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis

Poster presentation

Presenter: Marlene Kohlhepp

3136

Tumour, immune and parenchymal cell neighbourhoods correlate with survival after cholangiocarcinoma resection

Oral presentation

Presenter: Adrien Guillot

3322

Deciphering the role of FXR in the rewiring of Treg polarization in hepatocellular carcinoma

Poster presentation

Presenter: Yasmeen Attia

3333

Role of ganglioside GD2 in the stem-like compartment of intrahepatic cholangiocarcinoma

Poster presentation

Presenter: Mirella Pastore

Liver tumours: Therapy

193

Efficacy and safety of neoadjuvant therapy in narrow-margin hepatocellular carcinoma: a propensity score matching analysis

Poster presentation

Presenter: Shizhong Yang

293

Predictive genomic biomarkers for Atezolizumab plus Bevacizumab combination immunotherapy response in liver cancer: insights from the IMbrave150 trial

Oral presentation

Presenter: Ju-Seog Lee

360

No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC

Poster presentation

Presenter: Francisca Copil

361

Treatment with Atezolizumab-Bevacizumab for hepatocellular carcinoma in the french population outside clinical trials: data from the prospective CHIEF cohort

Poster presentation

Presenter: Manon Allaire

387

Networks in focus: profile of immune-related adverse events in first-line immunotherapy for hepatocellular carcinoma

Poster presentation

Presenter: Marta Fortuny

395

Systemic therapy of hepatocellular carcinoma on non-cirrhotic liver: a prospective spanish multicentre study

Poster presentation

Presenter: Jorge Barajas

396

RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with Atezolizumab plus Bevacizumab

Poster presentation

Presenter: Bohyun Kim

419

Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy

Oral presentation

Presenter: Bernhard Scheiner

473

Tumor burden incorporating AFP improves survival prediction for patients with HCC undergoing TACE: an international multicentre observational study

Poster presentation

Presenter: Guohong Han

552

Selective internal radiation therapy for unresectable hepatocellular carcinoma in a tertiary center in France, update and final analysis

Poster presentation

Presenter: H el ene Regnault

650

Evaluation of overall survival by restricted mean survival time in advanced biliary tract cancer treated with immunotherapy: a systematic review and meta-analysis

Poster presentation

Presenter: Ezequiel Mauro

709

Safety and efficacy preliminary analysis of first-line systemic therapy with atezolizumab plus bevacizumab in Spanish patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy: phase IIIb ATHECA trial

Poster presentation

Presenter: María Reig

728

Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Poster presentation

Presenter: Kei Endo

736

The features of gut microbiota and metabolites in non-viral unresectable hepatocellular carcinoma undergoing immunotherapy

Poster presentation

Presenter: Pei-Chang Lee

752

Impact of varices on bleeding risks and overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Poster presentation

Presenter: Jeayeon Park

794

Fecal microbiota transplant combined with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab – interim analysis of the FAB-HCC phase II pilot study

Poster presentation

Presenter: Katharina Pomej

818

Safety and Efficacy of Atezolizumab-Bevacizumab in Non-Viral and Viral Etiologies of Hepatocellular Carcinoma: A Multicenter Retrospective Comparative Study

Poster presentation

Presenter: ANAND KULKARNI

840

Efficacy and Safety of Hypofractionated Radiotherapy Combined with Sintilimab and Bevacizumab in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A preliminary single-center prospective study

Poster presentation

Presenter: Xiao Fu

845

Predicting post-hepatectomy liver failure in patient with hepatocellular carcinoma: nomograms based on deep learning-analyzed gadoxetic acid-enhanced hepatobiliary phase images

Poster presentation

Presenter: Boryeong Jeong

846

Surgical outcomes of laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: Multicenter study

Poster presentation

Presenter: Jongman Kim

1050

Everolimus mitigates the risk of hepatocellular carcinoma recurrence after liver transplantation

Poster presentation

Presenter: Paolo De Simone

1072

Prognostic significance of liver decompensation, liver function and portal hypertension in cirrhotic patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab

Poster presentation

Presenter: Maria Pallozzi

1112

An artificial intelligence-derived model for classification of tumor morphology based on computed tomography images in patients with hepatocellular carcinoma

Poster presentation

Presenter: I-Cheng Lee

1113

Curative therapy after atezolizumab-bevacizumab and role of liquid biopsy in patient selection

Poster presentation

Presenter: ANAND KULKARNI

1285

Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitor-based therapy – first results from an international multicenter registry

Poster presentation

Presenter: Ursula Ehmer

1364

Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma: a multicentric retrospective study

Poster presentation

Presenter: Clémentine ALITTI

1426

Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease (MASLD): multicenter study comparing patients with or without underlying cirrhosis

Poster presentation

Presenter: Carole Vitellius

1593

Upfront multi-bipolar radiofrequency ablation for hepatocarcinoma in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence

Poster presentation

Presenter: Carina Boros

2047

Identification of biomarkers for the treatment efficacy of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, based on chemokine alterations during treatment

Poster presentation

Presenter: Tomoharu Yamada

2170

Hepatic resection in patients with hepatocellular carcinoma: the message coming from real world data

Poster presentation

Presenter: Lorenzo Lani

2234

Atezolizumab/bevacizumab as downstaging in hepatocellular carcinoma: an intention-to-transplant analysis

Poster presentation

Presenter: Marianna Maspero

2245

Analysis of treatment benefits and prognostic factors for post-transplant hepatocellular carcinoma recurrence in a large Euro-American-Asian cohort

Poster presentation

Presenter: Zhihao Li

2255

Baseline neutrophil-to-lymphocyte ratio, liver disease etiology and morphomolecular histological classification could predict clinical outcome in Atezolizumab-Bevacizumab treated cirrhotic patients with advanced hepatocellular carcinoma
Poster presentation
Presenter: Spyridon Pantzios

2324

ARMCENVIN: multibipolar radiofrequency ablation of HCC using intratumourous versus extratumourous “no-touch” techniques. French multicentric randomized controlled trial (NCT 01008657)
Oral presentation
Presenter: Olivier Seror

2399

Clinical efficacy of HAIC (FOLFOX) combined with tyrosine kinase inhibitors plus PD-1 inhibitors vs. HAIC combined with bevacizumab plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma
Poster presentation
Presenter: Wenwen Zhu

2429

External beam radiation therapy improves the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombosis
Poster presentation
Presenter: Yunjeong Lee

2466

Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis
Poster presentation
Presenter: Hyun Young Woo

2506

Liver transplantation following hepatocellular carcinoma downstaging with atezolizumab/bevacizumab: preliminary results of the prospective ImmunoXXL study
Oral presentation
Presenter: Sherrie Bhoori

2538

Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma
Poster presentation
Presenter: Alina Pascale

2609

Outcomes of ultrasound-guided artificial ascites induction to facilitate radiofrequency ablation for hepatocellular carcinoma in high-risk positions

Poster presentation

Presenter: Ahmed Hashim

2633

Off-label use of nivolumab beyond first-line in advanced hepatocellular carcinoma: experience from two international centres

Poster presentation

Presenter: Silvia Gaia

2657

From randomised clinical trials to clinical practice: a systematic review and meta-analysis of real-world data on atezolizumab plus bevacizumab for advanced hepatocellular carcinoma

Poster presentation

Presenter: Giulia Francesca Manfredi

2718

Hepatic and peripheral blood neutrophil: lymphocyte ratios offer paradoxical associations with clinical outcome in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors plus transarterial chemoembolization

Poster presentation

Presenter: Paul Armstrong

2730

Adoptive natural killer cell immunotherapy can increase the recurrence-free survival following transarterial-chemoembolization in patients with intermediate stage hepatocellular carcinoma

Oral presentation

Presenter: Jooho Lee

2871

Pre-treatment serum N-glycans predict poor immunotherapy response and survival in hepatocellular carcinoma

Poster presentation

Presenter: Nicky Somers

2916

aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Poster presentation

Presenter: Mathew Vithayathil

2927

Complications of transarterial chemoembolization for hepatocellular carcinoma- 10 years' experience of a tertiary center

Poster presentation

Presenter: Laura Iliescu

2942

Predicting the efficacy and prognosis of immunotherapy combination therapies for hepatocellular carcinoma based on radiomics and deep learning

Poster presentation

Presenter: Xin Song

2973

Immunotherapy in cholangiocarcinoma: understanding the immune landscape reveals treatment response

Poster presentation

Presenter: Rita Balsano

3098

Induction of systemic immune activation by liver transplant and effects of previous VEGF/PD-L1 blockade in HCC patients

Poster presentation

Presenter: Licia Rivoltini

3197

A multi-center comparison of Atezolizumab plus Bevacizumab and Lenvatinib as primary systemic therapy for unresectable hepatocellular carcinoma: focus on thrombotic and hemorrhagic adverse events

Poster presentation

Presenter: Marco Tizzani

3262

Sorafenib as a second-line treatment after failure of Atezolizumab/Bevacizumab

Poster presentation

Presenter: Benedetta Stefanini

3268

Analysis of varix bleeding after Atezolizumab plus Bevacizumab for advanced hepatocellular carcinoma patients

Poster presentation

Presenter: Ahlim Lee

3321

Impact of antibiotic exposure and co-medication on the efficacy of immunotherapy for the treatment of advanced hepatocellular carcinoma

Poster presentation

Presenter: Matthias Jeschke

3378

mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma

Oral presentation

Presenter: Bruno Sangro

MASLD: Clinical aspects except therapy

230

Causes of death, mortality rates, and the role of socio-demographic risk factors and biomarkers in metabolic dysfunction-associated steatohepatitis mortality in more than 18,000 real world patients from the United States

Poster presentation

Presenter: Jörn M Schattenberg

259

All-cause and disease-specific mortality in patients with metabolic-dysfunction associated steatotic liver disease

Poster presentation

Presenter: Eun Ju Cho

292

Risk factors for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: ian yang liew

340

Diagnosed prevalence of cardio-renal diseases, mental health disorders, sleep apnea, cancer, and mortality rates in more than 18,000 patients with metabolic dysfunction-associated steatohepatitis with and without cirrhosis from the United States

Poster presentation

Presenter: Jörn M Schattenberg

393

Insulin resistance and sarcopenia as comorbid conditions in patients with MASLD

Poster presentation
Presenter: Kateryna Pivtorak

445
Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up
Poster presentation
Presenter: Hun Jee Choe

469
Low-to-moderate alcohol consumption is associated with increased fibrosis in subjects with metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: María Teresa Arias Loste

537
Health-Related Quality of Life (HRQL) assessments in a 52-Week, double-blind, randomized, placebo-controlled phase 3 study of Resmetirom (MGL-3196) in patients with nonalcoholic steatohepatitis (NASH) and fibrosis (MAESTRO-NASH)
Poster presentation
Presenter: Zobair Younossi

567
Mendelian-randomization study revealed causal relationship between non-alcoholic fatty liver disease and osteoporosis/fractures
Poster presentation
Presenter: Wei Jiang

568
Non-obese nonalcoholic fatty liver disease and the risk of chronic kidney disease: a literature review and meta-analysis
Poster presentation
Presenter: Yixian You

617
Depression as a determinant of metabolic dysfunction-associated steatotic liver disease (MASLD) risk in the Paracelsus 10,000 study
Poster presentation
Presenter: Florian Koutny

643
Muscle function and walking time are associated with better quality of life in MASLD patients
Poster presentation
Presenter: Roberta Forlano

649

The unrecognised burden of pruritus in metabolic dysfunction associated steatotic liver disease

Poster presentation

Presenter: Nasir Hussain

661

Dynamic of cardiometabolic components are highly correlated with the risk of hypertension and diabetes among patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Chin-I Shih

783

Steatotic liver disease subclasses have prognostic relevance for liver-related outcomes in the general population

Poster presentation

Presenter: Ville Männistö

788

Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease is Independently Associated with Reduced Kidney Function

Poster presentation

Presenter: Gres Karim

848

qBallooning: AI-based ballooned hepatocyte detection and quantification by second harmonic generation/two photon excitation microscopy

Poster presentation

Presenter: Dean Tai

849

Validation of optimal liver biopsy size for reliable quantitation of fibrosis severity in different areas and structures of liver lobule using second harmonic generation microscopy with artificial intelligence analyses

Poster presentation

Presenter: Nikolai V Naoumov

878

Differential prevalence and prognostic value of metabolic syndrome components among metabolic-dysfunction associated steatotic liver disease (MASLD) patients

Poster presentation

Presenter: Jesse Pustjens

923

Modeling the burden of steatotic liver disease and its subcategories in people living with HIV in Germany

Poster presentation

Presenter: Maurice Michel

933

Risk of all-cause mortality and adverse outcomes from steatotic liver disease and its subgroups in the general population

Poster presentation

Presenter: Maurice Michel

956

Association between liver fibrosis, mental health, and lifestyle behaviors in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Poster presentation

Presenter: Tayla Robertson

960

In Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Clinically Significant Pruritus is Associated with High Serum Bile Acid (BA) Level and Advanced Fibrosis (AF)

Poster presentation

Presenter: Zobair Younossi

1054

Severity of hepatic steatosis measured with controlled attenuation parameter as a determinant of carotid atherosclerosis in the Raine Study

Poster presentation

Presenter: Oyekoya Ayonrinde

1055

An intergenerational study of the prevalence and cardiometabolic significance of steatotic liver disease in adults in the Raine Study

Poster presentation

Presenter: Oyekoya Ayonrinde

1082

Temporal trends in the profile of non-alcoholic fatty liver disease: a decadal experience

Poster presentation

Presenter: Prajna Anirvan

1100

Prevalence and mortality of the spectrum of steatotic liver disease (SLD) in the US populations

Poster presentation

Presenter: Zobair Younossi

1111

A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Ian P. O'Connor

1125

Increased risk of mortality in metabolic dysfunction-associated steatotic liver disease: a nationwide population-based cohort study

Poster presentation

Presenter: Seung Up Kim

1129

Racial disparities in incidence of cirrhosis and extrahepatic manifestations in metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Majd Aboona

1166

Characteristics and risk of major adverse liver outcomes & major cardiovascular events among Swedish patients with diagnosed and high risk of metabolic dysfunction-associated steatohepatitis – a REVEAL-MASH study

Oral presentation

Presenter: Hannes Hagström

1188

Hepatic steatosis contributes to cognitive impairment in patients with metabolic dysfunction-associated steatotic liver disease and/or type 2 diabetes-mellitus

Poster presentation

Presenter: Nuria Pérez Diaz del Campo

1223

Genetic determinants of disease progression in metabolic dysfunction-associated liver disease patients unresponsive to lifestyle intervention: implications for personalized medicine

Poster presentation

Presenter: Aruhan Yang

1239

Cost of inaction for metabolic dysfunction-associated steatohepatitis (MASH): the projected economic burden in the United States

Poster presentation

Presenter: Zobair Younossi

1241

Pruritus is frequent, burdensome, and persistent in metabolic dysfunction-associated steatohepatitis (MASH) and primary biliary cholangitis (PBC): a 6-month longitudinal study

Poster presentation

Presenter: Anna Halliday

1281

Association of severity of metabolic dysfunction-associated steatotic liver disease with gut dysbiosis and shift in the metabolic function of the gut microbiota in people with HIV

Poster presentation

Presenter: Luz Ramos Ballesteros

1300

Risk of non-alcoholic steatohepatitis disease progression to more severe liver disease in medicare patients

Poster presentation

Presenter: Robert G. Gish

1311

A real-life multidisciplinary clinic approach for the management of metabolic dysfunction associated steatotic liver disease

Poster presentation

Presenter: Raluca Pais

1314

Costs associated with non-alcoholic steatohepatitis disease progression in medicare patients

Poster presentation

Presenter: Robert G. Gish

1333

Genetically determined circulating protein biomarkers and risk of advanced fibrosis

Poster presentation

Presenter: Jun Wang

1385

Metabolic dysfunction-associated steatotic liver disease and low handgrip strength are independently associated with a higher risk for cardiovascular disease

Poster presentation

Presenter: Seung Up Kim

1393

Regional fibrosis progression analysed by digital pathology with artificial intelligence is associated with renal dysfunction

Poster presentation

Presenter: Dan-Qin Sun

1477

Lower aspartataminotransferase activity is associated with dynapenia in middle-aged patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Anna Sheptulina

1498

Hepatitis C infection increases the risk of new-onset HTN and DM among patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Ping-Tsung Shih

1510

Steatotic liver disease with normal liver enzyme: clinical use of ultrasound attenuation method and shear wave elastography

Poster presentation

Presenter: Shunsuke Sato

1515

Natural history of lean and non-lean metabolic dysfunction associated steatotic liver disease

Poster presentation

Presenter: Shun-ichi Wakabayashi

1545

Magnitude of steatotic liver disease before and after liver transplantation and the impact of immunosuppressive medication: a multidimensional study

Poster presentation

Presenter: Ibrahim Ayada

1570

Patients with metabolic-associated steatotic liver disease and portal hypertension have different skeletal muscle and adipose tissue mass than patients with other causes of cirrhosis

Poster presentation

Presenter: Ikram Abow-Mohamed

1649

Prevalence, characteristics and hepatic fibrosis burden of the different subtypes of steatotic liver disease among a cohort of Egyptian people living with HIV

Poster presentation

Presenter: Ahmed Cordie

1658

Clinical impact of pre-existing steatotic liver disease on clinical course in acute HEV infection

Poster presentation

Presenter: KAZUNARI TANAKA

1698

Insulin resistance in metabolic associated steatotic liver disease and its association with liver-related outcomes: a retrospective study and a nationwide, population-based study

Poster presentation

Presenter: Yeo Wool Kang

1704

Cost-effectiveness of one-time screening for advanced hepatic fibrosis using FIB-4 based two-step algorithm in the general population

Poster presentation

Presenter: JOO HYUN OH

1756

Increased risk of cancers in metabolic dysfunction-associated steatotic liver disease and MetALD

Poster presentation

Presenter: Yewan Park

1779

Histological and clinical disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy

Poster presentation

Presenter: Merve Ekelik

1787

Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in steatotic liver disease

Poster presentation

Presenter: Serena Pelusi

1811

Identifying patient characteristics associated with the risk of long-term liver and cardiovascular outcomes and high healthcare costs in metabolic dysfunction-associated steatohepatitis: a retrospective cohort analysis using an artificial intelligence mod
Poster presentation
Presenter: Kamal Kant Mangla

1876
Persistence of fatty liver index (FLI) ≥ 20 as a predictor for hepatocellular carcinoma (HCC) development in non-HBV/non-HCV infected population
Poster presentation
Presenter: Rachel Wen-Juei Jeng

1892
Intramyocellular lipids are associated with insulin resistance in metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Guillaume Henin

1943
Impact of antidiabetic medications on adverse liver outcomes in patients with type 2 diabetes mellitus: independent and interactive effects
Poster presentation
Presenter: Sherlot Juan Song

1965
Plasminogen activator inhibitor-1 (PAI-1) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic-dysfunction associated steatotic liver disease
Poster presentation
Presenter: Marta Guariglia

1981
An inference model of risk factors for liver-related complications among patients with type 2 diabetes mellitus
Poster presentation
Presenter: Sherlot Juan Song

2072
Metabolic dysfunction associated steatohepatitis (MASH) disease progression phenotyping features based on medical claims
Poster presentation
Presenter: Petar Nikolov

2089

Prevalence and predictors of steatotic liver disease and significant liver fibrosis in an integrated hepatological and non-hepatological healthcare pathway model: preliminary results from a prospective cohort of a tertiary center

Poster presentation

Presenter: Angelo Armandi

2096

Global prevalence, clinical characteristics, histology and outcomes of PNPLA3 I148M variant in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis

Poster presentation

Presenter: Matheus Souza

2110

MASL-B registry: results from a european cohort of patients with chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Roberta Forlano

2118

Metabolic dysfunction associated steatotic liver disease with development of decompensated cirrhosis as long-term complication after distal gastric bypass surgery

Poster presentation

Presenter: Pamela Meyer-Herbon

2135

Longitudinal follow-up of Fib-4 in patients at risk of steatotic liver disease (SLD) receiving low-dose Methotrexate treatment (LD-MTX): results from the CIRT randomized placebo-controlled Trial in 4769 patients

Poster presentation

Presenter: Vincent Di Martino

2163

Metabolic steatosis in renal transplant recipients does not correlate with CVD, a retrospective cohort study

Poster presentation

Presenter: Pietro Torre

2174

Identification of key predictors of significant weight loss in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a multicentre study

Poster presentation

Presenter: Ivan Arcari

2249

Influence of reproductive status, synthetic hormone use, and co-medication on serum homocysteine levels and disparities in its contribution to MASLD risk

Poster presentation

Presenter: Ayako Suzuki

2252

MASH not NASH: A contemporary study of the impact of cardiac arrhythmias

Poster presentation

Presenter: Charles Yang

2264

Evaluation of ChatGPT as a counselling tool for Italian-speaking MASLD patients: assessment of accuracy, completeness and comprehensiveness

Poster presentation

Presenter: Nicola Pugliese

2331

Liver fibrosis and Lipoprotein(a) levels in individuals with metabolic dysfunction

Poster presentation

Presenter: Sara Margarita

2363

Effect of antidiabetics on the risk of hepatocellular carcinoma in patients with diabetes and metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Han Ah Lee

2387

The interplay between alcohol consumption and cardiometabolic risk factors in patients with MASLD and MetALD

Poster presentation

Presenter: Yee Hui Yeo

2458

Stigma in steatotic liver disease (SLD): a survey of patients from Saudi Arabia

Poster presentation

Presenter: Khalid A Alswat

2477

The impact of baseline sarcopenia, over time, on liver and cardiovascular damage in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a prospective study

Poster presentation

Presenter: Floriana Santomenna

2566

Association between liver histology and long-term clinical outcomes in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease in Sweden: a real-world cohort study (BRIDGE-MASH)

Poster presentation

Presenter: Ying Shang

2586

Cardiovascular disease burden in patients with and without metabolic dysfunction-associated steatohepatitis: data from the unCoVer-MASH longitudinal cohort study

Poster presentation

Presenter: Elisabetta Bugianesi

2608

Assessment of ChatGPT-generated medical arabic responses for patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Saleh A Alqahtani

2636

Implication of recent international consensus criteria for metabolic hyperferritinemia diagnosis and grade in a large cohort of patient with hepatic iron content assessed by magnetic resonance imaging

Poster presentation

Presenter: Edouard Bardou-Jacquet

2641

The presence of autoimmune characteristics in metabolic associated steatosis liver disease patients increases the risk of liver disease progression. Study from the multicentric spanish register (HEPAMET)

Poster presentation

Presenter: Anna Soria

2652

GH agonist use in MASLD: a systematic review and meta-analysis of randomised controlled trials

Poster presentation

Presenter: Islam Mohamed

2655

Echocardiography-based markers of subclinical cardiac dysfunction in patients with MASLD and preserved ejection fraction: prospective data from the Turin cohort

Poster presentation

Presenter: Kamela Gjini

2677

Health care resource utilization for patients diagnosed and at high risk of metabolic dysfunction-associated steatohepatitis in Stockholm, Sweden – a REVEAL-MASH study

Poster presentation

Presenter: Hannes Hagström

2713

Clinical outcomes of metabolic liver disease versus non-alcoholic fatty liver disease: a meta-analysis of observational studies

Poster presentation

Presenter: Grazia Pennisi

2723

Redefining the relationship: the diminished correlation between MASLD and CKD after accounting for diabetes or insulin resistance

Poster presentation

Presenter: Tianyuan Yang

2858

Association between advanced fibrosis and NASH-CRN activity score (NAS) components: combined data from multiple therapeutic trials including more than 10,000 patients

Oral presentation

Presenter: Stephen A. Harrison

2862

The infamous ballooned hepatocyte – fact or fiction: combined data from multiple therapeutic trials including more than 10,000 patients

Poster presentation

Presenter: Julie Dubourg

2877

Insulin resistance as an independent predictor of metabolic dysfunction-associated steatohepatitis (MASH) severity: combined data from multiple therapeutic trials including more than 10,000 patients

Poster presentation

Presenter: Vlad Ratziu

2898

Association of plasma magnesium with MASH and cirrhosis: combined data from multiple therapeutic trials including more than 10,000 patients

Poster presentation

Presenter: Stephen A. Harrison

2904

Association between the duration of comorbidities and steatotic liver disease

Poster presentation

Presenter: HA IL KIM

2953

Association between uric acid concentration and MASH: combined data from multiple therapeutic trials including more than 10,000 patients

Poster presentation

Presenter: Stephen A. Harrison

2983

Compared to complete abstainers, non-significant alcohol use may be associated with more severe liver disease in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – The multicentre study of the indian consortium on MASLD

Poster presentation

Presenter: AJAY KUMAR DUSEJA

2998

The interplay between hyperglycemia, metabolic risk factors, and non-alcoholic fatty liver disease- a systematic review and meta-analysis

Poster presentation

Presenter: Fariba Ahmadizar

3025

Novel digital pathology adequacy score benchmarks the performance of pre-analytical method for digital pathology and AI end-to-end tissue assays

Poster presentation

Presenter: Louis Petitjean

3049

Prevalence and severity of steatotic liver disease in 3,123 at-risk individuals from the background population

Poster presentation

Presenter: Camilla Dalby Hansen

3087

The risk of cardiometabolic disease related to increasing amounts of liver fat above the cut-off of 5%

Poster presentation

Presenter: Gabrielle Alblas

3142

Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease

Oral presentation

Presenter: Timothy Kendall

3239

Barriers and motivators for implementation of lifestyle changes in a large population with MASLD

Poster presentation

Presenter: Sharon Oude Veldhuis

3250

A plant-based diet for liver health: the protective role of vegetable fat on MASLD and other liver diseases

Poster presentation

Presenter: Simon Schophaus

3252

Sarcopenia in metabolic-dysfunction associated steatotic liver disease (MASLD): unraveling its role in cardiovascular damage

Poster presentation

Presenter: Annalisa Cespiati

3260

The impact of light to moderate alcohol consumption on liver and cardiovascular damage in metabolic-dysfunction associated steatotic liver disease

Poster presentation

Presenter: Rosa Lombardi

3271

Recompensation and liver function improvement in patients with decompensated cirrhosis due to metabolic-dysfunction associated steatotic liver disease (MASLD): a retrospective cohort study

Poster presentation

Presenter: Alba Jiménez-Masip

3283

Poor diet quality is associated with higher cardiovascular risk in a cohort of non-cirrhotic Italian MASLD (Metabolic dysfunction associated steatotic liver disease) outpatients

Poster presentation

Presenter: Rusi Chen

3315

Obese patients with sarcopenic obesity have a more severe metabolic phenotype and hepatic disease and exhibit less metabolic improvement after bariatric surgery

Poster presentation

Presenter: Vittoria Zambon Azevedo

3335

Platelet dynamics in metabolic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and liver cirrhosis

Poster presentation

Presenter: Mirko Zoncapè

MASLD: Diagnostics and non-invasive assessment

141

Understanding barriers to adoption of clinical guidelines for metabolic dysfunction-associated steatotic liver disease among hepatologists in Europe

Poster presentation

Presenter: Laurent Castera

212

Metabolomics-based model for predicting metabolic dysfunction-associated steatotic liver disease and stratifying risk

Poster presentation

Presenter: Takeshi KIMURA

276

The non-invasive assessment of liver fibrosis in metabolic dysfunction associated steatotic liver disease (MASLD) in the chinese population: a scoping review

Poster presentation

Presenter: Lai Wei

341

How many real world patients diagnosed with metabolic dysfunction-associated steatohepatitis meet clinical trial eligibility criteria? Findings from a large cohort study of more than 18,000 patients from the United States

Poster presentation

Presenter: Jörn M Schattenberg

353

PNPLA3 I148M a useful diagnostic marker for significant fibrosis metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Elias Rashu

363

Prediction of the risk of liver related events with non-invasive models is better than liver biopsy in MASLD cACLD patients

Oral presentation

Presenter: Laia Aceituno

371

Liver fibrosis assessed via non-invasive tests is associated with incident heart failure in a general population cohort: a UK Biobank study

Poster presentation

Presenter: Theresa Hydes

478

Non-invasive biomarkers of liver fibrosis may be used for diagnosing fibrosis and prognostication in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Liv Eline Hetland

514

The use of the FibroScan-AST score and AST to pre-identify metabolic dysfunction-associated steatohepatitis patients with active fibrogenesis in a Phase 1b open-label clinical trial

Poster presentation

Presenter: Mazen Nouredin

559

Gadoxetic acid-enhanced MRI enables detection of fibrosis and inflammation in MASLD/MASH

Poster presentation

Presenter: Edvin Johansson

563

A machine learning approach to identify patient features associated with metabolic dysfunction-associated steatohepatitis from the United Kingdom biobank

Poster presentation

Presenter: Jörn M Schattenberg

618

High pancreatic fat and reduced volume stratify patients with F4 liver fibrosis

Poster presentation

Presenter: Edward Jackson

620

A non-invasive score model for prediction of significant fibrosis and fibrotic metabolic dysfunction-associated steatohepatitis based on serum biomolecules

Poster presentation

Presenter: Nateneal Beyene

621

BOS-580, a long-acting FGF-21 analogue, treatment shows beneficial changes in the circulating lipidome and improves MASEF score in patients with phenotypic metabolic dysfunction-associated steatohepatitis in a phase 2a randomized, placebo-controlled, 12-w

Poster presentation

Presenter: Gerard Bain

635

Nash-FibroTest for the diagnosis of significant fibrosis, in severe obesity treated with bariatric surgery and external non-linear trajectories of test' components among obesity classes in a large US population

Poster presentation

Presenter: Thierry Poynard

667

Proteomics identifies a subpopulation of plasma extracellular vesicles able to improve non-invasive diagnosis of MASH in patients with type 2 diabetes: results of the RHU QUID-NASH study

Poster presentation

Presenter: Laure Elkrief

694

Diagnostic performance of non-invasive tests and comparison of AGA and EASL algorithm for the screening of MASLD-related advanced fibrosis in diabetes and nutrition clinics

Poster presentation

Presenter: Cyrielle Caussy

698

MASLD assessment using a novel point of care device the Hepatoscope™ in diabetes and obesity clinics

Poster presentation

Presenter: Cyrielle Caussy

706

FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Laura Martínez-Arenas

711

Natural history and expected change over time for MRI derived cT1: Data from clinical trials and the UK Biobank

Poster presentation

Presenter: Charlie Diamond

724

Transient elastography performance for the diagnosis of liver fibrosis in MASLD is independent of steatosis level as determined by MRI proton density fat fraction in a prospective multicentre study

Poster presentation

Presenter: Edouard Bardou-Jacquet

753

Novel deep learning models utilising domain adaptation outperform conventional statistical models for predicting the risk of liver-related complications in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Terry Cheuk-Fung Yip

757

The use of ELF test, FIB-4 and sequential algorithms to screen the Type 2 Diabetes Mellitus (T2DM) population for advanced fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Poster presentation

Presenter: Yiyang Pei

805

A self-testing index for detecting hepatic steatosis and prognostication in the general population

Poster presentation

Presenter: Chuan Liu

834

Prevalence of Low Fibrosis-4 Score in Patients with MASLD-related Hepatocellular Carcinoma: Results from a Multicentre Cohort Study

Poster presentation

Presenter: Benedix Sim

852

A novel point-of-care prediction model for steatotic liver disease: based on bioimpedance analysis

Poster presentation

Presenter: Jeayeon Park

862

Evaluation of iATT liver fat quantification for steatosis grading with reference to magnetic resonance imaging-based proton density fat fraction: a multicenter study

Poster presentation

Presenter: Masashi Hirooka

873

Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography – a multicenter cohort study of 10,920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Oral presentation

Presenter: Vincent Wai-Sun Wong

954

Association of Quantitative Hepatic Collagen with Non-Invasive Tests (NITs) for Fibrosis in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)

Poster presentation

Presenter: Zobair Younossi

958

Longitudinal changes in liver stiffness measurements in a population-based screening cohort of 5,517 participants

Poster presentation

Presenter: Katrine Tholstrup Bech

963

IMPACT OF AUTOMATED FIB-4 REPORTING ON LIVER-RELATED REFERRAL OF PATIENTS WITH DIABETES

Poster presentation

Presenter: Theodore Feldman

1004

Machine learning-based mortality prediction models for non-alcoholic fatty liver disease in the general United States population

Poster presentation

Presenter: Jiarui Zheng

1019

Optimizing MASLD trial recruitment: LiverPRO vs. FIB-4 in reducing false positives and unnecessary biopsies

Poster presentation

Presenter: Katrine Lindvig

1023

The distribution of fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction associated steatotic liver disease in the general population.

Poster presentation

Presenter: Yuji Ogawa

1036

The Fatty Liver Index (FLI) is more accurate than FIB-4 for detection of advanced liver fibrosis in patients with type-2 Diabetes Mellitus (T2DM) in Primary Care.

Poster presentation

Presenter: Ruth Nadal

1042

Guided Vibration-Controlled Transient Elastography, a new vibration-guided FibroScan examination

Poster presentation

Presenter: Cyrielle Caussy

1116

Unmasking racial disparities of MASLD screening guidelines: underdiagnosis of MASLD among black patients with obesity

Poster presentation

Presenter: Gres Karim

1117

Assessment of fibrosis change rates in placebo arm of metabolic dysfunction-associated steatohepatitis drug trials based on pathologist readouts and qFibrosis continuous values

Poster presentation

Presenter: Kutbuddin Akbary

1162

Irisin level as a potential biomarker for hepatic steatosis improvement after a 6-month lifestyle intervention in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Gabriele Castelnovo

1171

The diminished diagnostic accuracy of existing non-invasive tools for significant fibrosis in MASLD patients concurrent with CHB

Poster presentation

Presenter: Yee Hui Yeo

1216

Clinical, biological and imaging predictors of at-risk MASH: combined data from multiple therapeutic trials including more than 10,000 patients

Poster presentation

Presenter: Stephen A. Harrison

1229

Should specific cutoffs be used for diagnosing fibrotic MASH in patients with type 2 diabetes using FAST, MAST, MEFIB and FNI?

Poster presentation

Presenter: Laurent Castera

1282

Steatotic liver disease in diabetic patients: more serious diabetes mellitus, more serious liver disease

Poster presentation

Presenter: Zülal İstemihan

1308

Predicting significant hepatic steatosis from routine biochemistry in people with and without type 2 diabetes (T2D)

Poster presentation

Presenter: Magdalena Nowak

1332

Association between psoriasis severity and steatosis measured by artificial Intelligence-based algorithm (LIVERFAST)

Poster presentation

Presenter: Sabrina Ab Wahab

1361

Screening candidates for therapeutic trials in MASH: choose the right non-invasive test for the diagnostic target considered

Oral presentation

Presenter: Jerome Boursier

1391

Non-invasive assessment of hepatic steatosis by ultrasound-derived fat fraction (UDFF) in individuals at high-risk for metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Federica Tavaglione

1403

Screening for liver fibrosis in tertiary care using automatic calculation of FIB4 in patients at-risk of diabetes

Poster presentation

Presenter: Clémence M Canivet

1432

Diagnostic accuracy of two-dimensional shear wave elastography (2D-SWE) for non-invasive assessment of liver fibrosis in biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD). Systematic-review and multi-level random effects model

Poster presentation

Presenter: Madalina-Gabriela Taru

1442

New optimal cut-points for vibration controlled transient elastography and MR elastography for advanced fibrosis in hispanic versus non-hispanic adults with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Monica Tincopa

1447

The performance of the enhanced liver fibrosis test by cardiometabolic risk factors in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Kazuhito Kawata

1456

Serum GDF15 level, in combination with the FIB-4 index, is useful for refining the identification of high-risk patients for clinical event occurrence in MASLD patients

Poster presentation

Presenter: Hayato Hikita

1459

An intergenerational population-based cross-sectional study of MASLD in children and their parents

Poster presentation

Presenter: Oyekoya Ayonrinde

1485

Ferritin is a predictor of fibrosis, but not liver iron in metabolic hyperferritinaemia

Poster presentation

Presenter: Maria Rosina Troppmair

1493

Head fat correlates with the severity of nonalcoholic fatty liver disease: based on NHANES 2017-2018 data

Poster presentation

Presenter: Jiao Liu

1526

EUS-guided assessment of steatotic liver disease in bariatric surgery patients

Poster presentation

Presenter: Paula Fernandez Alvarez

1533

A non-invasive index for significant liver fibrosis and stratifying risk of cirrhosis in patients with type 2 diabetes mellitus in primary care

Poster presentation

Presenter: Xiaolong Qi

1617

Can we define MASLD in liver outpatient clinics? Keeping up with the changing nomenclature

Poster presentation

Presenter: Mercy Karoney

1625

FAST and Agile – the MASLD Drift: validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven MASLD patients of prevalent caucasian origin

Poster presentation

Presenter: Madalina-Gabriela Taru

1671

Identification of serum metabolome signatures associated with hepatocellular carcinoma in metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Atsumasa Komori

1719

Transcriptomic analysis reveals novel biomarkers and PI3K-AKT signaling pathway findings of at-risk metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Yanhua Ding

1765

Sequential diagnostic approach utilizing FIB-4 and ELF for predicting advanced fibrosis in metabolic-associated steatotic liver disease

Poster presentation

Presenter: Yeo Wool Kang

1772

The single nucleotide polymorphism rs780094 C>T in the glucokinase regulator gene (GCKR) is associated with hepatic steatosis improvement after lifestyle intervention in overweight/obese subjects with metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Eleonora Dileo

1776
Noninvasive diagnosis of significant portal hypertension based on prealbumin proteomics model
Poster presentation
Presenter: Xiaoyan Wang

1839
HeparDx™ (by Metadeq, Inc.) is a reliable biomarker-based non-invasive test for MASH, capable of detecting the presence of inflammation and ballooning
Poster presentation
Presenter: Giulia Angelini

1861
PLIN2 is a specific marker for liver related disease
Poster presentation
Presenter: Giulia Angelini

1875
Diagnostic performances of FIB-4 and NFS in metabolic dysfunction-associated steatotic liver disease in primary care clinic of Asia
Poster presentation
Presenter: JOO HYUN OH

1886
Characterization of the evolution of liver elasticity in a real-life population with metabolic dysfunction-associated steatotic liver disease: a prospective study
Poster presentation
Presenter: Joyce Scholtens

1887
An algorithm based on serum phospholipid profiles to predict liver fibrosis degree in metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Mayuko Shimizu

1891
Landscape of the steatotic liver disease and its risk factors in the point-of-care liver screening program SIRIUS

Poster presentation
Presenter: Tomas Koller

1906
Unravelling metabolic dysfunction-associated steatotic liver disease with a Bayesian network approach in the UK biobank
Poster presentation
Presenter: Benjamin P.M. Laevens

1946
Simultaneous assessment of skeletal muscle mass and handgrip strength to identify patients with NAFLD at high risk of advanced liver fibrosis
Poster presentation
Presenter: Seung Up Kim

1968
Effectiveness of on different models of care based on Fibrosis-4 and/or liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease
Poster presentation
Presenter: Gian Paolo Caviglia

1971
Prevalence of metabolic-dysfunction associated steatotic liver disease among diabetic and non-diabetic patients in a dutch cohort: evaluation of hepatic steatosis and fibrosis using Fibroscan™
Poster presentation
Presenter: Alina Saidi

1974
Prevalence and tissue characteristics of steatotic liver disease subclassifications in the adult UK population using quantitative MRI clinical thresholds: a UK biobank study
Poster presentation
Presenter: Charlie Diamond

1980
Longitudinal changes of FIB-4 do not predict outcomes in patients with metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Hannes Hegmar

1992
A four-country modelling study on doubling MASH diagnostic rates by 2027
Poster presentation

Presenter: Jeffrey V Lazarus

2012

Sequential approach using combination of newly developed HOMA2-IR-ALT-TE-MASH (HALT-M) score and magnetic resonance elastography for non-invasive identifying at-risk metabolic dysfunction-associated steatohepatitis in obese subjects

Poster presentation

Presenter: Seung Kak Shin

2063

Subclinical myocardial fibrosis is related to disease severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Poster presentation

Presenter: Puria Nabilou

2108

Improved risk stratification by combination of FIB-4 with FGF21 serum levels in steatotic liver disease

Poster presentation

Presenter: Heike Bantel

2122

Association of clinical and biochemical parameters and polygenic risk score in a metabolic steatosis population of southern Italy

Poster presentation

Presenter: Benedetta Maria Motta

2161

Myosteatosi is associated with metabolic-associated steatotic liver disease (MASLD) but not liver fibrosis - Results from an Indian cohort

Poster presentation

Presenter: Dinesh Walia

2164

Artificial intelligence-based measurement of nonalcoholic steatohepatitis is an accurate tool for clinical trial enrollment and endpoint assessment

Poster presentation

Presenter: Hanna Pulaski

2172

Muscle composition as a predictor of advanced fibrosis in chronic liver disease

Poster presentation

Presenter: Wile Balkhed

2198

Age impacts the diagnostic ability of the enhanced liver fibrosis test for advanced fibrosis in MASLD

Poster presentation

Presenter: Katrina Pekarska

2215

Plasma metabolite profile associates with liver fibrosis and incident liver-related death in men from Finnish general population

Poster presentation

Presenter: Ville Männistö

2226

Head-to-head comparison of two different ultrasound systems to measure the liver attenuation parameter

Poster presentation

Presenter: Laura De Rosa

2259

Effects of weight loss on overweight or obese MASLD patients after six months of dieting

Poster presentation

Presenter: Pietro Torre

2275

Impact of sex, body mass index, elevated liver enzymes, and diabetes mellitus on risk-stratification of a large cohort of patients with MASLD

Poster presentation

Presenter: Abdel-Aziz Shaheen

2286

Non-invasive predictive markers of resmetirom biopsy response

Poster presentation

Presenter: Jörn M Schattenberg

2318

Validation of the Baveno VII 'rule of 5' in a real-life multicentre cohort of patients with metabolic dysfunction associated steatotic liver disease

Oral presentation

Presenter: Elba Llop Herrera

2319

Transducer reproducibility in liver ultrasound-derived fat fraction measurements

Poster presentation

Presenter: Reinhard Kubale

2332

Comparison of Hepatoscope® and FibroScan® for non-invasive assessment of hepatic steatosis and fibrosis among mexican immigrant adults along the southern Arizona United States/Mexico border

Poster presentation

Presenter: Edgar Villavicencio

2339

Identifying the optimal cut off for relative reduction in liver fat content on MRI-PDFF to predict histologic response in MASH clinical trials

Poster presentation

Presenter: Naim Alkhouri

2353

MASLD patients with liver cirrhosis have an increased early cardiovascular risk measured by epicardial adipose tissue

Poster presentation

Presenter: Marta Hernández Conde

2360

Agreement between two-dimensional shear wave elastography and transient elastography in metabolic dysfunction-associated steatotic liver disease: implications for primary care screening

Poster presentation

Presenter: Shelley Keating

2368

Prediction of metabolic dysfunction-associated steatohepatitis resolution

Poster presentation

Presenter: Rohit Loomba

2415

AI digital pathology unmasked the “No Change” in conventional pathological assessment of MASLD patients with one year lifestyle intervention in a prospective cohort study

Poster presentation

Presenter: Yanhua Ding

2448

Combination of Liverfast (LF) & Liver Stiffness Measurement (LSM) using fibroscan outperforms FIB-4 & LSM, for the identification of MASLD advanced fibrosis (AF) in patients with type 2 diabetes (T2D)

Poster presentation

Presenter: Victor de Lédighen

2452

Assessment of transient elastography (FibroScan) in obesity patients with nonalcoholic fatty liver disease: a meta-analysis

Poster presentation

Presenter: Ziping Lin

2459

The FAP Index: A statistical model aiding the detection of advanced liver fibrosis in people with diabetes, obesity or metabolic dysfunction-associated steatosis using a marker of activated stellate cells and myofibroblasts

Poster presentation

Presenter: Mark Gorrell

2483

Metabolic dysfunction-associated steatotic liver disease prevalence and predictors in patients with type 2 diabetes in primary care

Poster presentation

Presenter: Wile Balkhed

2539

Use of FIB4 as a screening test in the bariatric population instead of the NAFLD fibrosis score reduces referral rate to hepatology without reducing identification of significant fibrosis: a retrospective audit

Poster presentation

Presenter: Michael Carbonell

2572

NASH-PI: a randomized trial to compare cost-effectiveness across strategies for screening, referring and management of MASLD patients in clinical practice

Poster presentation

Presenter: Manuel Romero-Gómez

2617

Circulating mitochondrial bioenergetic profile reflects the hepatic one and represents a non-invasive biomarker of disease severity in MASLD genetically predisposed individuals

Poster presentation

Presenter: Erika Paolini

2623

Clinical profile of patients considered at-risk for MASH with fibrosis identified through an ongoing global screening program with genetics

Poster presentation

Presenter: Samuel Daniels

2656

Circulating vesicle microRNAs for metabolic dysfunction-associated steatotic liver disease (MASLD) staging and progression towards liver cancer

Poster presentation

Presenter: Laura Izquierdo-Sánchez

2668

Assessment of the correlation and concordance between ELF and VCTE in the AASLD algorithm for MASLD severity assessment

Poster presentation

Presenter: siham abdelgani

2683

Utility of ultrasound attenuation imaging in the detection and grading of hepatic steatosis severity as compared to magnetic resonance imaging proton density fat fraction

Poster presentation

Presenter: Ross Apostolov

2733

Optimizing non-alcoholic fatty liver disease care using mac-2 binding protein glycosylation isomer and correlations with advanced diagnostics

Poster presentation

Presenter: Thu Thuy Pham Thi

2745

Real world evaluation of a primary care pathway for the assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)

Poster presentation

Presenter: Basil Ahmad

2825

Clinical, biological and imaging predictors of advanced fibrosis (F3-F4): combined data from multiple therapeutic trials including more than 10,000 patients

Poster presentation

Presenter: Mazen Nouredin

2879

Comparative analysis of Agile 3+, NFS, and BARD scores for diagnosing advanced fibrosis in MASLD and MetALD

Poster presentation

Presenter: Yun Kyu Lee

2881

Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model
Poster presentation
Presenter: Stephen A. Harrison

2887
Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD
Poster presentation
Presenter: Eveline Gart

2909
The influence of rifaximin on bile acids composition
Poster presentation
Presenter: Olena Barabanchyk

2919
Performance of non-invasive tests to diagnose cirrhosis in MASH trials: combined data from multiple therapeutic trials
Poster presentation
Presenter: Naim Alkhouri

2929
The 2023 AASLD practice guidance for MASLD does not adequately risk stratify MASLD patients in the context of therapeutic trials
Poster presentation
Presenter: Naim Alkhouri

2932
Time-trends of fibrosis and steatosis in metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective cohort analysis
Poster presentation
Presenter: Umang Arora

2945
Clinical and biological predictors of liver fat content $\geq 8\%$ as assessed by MRI-PDFF: combined data from multiple therapeutic trials including more than 10,000 patients
Poster presentation
Presenter: Mazen Nouredin

2969
Fibrosis detection in MASLD: A two steps comparative study
Poster presentation
Presenter: Manuel Romero-Gómez

2972

RESIST-NASH: a regional network for identification and referral of masld patients at risk for liver fibrosis

Poster presentation

Presenter: Grazia Pennisi

2974

Diagnosis of advanced liver fibrosis: the synergy of open data, synthetic data generation, CatBoost, and feature engineering

Poster presentation

Presenter: Athanasios Angelakis

2985

Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steato

Poster presentation

Presenter: John Suschak

3002

Pemvidutide treatment is associated with improvement in noninvasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-control

Poster presentation

Presenter: Naim Alkhouri

3071

Utility of transient elastography in inflammatory bowel disease

Poster presentation

Presenter: Arun Vaidya

3085

Paired assessment of enhanced liver fibrosis (ELF) and fibrosis-4 (FIB-4) scores is associated with an elevated risk of liver-related clinical events in participants with advanced fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH)

Poster presentation

Presenter: Rohit Loomba

3091

Novel circulating exosomal miRNA-mRNA network is linked to MASL-MASH and offers pathophysiologic insights with potential for biomarkers related to MASLD and hepatocellular carcinoma

Poster presentation

Presenter: Jing Zeng

3148

Prognostic significance of ELF test compared to liver biopsy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Poster presentation

Presenter: Antonio Liguori

3183

Validation of Fibrosis-6, a novel machine learning non-invasive score to rule out advanced fibrosis and cirrhosis in patients with metabolic-associated fatty liver disease

Poster presentation

Presenter: Mona Ismail

3216

Analyses of fibrosis biomarkers PRO-C3 and ELF in resmetirom treated patients from MAESTRO-NASH, a 52 Week NASH/MASH serial liver biopsy study

Poster presentation

Presenter: Quentin M. Anstee

3248

A data-driven approach to determine minimum re-testing interval in persons with metabolic dysfunction associated steatotic liver disease

Poster presentation

Presenter: Callum Wood

3261

Spectroscopy of blood plasma has the potential to differentiate metabolic dysfunction-associated steatohepatitis from steatosis

Poster presentation

Presenter: Barbora Nováková

3267

Accuracy of the recommended algorithm using Fib4 Score and fibroscan to identify MASLD patients with low risk for advanced liver fibrosis in "real world" practice

Poster presentation

Presenter: Eli Zuckerman

3298

The true diagnostic performance of magnetic resonance elastography for the detection of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease exceeds the diagnostic performance of liver biopsy

Poster presentation

Presenter: Ian Rowe

3344

Description of a cohort of patients with metabolic dysfunction-associated steatotic liver disease followed at an urban liver centre (Toronto liver centre), high prevalence of extrahepatic conditions

Poster presentation

Presenter: Magdy Elkhashab

3353

High prevalence of liver fibrosis and cirrhosis among cohort of patients referred to an urban liver centre for evaluation of metabolic dysfunction-associated steatotic liver disease (utility of transient elastography)

Poster presentation

Presenter: Magdy Elkhashab

3356

Comparison of two non-invasive models for advanced fibrosis (AF) detection in patients with type 2 diabetes (T2D) and MASLD using LiverSTAT, FIB-4 and liver stiffness measurement (LSM) with transient elastography (TE)

Poster presentation

Presenter: Mona Ismail

3358

AI-assisted, quantitative digital pathology-based continuous fibrosis scores perform better than conventional pathology in documenting fibrosis reduction

Poster presentation

Presenter: Vlad Ratziu

MASLD: Experimental and pathophysiology

125

Synergistic effects of thyroid hormone treatment and mitochondrial thyroid receptor p43 overexpression on regression of metabolic dysfunction-associated steatotic liver disease in mice by improving key mitochondrial quality markers

Poster presentation

Presenter: Raghu Ramanathan

143

CD36-mediated hepatocyte-macrophage coordination drives hepatic fibrosis in MASLD

Poster presentation

Presenter: Zhe Dai

165

GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis by attenuating SMAD3 phosphorylation

Poster presentation

Presenter: Javier Jurado-Aguilar

205

Use of dynamic versus fixed projection vector AI-based system for collagen detection and quantification on picrosirius red-stained liver biopsies from patients with metabolic-dysfunction associated steatotic liver disease

Poster presentation

Presenter: Cindy Serdjebi

235

Oxysterol treatment causes indirect stellate cell activation: a potential mechanism linking steroid metabolising enzyme dysregulation with fibrosis

Poster presentation

Presenter: Hamish Miller

278

Protein tyrosine phosphatase non-receptor type 2 controls hepatic function of cytotoxic T cells in metabolic dysfunction-associated steatohepatitis

Oral presentation

Presenter: Madita Determann

308

DC-SIGN+ macrophages alleviates non-alcoholic steatohepatitis by modulating inflammatory cytokine secretion

Poster presentation

Presenter: Jinxia Liu

518

Selective ablation of Caspase 8 in hepatocytes ameliorates development of metabolic dysfunction-associated steatohepatitis following hepatocyte-specific JNK deletion

Oral presentation

Presenter: Ines Volkert

675

A 4-week mouse model allows the rapid evaluation of resmetirom and tirzepatide benefits on metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Francois Briand

712

Study of alternative splicing changes during metabolic dysfunction-associated liver disease development and progression

Poster presentation

Presenter: Eirini Giannousi

740

S100A11 is a pro-inflammatory lipotoxic damage associated molecular pattern in metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Gopanandan Parthasarathy

810

Cellular senescence is a common hallmark in diverse models of steatotic liver diseases

Poster presentation

Presenter: Charalampos Pavlidis

866

Validation of fibrosis and inflammation response in the biopsy-confirmed GAN DIO-MASH mouse model following lanifibranor or semaglutide treatment using fully automated deterministic analysis

Poster presentation

Presenter: Cindy Serdjebi

914

Differential transcriptomic profile in platelet-derived extracellular vesicles in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Poster presentation

Presenter: Sheila Gato-Zambrano

974

Metabolic dysfunction-associated steatotic liver disease (MASLD) modeling with hepatocyte-like cells derived from adult liver stem cells via air-liquid interface

Poster presentation

Presenter: Soe Einsi Lynn

976

Distinct gut microbiome and intestinal permeability biomarker in patients with lean MASLD without type 2 diabetes

Poster presentation

Presenter: Natthaya Chuaypen

1138

Effects of semaglutide, Peptide YY3-36 and empagliflozin on metabolic dysfunctions-associated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthase-inhibition
Poster presentation
Presenter: Niklas Geiger

1220
Targeting mitochondrial complex I modulates lipid metabolism, inflammation and hepatic fibrosis in a MCD-diet model of benign steatosis
Poster presentation
Presenter: Francesca Protopapa

1262
Association of non-invasive tests (NITs) with genetic polymorphism in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
Poster presentation
Presenter: Zobair Younossi

1280
Non-invasive staging of liver disease in C57BL/6NTac mice preconditioned on the modified-Amylin NASH diet using automated shear wave elastography
Poster presentation
Presenter: Laura Griffin

1298
In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated steatohepatitis
Poster presentation
Presenter: Jieun Song

1310
Inhibition of HSD17B13 by INI-822 phenocopies the hepatic lipidomic profile of humans with the protective allele
Poster presentation
Presenter: Heather Hsu

1324
Interleukin 10 reduces fat accumulation and promotes fatty acid degradation and intracellular glucose maintenance in a high-fat-diet mouse model of metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Akira Kado

1326

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of NASH and cardiovascular health in LDL receptor knockout NASH mice

Poster presentation

Presenter: Wen-Wei Tsai

1357

The exercise-induced metabokine beta-aminoisobutyric acid regulates hepatic lipid metabolism and reduces hepatic metabolic dysfunction and fatty liver in a dietary obese mouse model

Poster presentation

Presenter: Shaimaa Gad

1437

The interaction of thioredoxin and thioredoxin interacting protein controls high fat diet-induced hepatic insulin resistance

Poster presentation

Presenter: Sezin Dagdeviren

1445

CAMSAP1 aggravates liver fibrosis in metabolic dysfunction-associated steatohepatitis by promoting microtubule acetylation

Poster presentation

Presenter: Zhiping Wan

1512

Clinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Poster presentation

Presenter: Michael Feigh

1519

Multi-tissue profiling of oxylipins reveal a conserved up-regulation of epoxide: diol ratio that associates with white adipose tissue inflammation and liver steatosis in obesity

Poster presentation

Presenter: Charlotte Hateley

1543

Restoration of natural killer cell antifibrotic activity via a novel immune target; the Neuroligin-4/ β -Neurexin pathway

Poster presentation

Presenter: Johnny Amer

1548

Liver sinusoidal endothelial cells induce senescence in activated hepatic stellate cells via extracellular vesicles

Poster presentation

Presenter: Junyu Wang

1597

Artificial intelligence-assisted multiomics depicting the immunometabolism landscape of steatotic livers undergoing bariatric surgery

Poster presentation

Presenter: Hanyang Liu

1602

Differential gene expression profiles of liver tissue, subcutaneous and visceral adipose tissue delineates severity of MASLD in heavily obese patients

Poster presentation

Presenter: Lina Jegodzinski

1611

The E2F2 target glycerophosphodiester phosphodiesterase domain containing 3 is involved in MASLD progression to HCC and related dyslipidemias

Poster presentation

Presenter: Maider Apodaka-Biguri

1619

Exploring the role of FXR activation in mitigating ceramides-driven lipotoxicity and endoplasmic reticulum stress in metabolic dysfunction associated steatohepatitis

Poster presentation

Presenter: Basma Abdelrahman

1622

Peripheral natural cytotoxic cells are associated with development of non-alcoholic liver fatty disease (NAFLD) in children

Poster presentation

Presenter: Piotr Socha

1636

Role and therapeutic potential of miR-22 in MAFLD and obesity: from mouse model to human relevance

Poster presentation

Presenter: Riccardo Panella

1656

Calcitriol modulates intestinal AMPK/SIRT1 signaling towards alleviating compromised barrier integrity in MASH: a potential autophagy-dependent role

Poster presentation

Presenter: Andrew Hakeem

1673

Sex and age disparities in MASH and the beneficial effects of estradiol for MASH in old female mice

Oral presentation

Presenter: Madhulika Tripathi

1679

Development of cardiometabolic dysfunction and sarcopenia in a mouse model of MASH

Poster presentation

Presenter: Brijesh Kumar Singh

1724

Targeting lysyl-tRNA synthetase alleviates metabolic dysfunction-associated steatohepatitis through inhibition of monocyte-derived macrophages in preclinical models

Poster presentation

Presenter: Wonseok Kang

1760

Characterisation of peptidylprolyl isomerase C as a novel player in the pathogenesis of chronic liver disease

Poster presentation

Presenter: Isabel Fuster-Martínez

1774

Prophylactic and therapeutic hepatoprotective effects of the dual FXR/TGR5 agonist INT-767 in the GAN diet-induced ob/ob mouse model of advanced MASH with progressive fibrosis

Poster presentation

Presenter: Jacob Nøhr-Meldgaard

1797

Integrated spatial transcriptomics and machine learning derived histopathology measurements in steatotic liver disease unmasks biological heterogeneity of steatosis

Poster presentation

Presenter: Stephen Atkinson

1803

Serum thrombospondin-2 and insulin-like growth factor binding protein 7 predict liver fibrosis and fibrosis regression in patients with MASLD post bariatric surgery

Poster presentation

Presenter: Rambabu Surabattula

1806

Effect of inhibition of the protein tyrosine phosphatase 1B in liver progenitor cells under an steatohepatitis environment in mice

Poster presentation

Presenter: Pilar Valdecantos

1829

Macrophage phenotype is affected by longitudinal treatment with Zalfermin in a model of metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Benedicte Kapel

1860

Dysfunctional activation of the DNA damage response is associated with MASLD progression through an E2F2-dependent mechanism

Poster presentation

Presenter: Beatriz Gómez Santos

1888

Spatiotemporal non-invasive characterization of the hepatic microenvironment during metabolic dysfunction-associated liver disease progression

Poster presentation

Presenter: Rallia Velliou

1900

Gut dysbiosis is associated with the severity of liver fibrosis assessed by magnetic resonance elastography in patients with MAFLD

Poster presentation

Presenter: Thananya Jinato

1915

Genome-wide association study identifies PTPRD associated with metabolic dysfunction-associated steatotic liver disease in South Korea

Poster presentation

Presenter: Dong Yun Kim

1950

Additive hepatoprotective effects of DA-1241, a novel GPR119 agonist, in combination with semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Poster presentation

Presenter: Michael Feigh

2005

ATM, guardian of genome integrity, is a new player in NAFLD pathogenesis by modulating mitochondrial metabolism

Poster presentation

Presenter: Chantal Desdouets

2034

Hepatic mitochondrial reductive stress predicts liver mortality in the UK biobank

Poster presentation

Presenter: Juho Asteljoki

2039

Artificial intelligence models deployed at scale on hematoxylin and eosin-stained whole slide images reveal stage-dependent collagen composition in metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Adam Stanford-Moore

2099

MiR-4449-merlin-TAZ axis modulates fibrosis progression in MASH

Poster presentation

Presenter: Young-Sun Lee

2111

Non-invasive assessment of liver inflammation in metabolic dysfunction-associated steatohepatitis (MASH) using MRI cytometry

Poster presentation

Presenter: xiaoyu jiang

2149

Unraveling the interplay of FGF21 and GLP1 analogue in metabolic dysfunction-associated steatohepatitis in vivo

Poster presentation

Presenter: Anouk Oldenburger

2154

Artificial intelligence-derived granular histological markers of fibrosis from hematoxylin and eosin-stained whole slide images associate with non-invasive tests of fibrosis and prognosis to cirrhosis in patients with metabolic dysfunction-associated stea

Poster presentation

Presenter: Lara Murray

2157

Brain inflammation and cognitive impairment is not mitigated by a low-fat dietary intervention in ageing mice with MASLD

Poster presentation

Presenter: Matthew Siddle

2160

Targeting macrophage BTK, a potential therapeutic strategy for metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Shiwei Chen

2162

Transgenerational maternal obesity induces mitochondrial dysfunction and aggravates MASLD, which can be reversed by metabolic drug candidates

Oral presentation

Presenter: Anneleen Heldens

2165

Deep learning-based predictive modeling of patatin-like phospholipase domain-containing protein 3 variant carriers using magnetic resonance imaging data

Poster presentation

Presenter: Yazhou Chen

2208

The role of the ferroptosis brake glutathione peroxidase 4 in a preclinical model of metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Cédric Peleman

2305

Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model

Poster presentation

Presenter: Radina Kostadinova

2321

Without effect on weight loss, semaglutide does not improve MASLD in a dietary mice model for MASLD

Poster presentation

Presenter: Katharina Luise Hupa-Breier

2335

Clearance of senescent cells alleviates metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Nilofer Sayed

2364

External validation of machine learning model (MASML) adjusted for prevalence for determining the histologic severity of MASLD in a large cohort of patients with biopsy-proven disease

Poster presentation

Presenter: Joseph Rubinsztain

2384

Comparison of machine learning model (MASML), VCTE, and FIB-4 scores for predicting the presence of MASLD in a large cohort of patients in the U.S. using the NHANES database

Poster presentation

Presenter: Joseph Rubinsztain

2407

Prediction of MASH features from liver biopsy images using a pre-trained self-supervised learning model

Poster presentation

Presenter: Saurabh Vyawahare

2423

Human embryonic stem cell-derived mesenchymal stem cells improve mitochondrial oxidative dysfunction in metabolic dysfunction-associated liver disease via the AMPK pathway

Poster presentation

Presenter: Yun Bin Lee

2428

A novel circular RNA therapy expressing a long-acting FGF21 analog protein reversed obesity, insulin resistance, and steatosis in mouse models

Poster presentation

Presenter: Lu Gao

2500

Evaluation of suitable in vitro and in vivo models for metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Anja Geisler

2508

Macrophage driven fibrosis resolution assessed by a cross-linked and MMP degraded type III collagen fragment (CTX-III) declines with age and is prognostic for survival in chronic liver disease

Poster presentation
Presenter: Alejandro Mayorca Guiliani

2510

Brain dysfunction is prevented by alpha 2A adrenergic receptor antagonism in a rodent model of diet-induced metabolic dysfunction-associated steatotic liver disease

Poster presentation
Presenter: Anne Catrine Daugaard Mikkelsen

2524

Low nonpsychedelic doses of psilocybin for the therapy of MASLD

Poster presentation
Presenter: Martina Colognesi

2551

PNPLA3 p.I148M variant affects lipid droplets number and size in patient-derived liver organoids

Poster presentation
Presenter: Elia Casirati

2560

Time-restricted feeding alleviates metabolic associated fatty liver disease via PPAR-related lipid metabolism signaling pathway

Poster presentation
Presenter: Jiang Deng

2568

Untargeted lipidomics unveils distinct signature of metabolic dysfunction-associated steatohepatitis in the context of obesity

Poster presentation
Presenter: Alina-Iuliana Onoiu

2597

Synergistic hepatoprotective effects of semaglutide and resmetirom combination therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Poster presentation
Presenter: Kristoffer Voldum-Clausen

2647

MASH-associated endothelial dysfunction in mice: is there no effect?

Poster presentation
Presenter: Justine Lallement

2737

Unveiling immune-microenvironment remodeling for MASH-related hepatocellular carcinoma immunotherapy resistance through single-cell RNA sequencing

Poster presentation

Presenter: Yiling Zhang

2740

Dysregulation of ureagenesis and glutaminolysis in DIAMONDTM mice played a major role in MASLD progression

Poster presentation

Presenter: Rocío Gallego-Durán

2765

Hepatoprotective effects of a HSD17b13 inhibitor in the CDAA-HFD mouse model of advanced MASH with progressive fibrosis

Poster presentation

Presenter: Joo Hyun Park

2768

CRISPR/Cas9-mediated somatic gene editing in adult mice reveals hepatic KLB as a regulator of bile acid synthesis and hepatic lipid metabolism

Poster presentation

Presenter: Alexandra Aaldijk

2816

A novel role for the epigenetic regulator SUV420H1 in MASLD and its complications

Poster presentation

Presenter: Alessia Pagani

2818

Identification and assessment of new circulating serological biomarkers for the evaluation of liver disease severity in MASLD patients

Poster presentation

Presenter: Douglas Maya

2854

Semaglutide links with improved survival and liver outcomes in MASLD patients, a large multicenter retrospective real-world cohort study

Poster presentation

Presenter: Mohammed Suki

2861

Development of a new mouse model combining rapid and robust MASH, liver fibrosis and atherosclerosis: time- and sex-dependent effects

Poster presentation

Presenter: Fanny Lalloyer

2922

Evaluation of performance of a cellular profiling technique for quantification of inflammation and steatosis in liver biopsies of patients with MASH

Poster presentation

Presenter: Adi Lightstone

2925

Treatment with the CCR2/CCR5 antagonist Cenicriviroc does not affect MASH and fibrosis development in Ldlr^{-/-}.Leiden mice, translational to clinical phase 3 trial results

Poster presentation

Presenter: Martine C. Morrison

2967

Metabolic profiling of adipose tissues in metabolic dysfunction-associated steatohepatitis (MASH): insights from lipidomic, proteomic, and epigenetic analyses in morbidly obese patients undergoing bariatric surgery

Poster presentation

Presenter: Cristina Placed-Gallego

2976

Evaluation of the performance of AI digital pathology method (FibroNest) on subsections of biopsies to assess performance variability due to region selection

Poster presentation

Presenter: Adi Lightstone

2978

Resmetirom protects against diet-induced MASLD and reduces atherogenic risk factors in obese Ldlr^{-/-}.Leiden mice

Poster presentation

Presenter: Eveline Gart

3064

Metabolomic and genomic prediction of metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Luke Jostins-Dean

3066

Altered liver vascular biology occurring in early stages of metabolic dysfunction-associated steatotic liver disease is significantly improved by the pan-peroxisome proliferator-activated receptor agonist lanifibranor, associating with improved liver hist

Poster presentation

Presenter: Shivani Chotkoe

3168

Elevated SIRT1 levels in arterial hypertension patients with a heightened risk of non-alcoholic fatty liver disease

Poster presentation

Presenter: Anastasiia Radchenko

3198

Significance of adipose tissue fibrosis and adipocyte in the progression of metabolic dysfunction-associated steatohepatitis in severe obesity patients

Poster presentation

Presenter: Andrea Jiménez-Franco

3264

Single nucleotide polymorphism analysis for predicting metabolic-associated fatty liver disease development in patients with severe obesity (types II and III)

Poster presentation

Presenter: Juan Manuel Jiménez-Aguilar

3312

Evaluation of performance of AI digital pathology on the reproducibility and repeatability of fibrosis phenotyping in MASH liver biopsies

Poster presentation

Presenter: Li Chen

3337

Performance of non-invasive indexes in the assessment of metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Álvaro Yagüe Parada

3350

Suitability of non-invasive tests in the evaluation of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Álvaro Yagüe Parada

3352

Bridging hepatic pathologies: protein expression dynamics in metabolic dysfunction-associated liver disease (MASLD), benign liver tumours and hepatocellular carcinoma

Poster presentation

Presenter: Saima Ajaz

MASLD: Therapy

294

CVI-2742, a highly potent and liver-targeted new generation THR- β selective agonist, strongly reduces liver steatosis and bridging fibrosis in rodent MASH model

Poster presentation

Presenter: Jingwen Liu

388

Statins are not associated with an increased risk of decompensated cirrhosis in patients with type 2 diabetes mellitus

Poster presentation

Presenter: Jonathan Tjerkaski

579

Efruxifermin treatment improved collagen biomarkers consistent with remodelling of the extracellular matrix in patients with F2-F3 fibrosis due to MASH

Poster presentation

Presenter: Erik Tillman

581

Berberine Ursodeoxycholate (HTD1801) provides a unique therapeutic approach for patients with metabolic diseases and severe insulin resistance

Poster presentation

Presenter: Leigh MacConell

583

Evaluation of efficacy of Berberine Ursodeoxycholate (HTD1801) compared to ongoing use of GLP-1 receptor agonists in patients with MASH and T2DM

Poster presentation

Presenter: Stephen A. Harrison

589

Time course of onset, incidence and prevalence of gastrointestinal adverse events with HTD1801 (Berberine Ursodeoxycholate) in patients with MASH and T2DM

Poster presentation

Presenter: Guy Neff

762

ASC41, a selective THR β agonist significantly reduces liver fat and ALT in biopsy-confirmed MASH patients after 12-week treatment: an interim analysis of a 52-week serial liver biopsy study

Poster presentation

Presenter: Jiangaofan

780

GL0034 (Uretilutide), a long acting, glucagon-like peptide-1 receptor agonist, improves body weight loss, lipid and liver injury markers in individuals with obesity: A phase 1 multiple ascending dose study

Poster presentation

Presenter: Rajamannar Thennati

815

Statin prescriptions and progression to a high-risk for advanced fibrosis in primary care patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Poster presentation

Presenter: Andrew Schreiner

853

A phase 4, multicenter, open-label, single-arm study to evaluate the safety and efficacy of saroglitazar 4 mg in patients with non-alcoholic fatty liver disease with obesity, type 2 diabetes mellitus, dyslipidemia, or metabolic syndrome

Poster presentation

Presenter: Deven Parmar

880

Statin use is associated with liver fibrosis regression in the general population: a longitudinal analysis of The Rotterdam Study

Poster presentation

Presenter: Jesse Pustjens

932

Clinical pharmacokinetics of INI-822, a small molecule inhibitor of HSD17B13

Poster presentation

Presenter: Heather Hsu

942

Safety and efficacy outcomes of endoscopic sleeve gastroplasty and lifestyle intervention in post-orthotopic liver transplant patients: A single-center, prospective pilot study

Poster presentation

Presenter: Jaclyn Tuck

943

Week 48 results from the phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis

Oral presentation

Presenter: Rohit Loomba

982

Effectiveness of Polyene phosphatidylcholine in metabolic-associated fatty liver disease treatment : a real-world study in China

Poster presentation

Presenter: Lai Wei

1007

Results from a phase 2a randomized trial with the transglutaminase 2 inhibitor ZED1227 in patients with MASLD

Oral presentation

Presenter: Jörn M Schattenberg

1081

Efficacy and safety of FGF-analogs for the treatment of MASH: a systematic review and meta-analysis

Poster presentation

Presenter: Maria Viana

1146

Effects of icosabutate, a dual free fatty acid receptor-1 and -4 agonist, on elevated noninvasive markers of liver injury, fibrosis and glycemic control in type 2 diabetic MASH patients and F1-F3 fibrosis

Poster presentation

Presenter: Stephen A. Harrison

1250

Healthcare cost and resource utilization among patients with non-alcoholic steatohepatitis (NASH), stratified by glucagon-like peptide 1 receptor agonist (GLP-1) use in real world data

Poster presentation

Presenter: Yestle Kim

1268

Pegozafermin added to background GLP-1 therapy in patients with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: ENLIVEN 48-week extension data

Poster presentation

Presenter: Arun J Sanyal

1316

TERN-501, a highly selective thyroid hormone receptor β agonist, significantly improved MRI-PDFF, cT1, and liver volume in clinically relevant patient populations with presumed MASH: subgroup analyses from a 12-week phase 2a trial

Poster presentation

Presenter: Stephen A. Harrison

1435

Pharmacokinetics of the selective glucocorticoid receptor modulator miricorilant in healthy volunteers and patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)

Poster presentation

Presenter: Joseph M. Custodio

1451

Efficacy and safety of incretin-based therapies in patients with metabolic dysfunction-associated steatotic liver disease complicated by type 2 diabetes mellitus

Poster presentation

Presenter: Tadamichi Kawano

1458

Improvements in MACK-3, a diagnostic test for active metabolic dysfunction-associated steatohepatitis, parallel response to lanifibranor therapy

Poster presentation

Presenter: Michael Cooreman

1577

Liver fibrosis and obesity associated with stroke in an elderly population: protected effect by pravastatin

Poster presentation

Presenter: Willy Theel

1700

Effect of omega 3 fatty acid supplementation on hepatic steatosis and liver stiffness in patients with non-alcohol-related fatty liver disease

Poster presentation

Presenter: Muhammad Abedur Rahman Bhuyan

1701

The three strain probiotics for metabolic dysfunction-associated steatotic liver disease improvement: a parallel, double-blind, randomized, placebo-controlled trial

Poster presentation

Presenter: Sung-Min Won

1749

FGF-19 analogues for the treatment of metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis

Poster presentation

Presenter: Gilmara Coelho Meine

1936

Consumption of a mediterranean diet with high-polyphenol content extra-virgin olive oil (EVOO) in patients with MASLD: effects on clinical parameters and gene expression on peripheral blood mononuclear cells (PBMCs)

Poster presentation

Presenter: Lydia Giannitrapani

1954

Inhibition of sodium-glucose cotransporter-2 and liver-related complications in diabetic patients

Poster presentation

Presenter: Sung Won CHUNG

2177

Effect of a physical exercise program on the cerebral hemodynamics of patients with metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Berenice M. Román-Calleja

2179

A significant decrease in steatosis using non-invasive measurements during monitoring for life style changes in patients with MASLD: interim 6m results of a monocentric study

Poster presentation

Presenter: Wouter Robaey

2246

Role of Saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in nondiabetic patients: a prospective observational study

Poster presentation

Presenter: JATA SHANKAR KUMAR

2307

Semaglutide for type 2 diabetes control in metabolic dysfunction-associated steatotic liver disease (MASLD): a two-way effect?

Poster presentation

Presenter: Giovanni Petralli

2325

Higher serum vitamin D levels is associated with lower MASLD prevalence and incidence: the Rotterdam study

Poster presentation

Presenter: Ibrahim Ayada

2342

Efficacy and safety of FGF21 analogues in the treatment of metabolic dysfunction-associated steatohepatitis: an updated systematic review and meta-analysis

Poster presentation

Presenter: Gilmara Coelho Meine

2349

Liver stiffness improvement with pioglitazone in brazilian patients with metabolic dysfunction-associated steatohepatitis: a multicentric pilot study

Poster presentation

Presenter: Mário Pessoa

2418

Sex hormone binding globulin as an effective predictor of treatment response to TERN-501, a potent, highly selective thyroid hormone receptor β agonist: post-hoc analyses from a 12-week phase 2a trial

Poster presentation

Presenter: Naim Alkhouri

2425

A randomized, placebo-controlled phase Ib/IIa trial to evaluate the safety, tolerability, and efficacy of BGT-002, an adenosine triphosphate citrate lyase inhibitor in patients with NAFLD: interim analysis

Poster presentation

Presenter: Yue Hu

2678

Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-

Poster presentation

Presenter: Philip N. Newsome

2685

Postbiotic supplementation for metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Nazarii Kobylak

2690

A Markov model unveiling the impact of Resmetirom on the natural history of MASLD patients with baseline significant or severe liver fibrosis

Poster presentation

Presenter: Grazia Pennisi

2981

Real-world use of Glucagon-like peptide 1 receptor agonists in patients with MASLD: a cross-sectional analysis from TARGET-NASH

Poster presentation

Presenter: A. Sidney Barritt IV

3080

Structured exercise plus mediterranean diet intervention in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a randomized controlled trial. The EHmet-DIA study

Oral presentation

Presenter: Manuel Romero-Gómez

3178

Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial

Oral presentation

Presenter: Jörn M Schattenberg

3191

Effect of statin therapy in patients with obesity and cirrhosis secondary to metabolic dysfunction-associated steatotic liver disease (MASLD) on pre-liver transplant mortality

Poster presentation

Presenter: Katherine Cooper

3195

Using machine learning models to predict baseline fibrosis stage in patients from phase 3 resmetirom trials (MAESTRO-NAFLD and MAESTRO-NASH)

Poster presentation

Presenter: Jörn M Schattenberg

3259

Long term outcomes of Saroglitazar in metabolic-dysfunction associated steatotic liver disease related cirrhosis - a prospective cohort study

Poster presentation

Presenter: Rakhi Maiwall

3272

Discovering 1-piperidine propionic acid inhibiting effect on protease activated receptor 2 and serpinb3 as a new therapeutic strategy for metabolic dysfunction-associated steatohepatitis

Poster presentation

Presenter: Monica Chinellato

3377

Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: results from a randomized, double-blind, placebo-controlled phase 2 trial
Oral presentation
Presenter: Arun J Sanjal

3379

Survodutide (BI 456906), a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial
Oral presentation
Presenter: Eric Lawitz

Non-invasive assesment of liver disease except MASLD

241

Radiomics based on MRI for predicting microvascular invasion at edge of hepatic alveolar echinococcosis
Poster presentation
Presenter: Wenya Liu

392

Validation of transient elastography and the enhanced liver fibrosis test as prognostic biomarkers across the spectrum of steatotic liver disease
Poster presentation
Presenter: Nikolaj Torp

420

Diagnostic and prognostic performance of the LiverRisk score in tertiary care
Poster presentation
Presenter: Georg Semmler

597

Determination of normal range of spleen stiffness by using novel spleen-dedicated fibroscan
Poster presentation
Presenter: Ji-hwan Kang

628

Longitudinal association of magnetic resonance elastography with liver-related events and cardiovascular events in chronic hepatitis
Poster presentation
Presenter: Nobuharu Tamaki

631

A non-invasive predictive model based on CT radiomics for hepatic venous pressure gradient in liver cirrhosis

Poster presentation

Presenter: Xu Guo

695

Development and validation of a home-based score to detect advanced liver fibrosis and long-term liver-related outcomes in the general population: a multicohort study

Poster presentation

Presenter: Xiaolong Qi

944

Comparison of two ultrasound diagnostic systems for measuring liver stiffness in clinical practice

Poster presentation

Presenter: Simone Cappelli

1021

Intelligent liver function test 5 years on – the evolution of an intelligent platform

Oral presentation

Presenter: Damien Leith

1167

N-terminal type III collagen propeptide, golgi protein 73 and their combination accurately assess significant and advanced fibrosis in chronic hepatitis B patients

Poster presentation

Presenter: Jie Li

1293

Stabilization of enhanced liver fibrosis and liver stiffness measures in the open-label extension of the phase 3 POISE trial of obeticholic acid for the treatment of primary biliary cholangitis

Poster presentation

Presenter: Robert G. Gish

1301

Association of elevated liver biochemistries and clinical outcomes within strata of alkaline phosphatase levels in patients with primary biliary cholangitis

Poster presentation

Presenter: David W. Victor III

1315

Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis-4 index stabilization in the phase 3 POISE trial of obeticholic acid for the treatment of primary biliary cholangitis

Poster presentation

Presenter: Alan Bonder

1322

Effect of obeticholic acid on reduction and normalization of alanine aminotransferase and aspartate aminotransferase in the phase 3 POISE trial in primary biliary cholangitis

Poster presentation

Presenter: Robert G. Gish

1461

Fibrosis activity versus disease stage: systemic markers of fibrosis activity have better prognostic performance than the liver biopsy in patients with alcohol-related liver disease

Poster presentation

Presenter: Stine Johansen

1465

An integrative machine learning method enhances postoperative liver failure risk assessment with preoperative indicators

Poster presentation

Presenter: Zongkun Zhang

1479

Validation of FIB-6 Score in assessment of liver fibrosis in chronic hepatitis B

Poster presentation

Presenter: Khalid A Alswat

1893

Fibroblast activity kills - circulating endotrophin (PRO-C6) is prognostic for liver-related events in patients with cirrhosis from chronic hepatitis C

Poster presentation

Presenter: Thomas Møller

2056

Development of a non-invasive machine learning-based model for predicting hepatic steatosis in patients with chronic hepatitis B

Poster presentation

Presenter: Zhiyi Zhang

2287

Enhancing MRCP precision: a comprehensive analysis of intramuscular glucagon administration impact on biliary visualization

Poster presentation
Presenter: Fadi Abu Baker

2297

Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced chronic liver disease of mixed etiology
Poster presentation
Presenter: Giulia Francesca Manfredi

2334

Shear wave elastography predicts risk categories in patients with cirrhosis, PANDORA study
Poster presentation
Presenter: Jorge Poo

3036

PT-LIFE model for the diagnosis of pediatric liver fibrosis after pediatric liver transplantation
Poster presentation
Presenter: Hao Feng

3307

Procalcitonin as a predictive marker of incident liver disease
Poster presentation
Presenter: Amanda Finnberg-Kim

Nurses and Allied Health Professionals

15

The second stage of the mobile health application developed for patients with liver cirrhosis: results of the randomized controlled trial
Oral presentation
Presenter: Ferya Celik

257

Feasibility of a digital lifestyle intervention (VITALISE) to support self-management in patients with metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Hollie Smith

268

Does the use of liver frailty index in liver transplant assessment aid clinical decision making and correlate with patient outcomes?
Poster presentation

Presenter: Rachel Edwards

516

Outcomes from a nurse-led home-based care program for patients with liver cirrhosis

Poster presentation

Presenter: Siddharth Sood

607

Streamlining rifaximin access: a digital innovation for improved medication access and cost efficiency

Poster presentation

Presenter: Fatema Jessa

776

Implementation of food insecurity screening within outpatient hepatology services: a clinical audit.

Poster presentation

Presenter: Rachel Howarth

1003

Patients' experiences of liver cirrhosis health care

Oral presentation

Presenter: Maria Hjorth

1093

Screening for liver disease in alcohol use disorder – is it worthwhile?

Poster presentation

Presenter: Marie Archibald

1115

Exploring the feasibility of ultrasound liver imaging reporting and data system (US LI-RADS) and visualisation score in clinical application

Poster presentation

Presenter: Dorothy Seng

1190

Dietary composition in individuals with primary sclerosing cholangitis – high prevalence of inadequate fat-soluble vitamin intake

Poster presentation

Presenter: Catarina Lindqvist

1245

Evolution of health-related quality of life in liver transplantation patients in relation to acceptance and metabolic liver disease

Poster presentation
Presenter: Janne Suykens

1363
Testing for hepatitis C virus infection in prisons in England: room for improvement
Oral presentation
Presenter: Kathryn Jack

1601
Usefulness of an educational activity through an informatic tool in participants with chronic hepatitis B infection
Poster presentation
Presenter: Judit Romero-Vico

1641
A meta-ethnographic review of experiences and perceptions of physical activity and exercise in people with metabolic dysfunction-associated steatotic liver disease
Poster presentation
Presenter: Shelley Keating

1951
"Ama il tuo Fegato" program: screening for hepatic fibrosis using liver stiffness measurement (LSM)
Poster presentation
Presenter: Paolo Scivetti

2064
Early evaluation of a pharmacist-led clinic for the management of patients with chronic hepatitis B on antiviral treatment
Poster presentation
Presenter: Aya Al-Hasani

2123
Nurse-led hepatocellular cancer surveillance in district general hospital
Poster presentation
Presenter: Kate Pingoy

2238
Longitudinal symptom burden in caregivers for patients with end-stage liver disease
Oral presentation
Presenter: Lissi Hansen

2293

A pilot pharmacist led carvedilol titration service leads to sustained doses of high dose carvedilol in patients with clinically significant portal hypertension

Poster presentation

Presenter: Yun Jung Kim

2588

Establishment of the Irish hepatology nurses association: an association for nurses working in liver disease in Ireland

Poster presentation

Presenter: Michèle Bourke

2774

Development of a nurse-led out-patient service to support earlier diagnosis and management of liver disease

Poster presentation

Presenter: Amy Thatcher

2980

Educational intervention in cirrhotic outpatients with hepatic encephalopathy secondary to constipation

Poster presentation

Presenter: Martina Perez-Guasch

3113

Medicines optimisation in patients admitted with hepatic encephalopathy in UK centres

Poster presentation

Presenter: Arron Jones

3171

Impact of a joint clinical nurse specialist and dietitian clinic on health related quality of life outcomes for patients with decompensated liver disease

Poster presentation

Presenter: Leah Cox

3190

Global subjective assessment and global leadership initiative on malnutrition as predictors of mortality in patients with cirrhosis

Poster presentation

Presenter: Vittoria Zambon Azevedo

Public Health: Except viral hepatitis

120

Evolving patterns in the clinical burden of liver cirrhosis: comprehensive analysis from a leading German tertiary center

Poster presentation

Presenter: Julian Pohl

243

Metabolic risk factors and disease risk in patients with metabolic dysfunction-associated steatotic liver disease: findings from an electronic health record biobank

Poster presentation

Presenter: Xuehong Zhang

323

Fibro-Predict risk score for liver cirrhosis from nationwide electronic health records

Poster presentation

Presenter: Iris Kalka

466

CORE: a new risk score measuring GGT, AST, and ALT outperforms FIB-4 when predicting the risk of cirrhosis in a primary care setting

Oral presentation

Presenter: Rickard Strandberg

570

The interplay between steatotic liver disease and viral infections: systematic review, meta-analysis and data synthesis

Poster presentation

Presenter: Jiajing Li

645

Exploring liver vitamin A status and histopathological associations in a Guatemalan cohort: insights into prolonged consumption of vitamin A fortified sugar

Poster presentation

Presenter: Giorgio Cazzaniga

653

TRANSAMINASES AND OLDER ADULTS: DISTRIBUTION AND ASSOCIATIONS WITH ALL-CAUSE MORTALITY

Poster presentation

Presenter: Daniel Clayton-Chubb

701

Hepatocellular carcinoma surveillance in the United Kingdom: a multi-centre study assessing uptake and inequalities

Poster presentation
Presenter: Maria Qurashi

952

Transient elastography identifies previously undiagnosed advanced liver disease among those presenting with alcohol dependence

Poster presentation
Presenter: Rachel Edwards

995

Unveiling Socioeconomic Disparities on Liver Disease: A Comparative Study of ALD, MASLD, and MetALD Patients

Oral presentation
Presenter: Helle Lindholm Schnefeld

1048

Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Poster presentation
Presenter: Zobair Younossi

1090

Impact of body mass index on non-invasive test accuracy for the diagnosis of at-risk metabolic dysfunction-associated steatohepatitis

Poster presentation
Presenter: Cristina Alonso

1099

Prioritisation of research to tackle stigma in alcohol-related liver disease: results from the ARMS-Hub partnership

Poster presentation
Presenter: Ashwin Dhanda

1253

FIB-4 based referral pathways to identify advanced liver disease have poor clinical utility in a United States general population

Poster presentation
Presenter: Laurens van Kleef

1295

Use of FibroScan® to assess hepatic steatosis and fibrosis in community-based settings to promote clinical care linkages along the Southern Arizona United States/Mexico border

Poster presentation

Presenter: David Garcia

1296

A multi-channel educational communication campaign to improve liver disease screening and awareness for clinical care in Southern Arizona along the United States/Mexico border

Poster presentation

Presenter: David Garcia

1318

Assessments of health utilities in patients with metabolic dysfunction-associated steatohepatitis (MASH): cross-walk between CLDQ-NASH, SF-6D, and the EuroQol EQ-5D

Poster presentation

Presenter: Zobair Younossi

1325

Prevalence and association between chronic kidney disease and steatotic liver disease in a nationally representative sample in the United States

Poster presentation

Presenter: Mason Lai

1436

Food swamps and easy access to unhealthy food increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) mortality in the United States (U.S.)

Poster presentation

Presenter: Zobair Younossi

1482

The impact of air pollution on the occurrence of steatotic liver disease in Korea

Poster presentation

Presenter: Jae Moon Yun

1520

Benefits and harms of post-treatment surveillance in patients with early-stage of HCC after curative ablation

Poster presentation

Presenter: Awassada Yangcharoen

1620

Associations of food insecurity and healthcare access with the prevalence and mortality of metabolic dysfunction-associated steatotic liver disease (MASLD): a global study of the United Nation and the global burden of disease data

Poster presentation

Presenter: Zobair Younossi

1621

A review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease

Poster presentation

Presenter: Dana Ivancovsky Wajcman

1642

Large-scale community outreach Fibroscan program to detect advanced fibrosis and cirrhosis for early detection of liver cancer

Poster presentation

Presenter: Basil Ahmad

1691

Age and sex differences in the incidence of cirrhosis caused by metabolic dysfunction associated steatohepatitis in Manitoba, Canada: a population-based study

Poster presentation

Presenter: NABIHA FAISAL

1899

Increasing awareness among primary care physicians about MASLD reduced unnecessary referral rates and an increased cardiovascular evaluation

Poster presentation

Presenter: Hyunwoo Oh

1921

Socioeconomic deprivation is independently associated with hepatocellular carcinoma mortality in a western european country with single-payer healthcare

Poster presentation

Presenter: Massih Ningarhari

1956

Diagnostic accuracy of the LiverRisk score to detect significant and advanced fibrosis among a United States general population and important subgroups

Poster presentation

Presenter: Laurens van Kleef

1978

MAF-5 improves the detection of advanced and significant fibrosis in FIB-4 underserved individuals in a United States general population

Poster presentation

Presenter: Laurens van Kleef

2081

Identifying treatment naïve and undiagnosed primary biliary cholangitis patients using a novel case finding database and treatment pathway

Poster presentation

Presenter: Timothy Jobson

2269

Non-housing related socioeconomic factors increase risk of liver fibrosis in screening of an urban population with steatotic liver disease

Poster presentation

Presenter: Huw Purssell

2340

Vaccir study: evaluation of vaccination coverage against diphtheria-tetanus-poliomyelitis, pneumococcus, hepatitis A and B, influenza and SARS-COV2 in cirrhotic patients in 17 french general hospitals

Poster presentation

Presenter: Aurore Baron

2365

Defining the thresholds for alcohol intake on the risk of liver-related mortality in people with metabolic risk factors

Oral presentation

Presenter: Hyunseok Kim

2427

Association between air pollution and heat stress exposome and liver enzymes in NYC runners

Poster presentation

Presenter: Nicholas DeFelice

2543

Risk factors for future development of cirrhosis in UK primary care patients with elevated ALT: a survival analysis of the optimum patient care research database

Poster presentation

Presenter: Kris Bennett

2578

Who doesn't turn up? Exploring patient characteristics associated with non-adherence with regular hepatocellular carcinoma surveillance: a systematic review and meta-analysis

Poster presentation

Presenter: Hannah MacCarthy

2624

Changing from MAFLD to the new nomenclature: new opportunities to understand the role of alcohol and metabolism to adverse outcomes

Poster presentation

Presenter: Chenlu Yang

2763

Impacts of smoking on alcoholic associated liver disease: a nationwide cohort study

Poster presentation

Presenter: jeong-ju yoo

2804

The rise of metabolic dysfunction-associated steatotic liver disease (MASLD) among adults in Canada between 2012-2018

Poster presentation

Presenter: Jessica Burnside

2883

Exploring racial, ethnic, and demographics representativeness in MASH clinical trials: combined data from multiple therapeutic trials including more than 10,000 patients

Poster presentation

Presenter: Jörn M Schattenberg

3031

Community liver health champion support can optimise the engagement of underserved patients with hepatocellular cancer surveillance - results of a 1 year regional pilot

Poster presentation

Presenter: Ryan Buchanan

3045

The association of perceived neighborhood violence and allostatic load with metabolic dysfunction-associated steatotic liver disease in mexican-origin migrant and seasonal farmworkers along the southern Arizona United States/Mexico border

Poster presentation

Presenter: Adriana Maldonado

3062

The prevalence of steatotic liver disease in young adults: applying the new nomenclature to a UK birth cohort

Poster presentation

Presenter: Kushala Abeysekera

3107

A community-based pilot for proactive screening of high-risk groups for chronic liver disease can lead to sustained healthcare engagement of people diagnosed with cirrhosis

Poster presentation
Presenter: Ann Archer

3158
Characteristics and waitlist outcomes of liver transplant candidates at high risk for food insecurity
Poster presentation
Presenter: Therese Bittermann

3182
Prevalence of advanced liver fibrosis in the general population of the Paris region according to FIB 4 scores and liver risk score (Cerfabib)
Poster presentation
Presenter: Henri TRAN

Public Health: Viral hepatitis

93
Hepatitis B virus care cascade in Rwanda: a population based-study
Poster presentation
Presenter: Jean Damascene Makuza

222
Hepatitis C virus and HIV infection among persons who inject drugs in six sites in Tajikistan, 2022
Poster presentation
Presenter: Aziz Nabidzhonov

287
Peak mortality is on the horizon: will we flatten the curve?
Poster presentation
Presenter: Devin Razavi-Shearer

289
Viral hepatitis elimination: scale up now to avert the worst yet to come
Poster presentation
Presenter: Devin Razavi-Shearer

291
The cost of HBV and HCV elimination in Ethiopia based on the current disease burden
Poster presentation
Presenter: Alexis Voeller

426

HBV and HCV screening and linkage-to-care in vulnerable people permanently or temporarily living in Tuscany

Poster presentation

Presenter: Teresita Caruso

523

Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 – November 2023

Poster presentation

Presenter: Tengiz Tsertsvadze

528

Evaluation of hepatitis C treatment and care model in primary healthcare centers in the country of Georgia

Poster presentation

Presenter: Akaki Abutidze

544

Direct-acting antivirals in women of reproductive age infected with hepatitis C virus

Poster presentation

Presenter: Krystyna Dobrowolska

551

Linkage of anti-HCV reactive persons to HCV care and treatment services in Georgia

Poster presentation

Presenter: Vladimer Getia

580

Characterizing hepatitis B virus infection in children and household contacts in the Democratic Republic of Congo to inform elimination efforts in a resource-limited setting

Poster presentation

Presenter: Camille Morgan

642

Safety of direct-acting antivirals for hepatitis C infection and direct Oral anticoagulants co-administration: an Italian multicentric study

Poster presentation

Presenter: VALERIO ROSATO

729

Retreating the off-Nuc clinical relapse with Pegylated interferon much increased HBsAg seroclearance – a propensity score matching study

Poster presentation
Presenter: Yu-Ting Kao

758
Local Hepatitis Elimination & Prevention (LHEAP) – Doorstep Model for Elimination of Hepatitis B and Hepatitis C in Rawalpindi, Pakistan
Poster presentation
Presenter: Nida Ali

796
Identifying barriers of hepatitis C linkage to care among beneficiaries of harm reduction centers in Georgia
Poster presentation
Presenter: Maia Butsashvili

907
Sex disparities in initiation of direct-acting antivirals for hepatitis C treatment: data from the French national healthcare database (2014-2022, ANRS FANTASIO 2 study)
Poster presentation
Presenter: Fabienne Marcellin

979
Implementation of an Electronic Medical Record-Based Automatic Alert System for the Care Cascade of Hepatitis-C-Virus Infection in Patients Undergoing Elective Surgery
Poster presentation
Presenter: Jae Seung Lee

1035
Decreasing trend of hepatitis C in homeless people between 2019-2023: a retrospective study in Madrid, Spain
Poster presentation
Presenter: Daniel Sepúlveda-Crespo

1043
Community-based interventions to increase hepatitis B virus and hepatitis C virus infections screening among at-risk migrant and refugee populations in Italy, Greece, and Spain: 1-year results of the VH-COMSAVAC project
Poster presentation
Presenter: Camila Picchio

1058
Impact of direct-acting antiviral market access policy barriers and restrictions in patients with hepatitis C virus: A database analysis of US claims from states with and without Medicaid restrictions

Poster presentation
Presenter: Nancy S Reau

1071

Uptake in viral hepatitis screening, vaccination and linkage to care among at-risk migrants in Catalonia, Spain: three years of a community-based intervention

Poster presentation
Presenter: Camila Picchio

1077

Estimation of the prevalence of hepatitis delta virus infection in the European Union

Poster presentation
Presenter: Hugh Watson

1110

“I go as much and to as many doctors I can trust to not be stigmatised”: factors in the experience of hepatitis B that affect linkage to care and treatment

Poster presentation
Presenter: Mylisa Vu

1126

The impact of integration and decentralization of HBV services on enhancing the HBV care continuum: an interrupted time series

Poster presentation
Presenter: Jean Damascene Makuza

1137

Local elimination programs leading to global action in HCV(LEGA-C): implementation science studies in Europe aiming to streamline the HCV care pathway

Poster presentation
Presenter: Candido Hernández

1158

Poor referral of migrants with hepatitis B virus infection from primary care: a substantial missed opportunity for successful linkage to specialist care in Catalonia

Oral presentation
Presenter: Camila Picchio

1170

Implementing a hepatitis C virus patient search identification tool in primary care settings

Poster presentation
Presenter: Amber Copeland

1201

Progress in hepatitis C screening as part of the hepatitis C elimination program in Georgia
Poster presentation
Presenter: Maia Tsereteli

1255
Effects of direct-acting antivirals on end-stage liver disease and mortality among Florida Medicaid beneficiaries with chronic hepatitis C
Poster presentation
Presenter: Haesuk Park

1256
High rates of hepatitis C RNA positivity and engagement in care from community pharmacies with a high intensity test and treat (HITT) model
Poster presentation
Presenter: Samuel Uveges

1259
Epidemiological changes and clinical events in the hepatitis C virus HepCoVe cohort. The viral elimination after availability of novel 20-years observational study
Poster presentation
Presenter: Liliana Chemello

1275
Age at incident cirrhosis among individuals with hepatitis C virus infection: a United States administrative claims analysis
Poster presentation
Presenter: Laura Telep

1292
Investigating household hepatitis B transmission using whole-genome sequencing and serological analysis in Kinshasa Province, Democratic Republic of Congo
Poster presentation
Presenter: Camille Morgan

1334
Simplified criteria for antiviral initiation in patients with chronic HBV infection: an economic evaluation and budget impact analysis in Thailand
Poster presentation
Presenter: Pisit Tangkijvanich

1336
Disparities in hepatocellular carcinoma survival among people with hepatitis B or hepatitis C virus infection in Canada
Oral presentation

Presenter: Naveed Janjua

1462

Screening for viral hepatitis in the emergency department – the methodology to automate a feasible, acceptable and effective solution

Poster presentation

Presenter: Miriam Levy

1541

Semi-quantitative interviews with chronic hepatitis B patients to determine their knowledge of hepatitis B, personal experiences and views on decentralisation of care in London, United Kingdom

Poster presentation

Presenter: Alexander Cole

1592

Eliminating hcv infection from prisons in Sicily: the sintesi project(*)

Poster presentation

Presenter: Lorenza Di Marco

1595

Advancing HCV elimination: emergency department screening beyond risk factors

Poster presentation

Presenter: Marta Casado-Martin

1632

Predictors of treatment initiation for hepatitis C virus among pregnant and postpartum individuals using health administrative data from Ontario, Canada from 1999 to 2021

Poster presentation

Presenter: Andrew Mendlowitz

1692

Combatting blood-borne viral syndemics with automated electronic based screenings of HBV, HCV, HDV and HIV in a hospital

Poster presentation

Presenter: Su Wang

1767

Female, mild steatosis, low baseline hepatitis B surface level and over 11.35 months of treatment facilitate clinical cure with interferon therapy in chronic hepatitis B patients

Poster presentation

Presenter: Zhenhuan Cao

1834

Assessing the burden and knowledge, attitudes, and practices of hepatitis B and hepatitis C among dentists in the country of Georgia

Poster presentation

Presenter: Lika Karichashvili

1837

Screening emergency admissions at risk of chronic hepatitis 3 extension (SEARCH 3X) – universal is better than risk-based screening for viral hepatitis

Poster presentation

Presenter: Basheer Alshiwanna

1895

Implementation of the educate, test, and treat outreach model in Shabu village, Nigeria: lessons learned

Poster presentation

Presenter: Gamal Shiha

1896

Progression of hepatitis B virus (HBV)-related liver disease in immune-tolerant, inactive, and grey zone phases: a systematic review & meta-analysis

Poster presentation

Presenter: zakary warsop

1904

Cost-effectiveness of antiviral therapy in patients with chronic hepatitis B in the high viremic gray zone

Poster presentation

Presenter: Hye-Lin Kim

1975

Cost-effectiveness analysis of hepatitis B vaccination policy for newborns in Taiwan

Poster presentation

Presenter: Meng Lun Hsieh

2006

Real-world based cost effectiveness analysis of entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy

Poster presentation

Presenter: CHUN-TING HO

2026

Liver stiffness measurement before and after antiviral treatment for hepatitis C: results from an OST-based hepatology service facility

Poster presentation

Presenter: Nikolaos Papadopoulos

2106

Dried blood spot self-collection for hepatitis B, C, and COVID-19 antibodies

Poster presentation

Presenter: Ahreni Saunthar

2112

Material deprivation is associated with liver stiffness measurement and liver-related events in people with HIV

Poster presentation

Presenter: Felice Cinque

2147

Defining the data requirement to achieve the hepatitis C elimination in the United Kingdom: the Somerset liver improvement project

Poster presentation

Presenter: Emma Saunbury

2153

Performance comparison of four hepatitis E antibodies detection methods

Poster presentation

Presenter: Ana Avellon Calvo

2181

Presentations of acute hepatitis C in London, focussed in men who have sex with men (MSM)

Poster presentation

Presenter: Maeve Barlow

2232

Population-based hepatitis C screening in Lithuania: 18-month results of the program and scenarios for achieving WHO elimination targets

Poster presentation

Presenter: Limas Kupcinskas

2262

Testing practice and prevalence of hepatitis delta virus (HDV) among patients with chronic hepatitis B (CHB): a large canadian population-based study

Poster presentation

Presenter: Abdel-Aziz Shaheen

2313

Novel approach to re-engage untreated patients with chronic active HCV

Poster presentation

Presenter: Federico Garcia Garcia

2355

Reasons patients with hepatitis B and C declined linkage to care and strategies for re-engaging this reachable cohort

Poster presentation

Presenter: Anna Mageras

2391

Increasing hepatitis C screening rates at a New York City primary care clinic: a continuation

Poster presentation

Presenter: Jake Debroff

2401

Geographic variability in harm reduction uptake, risk behaviors, and network characteristics among people who inject drugs in Kenya: a key hurdle to hepatitis C elimination

Poster presentation

Presenter: Matthew Akiyama

2409

Telehealth accessibility and acceptability among people who use drugs

Poster presentation

Presenter: Zoi Papalamprakopoulou

2430

Patient, provider, and neighborhood-level factors associated with hepatitis delta testing in an academic health system

Poster presentation

Presenter: Lauren Alpert

2472

Usability and acceptability of blood-based hepatitis C virus self-testing (HCVST) among the urban slum population in northern India

Poster presentation

Presenter: Ajeet Bhadoria

2552

Automatic opportunistic age screening for hepatitis C virus. A public health strategy in Galicia, Spain. Project 2023

Poster presentation

Presenter: Juan Turnes Vázquez

2567

Precise estimation of national HBV prevalence: the importance of double hepatitis B surface antigen and hepatitis B core antibody testing in low endemic countries

Poster presentation

Presenter: Arno Furquim d'Almeida

2580

Optimizing a hepatitis C screening model for general population using easily accessible data

Poster presentation

Presenter: Chi Zhang

2619

Optimal strategies for eliminating mother-to-child transmission of hepatitis B in Burkina Faso

Poster presentation

Presenter: Andréa Gosset

2664

Low testing rates but high prevalence of hepatitis delta virus in Saudi Arabia

Poster presentation

Presenter: Faisal M Sanai

2748

Opt-out hepatitis B testing in urban emergency departments, linkage to healthcare and clinical outcomes

Poster presentation

Presenter: Jonathan Durban

2831

Retrospective analysis of longitudinal data for UK adults living with chronic HBV: characteristics of the population on dual therapy

Poster presentation

Presenter: Tingyan Wang

2902

Accessing healthcare: perspectives of people who use drugs

Poster presentation

Presenter: Zoi Papalamprakopoulou

2992

The burden of chronic hepatitis delta in Italy: potential impacts and effects of bulevirtide through cost of illness and cost consequence analysis

Poster presentation

Presenter: Andrea Marcellusi

3082

Prevalence of active hepatitis delta infection among new diagnoses of hepatitis B in the Barcelona metropolitan area

Poster presentation

Presenter: Maria Francesca Cortese

3099

Improved social outcomes after integrated hepatitis C and opioid use disorder treatment

Poster presentation

Presenter: Andrew Talal

3101

Long term outcome among HCV-infected people who use drugs (PWUD) successfully treated for HCV infection with Glecaprevir/Pibrentasvir (G/P)

Poster presentation

Presenter: Rossitta Yung

3111

From kitchen to table: unravelling hepatitis E virus inactivation in pork meat products

Poster presentation

Presenter: Thomas Vanwolleghem

3137

Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of the SIMPLIFY study

Poster presentation

Presenter: Shana Yi

3184

HCV reinfection among people who use drugs (PWUD) treated for HCV infection: a long-term view

Poster presentation

Presenter: Saina Beitari

3187

Maternal health progression: EMR system's contribution to understanding hepatitis prevalence in Uzbekistan

Poster presentation

Presenter: Samantha Hall

3207

Elimination days - How good clinical practice can contribute to the elimination of hepatitis C

Poster presentation

Presenter: Pedro Lages Martins

3222

Exploring the underlying causes of disengagement from hepatitis C care

Poster presentation

Presenter: Kathleen Bryce

3282

Systematic review and meta-analysis of barriers and enablers to hepatitis C direct-acting antiviral treatment initiation

Poster presentation

Presenter: Kathleen Bryce

3292

Characteristics of a prospective cohort undergoing assessment for hepatitis C treatment in London and time to treatment initiation

Poster presentation

Presenter: Kathleen Bryce

3340

Understanding barriers and enablers to hepatitis C treatment initiation: a systematic review of qualitative studies

Poster presentation

Presenter: Kathleen Bryce

Rare liver diseases (including paediatric and genetic) - Basic

14

Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease

Poster presentation

Presenter: Pavel Strnad

58

Correlation of non-invasive tests with histological features and intrahepatic Z-alpha-1 antitrypsin burden in patients with alpha-1 antitrypsin deficiency-associated liver disease

Poster presentation

Presenter: Pavel Strnad

199

Impaired nuclear glycogen metabolism affects liver homeostasis in Argininosuccinic aciduria

Poster presentation

Presenter: Leandro Soria

282

The cyst microenvironment is spatially patterned to promote polycystic liver disease

Poster presentation

Presenter: Scott Waddell

431

SarsCov2 vaccine does not increase the risk of autoimmune liver disease

Poster presentation

Presenter: Stanislas Pol

521

High prevalence of steatotic liver disease and systemic inflammation in hereditary fructose intolerance (HFI) patients independent of age, BMI and the presence of metabolic syndrome

Poster presentation

Presenter: Teresa Cardoso Delgado

763

Impact of helminth infection on the efficacy of COVID-19 mRNA vaccine in mice

Poster presentation

Presenter: Jinpeng Su

1247

A spatiotemporal map of the hepatocyte proteome in alpha-1 antitrypsin deficiency by single-cell and visual proteomics

Oral presentation

Presenter: Florian Rosenberger

1667

Copper overload promotes steatosis in Wilson disease by inhibiting peroxisome proliferator activated receptor alpha - fatty acid binding protein 1- glutathione peroxidase 4 signaling and inducing ferroptosis

Poster presentation

Presenter: Chen Liang

2007

Highly multiplexed spatial analysis of acute pediatric hepatitis of unknown origin indicates a characteristic immune infiltrate as a possible post-acute sequel of COVID-19

Oral presentation

Presenter: Felix Röttele

2150

Activation of the HIF-1alpha pathway in cholangiocytes of patients with biliary atresia and its association with cilia disruption

Poster presentation

Presenter: Patricia Quelhas

2328

p.Pro871Arg variant in JAG1 demonstrates a common manifestation of Alagille's syndrome

Poster presentation

Presenter: Preeti Sharma

2373

The whole genome sequence and transcriptome study on the HCCs derived from patients with Fontan-associated liver disease

Poster presentation

Presenter: Taiji Yamazoe

2582

Primary adult hepatocytes-derived organoids to characterize intrahepatic cholestasis

Poster presentation

Presenter: Benedetta Blarasin

2595

Pronounced vasculature phenotypes in new mouse models with ALGS and BA-associated mutations in Jag1

Poster presentation

Presenter: Anna Maria Frontino

2638

Modelling wolman disease using genetically engineered human liver organoids

Poster presentation

Presenter: Davide Selvestrel

2725

Gene editing to treat liver metabolic disorders: harnessing paired Cas9-Nickases for efficient and safe treatment of primary hyperoxaluria type 1

Poster presentation

Presenter: Laura Torella

2808

Paediatric solid organ transplant recipients (SOTR) demonstrate greater serological response to initial SARS-CoV-2 vaccination than adult SOTR, and comparable rates of antibody degradation

Poster presentation

Presenter: María Pilar Ballester

2835

RNA editing for the treatment of Alpha-1 antitrypsin deficiency

Poster presentation
Presenter: Prashant Monian

3017
Analysis of cellular crosstalk in fibrocystic liver disease (PKHD1^{-/-} mouse) reveals a central role for cholangiocytes, neutrophils and chronic biliary infection in disease pathogenesis
Poster presentation
Presenter: Zehra Syeda

3077
Mutational profile and correlation with Leipzig score in Wilson disease - a comprehensive analysis
Poster presentation
Presenter: ANAND KULKARNI

3117
Introduction of class I-III mutations of CFTR in isogenic human iPSCs-derived cholangiocytes and 3D organoids provides pathophysiological information relevant for treatment of cystic fibrosis-related liver disease (CFLD)
Poster presentation
Presenter: Romina Fiorotto

3150
Endoplasmic reticulum stress in biliary atresia: unravelling cholangiocyte dysfunction through organoid-based RNA sequencing
Poster presentation
Presenter: Yara Hamody

3277
Spectrum of UGT1A1 variations in chinese patients with Gilbert's syndrome
Poster presentation
Presenter: Wenting Tan

Rare liver diseases (including paediatric and genetic) - Clinical

16
Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6 months of givosiran treatment in a subgroup analysis of the phase 3 ENVISION study
Poster presentation

Presenter: Paolo Ventura

30

Evaluation of routine outpatient assessment methods for post-Fontan procedure liver complications

Poster presentation

Presenter: Yohei Koizumi

164

Interim safety results of the ongoing international phase I/II GATEWAY gene therapy trial with VTX-801 conducted in adult patients with Wilson disease

Poster presentation

Presenter: Thomas Damgaard Sandahl

232

Diagnosis and monitoring pathways using non-invasive tests in patients with alpha-1 antitrypsin deficiency-associated liver disease: results from an expert Delphi panel

Poster presentation

Presenter: Virginia C. Clark

266

Porto-sinusoidal vascular disease among patients undergoing surgery for liver metastases: prevalence, non-invasive diagnosis, and burden on surgical outcomes

Poster presentation

Presenter: Elton Dajti

298

Evaluation of secondary sarcopenia and Fontan circulatory failure in post-Fontan hepatic complications

Poster presentation

Presenter: Yohei Koizumi

322

Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: a multicenter retrospective case-control study

Poster presentation

Presenter: Laure Elkrief

358

Reviewing the largest experience of liver transplantation for Wilson's disease in the UK: single centre review of patient and graft outcomes and long term survival

Poster presentation

Presenter: James Liu Yin

359

Raising awareness of long term chelation therapy challenges in Wilson's disease - Potential implications of monitoring and developing skin and vascular complications

Poster presentation

Presenter: James Liu Yin

421

Routine cholestasis genetic testing in patients with intrahepatic cholestasis of pregnancy reveals high prevalence of genetic variants of bile acid transport defects

Poster presentation

Presenter: Naim Alkhouri

534

Quality of life in adults with Wilson disease: a study from the international Wilson disease registry

Poster presentation

Presenter: Claus Niederau

595

Patient survey of Wilsons disease patients in the United Kingdom

Poster presentation

Presenter: William J H Griffiths

746

Clinical and biochemical characteristics of a Danish and Turkish cohort of incident and prevalent patients with primary biliary cholangitis

Poster presentation

Presenter: Hasan Eruzun

766

Performance of spleen stiffness measurement by vibration-controlled transient elastography to rule out high-risk varices in patients with chronic extrahepatic portal vein obstruction without cirrhosis

Oral presentation

Presenter: Lucile Moga

779

Evolution of clinical presentation, treatment and prognosis of patients with alveolar echinococcosis treated at the university hospital Zurich: a 50-year experience

Poster presentation

Presenter: Ansgar Deibel

855

Frequency of ATP8B1, ABCB11 and ABCB4 gene mutations in adult patients with idiopathic chronic cholestasis

Poster presentation

Presenter: Paulo Bittencourt

911

Transaminase Pattern Over Time Is Not Associated with a More Aggressive Hepatic Evolution: Results from the AEEH Wilson Registry.

Poster presentation

Presenter: Marina Berenguer

917

Portal vein recanalization in non-cirrhotic patients with portal vein occlusion: first results of a VALDIG study

Oral presentation

Presenter: Pierre Deltenre

1064

Efficacy and safety of odevixibat in a subgroup of adult patients with progressive familial intrahepatic cholestasis in the PEDFIC 2 study

Poster presentation

Presenter: Christof Maucksch

1078

Sustained improvement of alanine aminotransferase levels in patients with lysosomal acid lipase deficiency treated with sebelipase alfa enzyme replacement therapy: longitudinal data from the international lysosomal acid lipase deficiency registry

Oral presentation

Presenter: Lorenzo D'Antiga

1187

Exchangeable copper quantification falls below normal range in a high proportion of patients with Wilson disease during follow-up

Poster presentation

Presenter: Zoe Mariño

1197

Clinical, radiological and demographic characteristics of a female cohort of polycystic liver disease patients from the United Kingdom

Poster presentation

Presenter: Avisnata Das

1246

A ratio of exchangeable copper below 15% accurately excludes Wilson disease and may be useful for the first-line etiologic work-up within a liver unit

Poster presentation

Presenter: Zoe Mariño

1252

Use of metallothionein 1 as an ancillary tool for the diagnosis of Wilson disease

Poster presentation

Presenter: Clàudia García-Solà

1274

Disease experience and care expectations in european patients with immune-mediated liver disease

Poster presentation

Presenter: Pierre-Antoine Soret

1327

Autoantibody diagnostics in pediatric non-viral liver diseases: a multicenter retrospective head-to-head comparison of immunofluorescence- and enzyme-linked immunosorbent assay-based testing

Poster presentation

Presenter: Theresa Kirchner

1384

Intrauterine blood transfusion causes dose- and time-dependent signal alterations in the liver and the spleen on fetal magnetic resonance imaging

Poster presentation

Presenter: Michael Schwarz

1640

Next-generation sequencing for non-cirrhotic portal thrombosis and its impact on portal hypertension

Poster presentation

Presenter: Ilias Kounis

1682

Recanalization for Budd-Chiari syndrome and development of a prognostic score: a multicentre study of 834 cases from China

Poster presentation

Presenter: Guohong Han

1799

Liver fibrosis status and circulating polymers in alpha-1 antitrypsin deficiency patients with a Z/rare genotype

Poster presentation
Presenter: Naomi Kappe

1869
TRISTAN- Retrospective real world data in management of Wilson disease therapies in Germany
Poster presentation
Presenter: Isabelle Mohr

2049
Treatment adherence and associated clinical outcomes for Wilson disease patients: a real-world, retrospective, multinational survey
Poster presentation
Presenter: Niall Hatchell

2166
Combination of liver steatosis and premenopausal is a risk factor for DILI due to cyclin-dependent kinase 4/6 inhibitors as first-line treatment for metastatic breast cancer
Poster presentation
Presenter: Mar Riveiro Barciela

2227
Impact of metabolic alterations on liver phenotype of patients with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ)
Poster presentation
Presenter: Christina Schrader

2289
Longitudinal assessment of individuals with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ genotype) provides evidence for clinical patient management
Poster presentation
Presenter: Malin Fromme

2294
Prevalence and predictors of porto-sinusoidal vascular disorder in patients with persistent and unexplained gamma-glutamyl transferase elevation: a multicenter study
Poster presentation
Presenter: Nicola Pugliese

2304
Safety and efficacy of direct oral anticoagulants in cirrhotic and non-cirrhotic splanchnic vein thrombosis
Poster presentation
Presenter: Lucia Giuli

2333

Heterozygosity for rare Apolipoprotein B variants predispose to severe metabolic associated steatotic liver disease

Poster presentation

Presenter: Matteo Mureddu

2345

Determination of liver biopsy quality criteria for the diagnosis of porto-sinusoidal vascular disorder (PSVD)

Poster presentation

Presenter: Chloé De Broucker

2348

Hepatopulmonary syndrome in patients with porto-sinusoidal vascular disease: prevalence, characteristics, risk factors and outcome

Oral presentation

Presenter: Ylang Spaes

2536

Von Willebrand factor antigen reflects portal hypertension severity in porto-sinusoidal vascular disorder and predicts liver-related outcomes

Poster presentation

Presenter: Lorenz Balcar

2546

The impact on adherence and patient satisfaction following a switch to trientine tetrahydrochloride for the maintenance therapy in Wilson's disease

Poster presentation

Presenter: Massimo Zuin

2548

Elevated hepatic copper content in porto-sinusoidal-vascular disorder: leading down a wrong track

Poster presentation

Presenter: Lorenz Balcar

2556

Spleen stiffness and VWF-based non-invasive tests reflect severity of prehepatic and presinusoidal portal hypertension

Poster presentation

Presenter: Lorenz Balcar

2559

Advances in the diagnosis of cholestatic liver diseases with the implementation of exome sequencing

Poster presentation

Presenter: Ignasi Olivas

2650

The enhanced liver fibrosis test in alpha-1 antitrypsin deficiency patients homozygous for the Z-allele

Poster presentation

Presenter: Naomi Kappe

2747

Patients with alpha-1-antitrypsin deficiency and the risk of developing liver events: a longitudinal cohort study

Poster presentation

Presenter: Pavel Strnad

2801

Neurodegeneration in aceruloplasminemia and carriers of heterozygous ceruloplasmin variants: brain atrophy or iron toxicity?

Poster presentation

Presenter: Marlene Panzer

2876

Liver steatosis and fibrosis in children with diabetes mellitus type 1: single-center analysis including MASLD-associated genetic variants

Poster presentation

Presenter: Wiktor Smyk

2920

Enhanced liver phenotyping in unexplained chronic liver disease: the LIPHE algorithm

Poster presentation

Presenter: Anna Sessa

2987

Role of transient elastography in diagnosis and prognosis of Fontan-associated liver disease

Poster presentation

Presenter: Marta Cuadros

2990

Early predictors of successful Kasai portoenterostomy for biliary atresia

Poster presentation

Presenter: Arjun Maria

3057

Design and study population of MITIGATE: the first multinational randomized controlled clinical trial in IgG4 related disease, evaluating the efficacy and safety of the CD19 B cell depleting agent inebilizumab

Poster presentation

Presenter: Emma Culver

3076

Clinical profile and outcomes of Wilson's disease in the young and adult population

Poster presentation

Presenter: ANAND KULKARNI

3159

Usefulness of serological scores in the diagnosis of Fontan-associated liver disease

Poster presentation

Presenter: Marta Cuadros

3201

Comorbidity burden associated with fatigue or pruritus in patients with primary biliary cholangitis in the United States: a matched case-control study

Poster presentation

Presenter: Nisreen Shamseddine

3320

Non-invasive testing reveals fibrosis risk in heterozygous Alpha-1 Antitrypsin deficiency

Poster presentation

Presenter: George Marek

3355

Performance of transient elastography, Fib4 and APRI in the diagnosis of severe liver fibrosis in patient with HFE hemochromatosis

Poster presentation

Presenter: Edouard Bardou-Jacquet

Viral hepatitis A/E: Clinical aspects

1330

Evaluation of molnupiravir as an antiviral against hepatitis E virus infection

Poster presentation

Presenter: Siddharth Sridhar

1457

Hepatitis E in Japan: a nationwide survey 2012-2017

Poster presentation

Presenter: Takeshi Matsui

Viral hepatitis B and D: Clinical aspects

36

HBV DNA thresholds and immune tolerance: unveiling new insights from cross-sectional hepatic histology data in hepatitis B

Poster presentation

Presenter: Tingyu Zhang

59

Are healthcare professionals appropriately screening for hepatitis delta virus in patients with chronic hepatitis B? Results from an interactive decision support app

Poster presentation

Presenter: Sarah Anderson

126

Detection of functional HBV-specific CD8+ response is associated with significant decrease of HBsAg level after treatment withdrawal in eAg(-)chronic hepatitis B

Poster presentation

Presenter: Henar Calvo Sánchez

172

Unique characteristics and risk of liver-related events among individuals with hepatitis D virus infection with and without concurrent hepatitis C virus infection: a United States administrative claims analysis

Poster presentation

Presenter: Laura Telep

263

Association between metabolic dysfunction, severity of liver fibrosis and fibrosis progression in patients with chronic hepatitis B – an individual patient data meta-analysis

Poster presentation

Presenter: Lisa M. van Velsen

373

The UK experience of liver transplantation for HBV: excellent clinical outcomes despite a significant burden of HBV/Delta disease and wide variation in hepatitis B immunoglobulin prophylaxis practices – time for a consistent approach?

Poster presentation
Presenter: Almuthana Mohamed

509

Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B

Poster presentation
Presenter: Robert Wong

613

Effectiveness of immunoprophylaxis for preterm infants of mothers having chronic hepatitis B virus infection: a retrospective study

Poster presentation
Presenter: Guorong Han

672

Evaluating the effectiveness and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus

Poster presentation
Presenter: Xiaofeng Sun

681

Decline of Serum HBV RNA level During the First Week of Nucleos(t)ide Analogues Therapy Is Associated with Liver Injury and More Efficient Clearance of Hepatitis B Virus

Poster presentation
Presenter: Liandong Wu

703

Improvement of liver stiffness during nucleo(s)tide analogue treatment in patients with chronic hepatitis B and advanced fibrosis is not associated with a reduction in hepatocellular carcinoma risk

Poster presentation
Presenter: Lesley A. Patmore

726

Chronic HDV coinfection (CHD) is characterized by a more elevated production of Middle and Large HBsAg than HBV mono-infection, that parallels HDV replicative and cytolytic activity

Poster presentation
Presenter: Lorenzo Piermatteo

835

The coinfection of hepatitis C virus or human immunodeficiency virus in chronic hepatitis B in South Korea: A population-based study using the Korean Health Insurance Review & Assessment Service database

Poster presentation
Presenter: Jae Yoon Jeong

841
Evaluation of a novel hepatitis B DNA test from fingerstick capillary blood at the point-of-care as a tool to enhance clinical management
Poster presentation
Presenter: Gail Matthews

856
Poor Performance of FIB-4 in Fibrosis Prediction for Chronic Hepatitis B Patients with Metabolic Dysfunction–Associated Liver Disease in Daily Clinical Practice
Poster presentation
Presenter: Fadi Abu Baker

871
Prediction of hepatocellular carcinoma risk and liver-related events in chronic hepatitis D, an international retrospective cohort study (RIDE)
Poster presentation
Presenter: Lesley A. Patmore

924
The effect of age and pregnancy on transition into Immune Active disease in Immune Tolerant patients – a retrospective cohort study of 245 patients
Poster presentation
Presenter: Edo J. Dongelmans

947
Impact of bulevirtide given with or without nucleos(t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection
Poster presentation
Presenter: Pietro Lampertico

948
Hepatitis B core-related antigen (HBcrAg) in a prospective French hospital database on chronic hepatitis B (HBVbiomark)
Poster presentation
Presenter: Erwan Vo Quang

1039
Prevalence, fate and implication of gray zone on the trajectory of hepatitis B surface antigen in treatment-naïve young adults with chronic hepatitis B infection
Poster presentation
Presenter: Lung Yi Loey Mak

1040

Hepatitis B treatment in Africa: experiences from a scale-up program in Ethiopia

Poster presentation

Presenter: Lasse Rossvoll

1075

Machine learning can improve prediction of hepatitis B surface antigen seroclearance: A large multicentre cohort study in the United Kingdom

Poster presentation

Presenter: Tingyan Wang

1080

Healthcare resource utilisation and costs of hepatitis delta virus infection vs hepatitis B virus mono-infection across disease states among hospitalised adults in Italy

Poster presentation

Presenter: Chong Kim

1105

Baseline and reduction at 1 year of hepatitis B surface antigen level predicts functional cure and low HBsAg titer: A long-term kinetics of hepatitis B surface antigen

Poster presentation

Presenter: Soon Kyu Lee

1123

Epidemiological characteristics of hepatitis D virus infection in patients with hepatitis B related hepatocellular carcinoma

Poster presentation

Presenter: Tangnuer Talafu

1153

To establish the threshold for transient elastography indicating advanced fibrosis in patients with chronic hepatitis B and hepatic steatosis

Poster presentation

Presenter: Fajuan Rui

1267

Bulevirtide efficacy and safety in chronic hepatitis delta patients on liver transplant waiting list

Poster presentation

Presenter: Magdalena Meszaros

1312

Off-treatment outcomes after discontinuing tenofovir-based treatment in hepatitis B e antigen-positive and hepatitis B e antigen-negative patients with chronic hepatitis B virus

Poster presentation
Presenter: Maria Buti

1339

Heterogeneity in the diagnostic performances of HDV-RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study

Poster presentation
Presenter: Romina Salpini

1371

Impact of pregnancy on global and HBV-specific B-cell immunity

Poster presentation
Presenter: Anna Pocerull

1417

High burden of cirrhosis and increasing response rates to bulevirtide-based regimens: insights from the austrian prospective hepatitis D registry

Poster presentation
Presenter: Michael Schwarz

1444

Comparing the impact of Interferon-based and direct-acting agents therapies on HBsAg seroclearance rates in patients with hepatitis B and hepatitis co-infection

Poster presentation
Presenter: Cheng Er Hsu

1449

Similarly low risk of hepatocellular carcinoma and cirrhotic complications in patients in the HBeAg-negative indeterminate phase compared with chronic infection

Poster presentation
Presenter: Vicki Wing-Ki HUI

1487

Clinically significant liver stiffness decrease, as defined by the Baveno VII consensus, is associated with improved long-term prognosis in chronic hepatitis B patients with compensated advanced chronic liver disease

Poster presentation
Presenter: Rex Wan-Hin Hui

1527

The predictive value of serum HBV RNA level in chronic hepatitis B patients treated with nucleos(t)ide analogues

Poster presentation
Presenter: Yandi Xie

1652

Risk of hepatocellular carcinoma decreases after antiviral therapy-induced HBsAg seroclearance

Poster presentation

Presenter: Han Ah Lee

1696

Real world outcomes of hepatitis delta patients with mild or moderate fibrosis

Poster presentation

Presenter: Sabela Lens

1702

Hepatitis B surface antigen (HBsAg) seroclearance following discontinuation of nucleos(t)ide analogues (NA) treatment has comparable durability to HBsAg seroclearance achieved during NA therapy

Poster presentation

Presenter: Terry Cheuk-Fung Yip

1715

A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B

Poster presentation

Presenter: Moon Haeng Hur

1721

The impact of alanine aminotransferase fluctuation on the hepatocellular carcinoma risk in chronic hepatitis B patients

Poster presentation

Presenter: Youngsu Park

1723

Optimizing HDV diagnosis algorithm in Israel: reflex testing, prevalence of HDV seropositive individuals identified in Maccabi HealthCare services and assessment of three commercially available HDV viral load assays

Poster presentation

Presenter: Orna Mor

1732

Serum HBsAg rather than HBV DNA reflects liver HBV transcript levels of hepatitis B patients treated by nucleoside analogues

Poster presentation

Presenter: Feng Ren

1745

Detectable HDV RNA is associated with worse outcome in patients infected with HBV and HDV: results from a meta-analysis

Poster presentation

Presenter: Jackie Bitton

1771

Real-world clinical data-driven modelling on the initiation time of peripartum antiviral prophylaxis among pregnant women with chronic hepatitis B virus infection

Poster presentation

Presenter: Naijuan Yao

1788

Targeted capture single-cell sequencing provides new insights into persistent hepatitis B virus (HBV) infection

Poster presentation

Presenter: Yanfang Huang

1810

The concentration of HDV-RNA correlates with the probability of developing clinical events in patients with chronic hepatitis D

Poster presentation

Presenter: Adriana Palom

1857

Burden of liver disease progression in patients with chronic HDV infection: a population-based study for France

Poster presentation

Presenter: Lucia Parlati

1873

An initial study of geospatial approach for molecular epidemiology of hepatitis B virus in Indonesia: tale from two regions

Poster presentation

Presenter: Sri Jayanti

1885

Hepatitis B core-related antigen is a good predictor for high risk of mother to child transmission in chronic hepatitis B

Poster presentation

Presenter: Ivana Carey

2019

Relapse incidence and severe flares in chronic hepatitis B patients with lymphoma post rituximab-based chemotherapy versus HBeAg-negative hepatitis B patients without cancer after nucleos(t)ide analogue cessation

Poster presentation

Presenter: Yen-Chun Liu

2237

Enhancing hepatitis delta diagnosis in southern Spain: efficacy and cost-effectiveness of double reflex testing

Poster presentation

Presenter: Federico Garcia Garcia

2330

Chronic HDV infection is sustained by an intense HBsAg production from integrated HBV-DNA in the setting of a limited or even absent HBV reservoir

Oral presentation

Presenter: Romina Salpini

2356

Mitochondrial dysfunction and metabolic plasticity in the hepatitis B virus specific immune response: new insights and implications for hepatitis B virus cure

Poster presentation

Presenter: Saima Ajaz

2380

Screening rates, prevalence, and natural history of hepatitis B/delta virus co-infection vs. hepatitis B mono-infection: data from a large US integrated healthcare system

Poster presentation

Presenter: Varun Saxena

2431

The unique role of hepatitis B virus enhancer 1 in unevenly activating preS1 and preS2 promoters of integrated HBV DNA which impacts HBsAg secretion efficiency

Poster presentation

Presenter: Fengmin Lu

2450

HBV precore and basal core promoter mutations exert direct cytopathic effect in humanized mice

Poster presentation

Presenter: Fengmin Lu

2479

Efficacy and safety of Tenofovir Amibufenamide in the treatment of chronic hepatitis B: a real-world multicenter clinical study

Poster presentation

Presenter: Yaping Li

2489

Proportions of indeterminate phase of patients with chronic hepatitis B virus infection according to different international guidelines

Poster presentation

Presenter: Shaoqiu Zhang

2528

Metabolic dysfunction-associated steatotic liver disease is not independently associated with complete response to oral antiviral treatment in chronic hepatitis B

Poster presentation

Presenter: Juseok Lee

2544

High levels of anti-HBc are associated with higher rates of immune control after 48 weeks of treatment with PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B

Poster presentation

Presenter: Maria Pfefferkorn

2555

High frequency of liver cirrhosis in european patients with hepatitis D: first data from a large multicentre study (D-SOLVE and HDV-1000 consortia)

Poster presentation

Presenter: Lisa Sandmann

2561

An online web-based calculator accurately diagnoses immune tolerant phase in chronic HBV-infected patients

Poster presentation

Presenter: Chi Zhang

2596

Limited use of established risk scores for the prediction of hepatocellular carcinoma in patients with chronic hepatitis D virus infection

Poster presentation

Presenter: Robin Iker

2615

Quantification of plasma hdv rna in untreated and bulevirtide-treated patients with chd: a comparison between robogene 2.0, eurobioplex and altostar

Poster presentation
Presenter: Maria Paola Anolli

2616
Effect of diabetes on the risk of fibrosis progression in patients with chronic hepatitis B
Poster presentation
Presenter: Mi Na Kim

2666
Feasibility of aMAP combined with liver stiffness assessed using transient elastography for prediction of hepatocellular carcinoma development in patients with chronic hepatitis B
Poster presentation
Presenter: Hye Yeon Chon

2695
Statins in untreated chronic HBV link with improved survival, liver outcome and inflammation: a large multicenter retrospective real-world cohort study
Poster presentation
Presenter: Mohammed Suki

2778
Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy
Poster presentation
Presenter: Fabien Zoulim

2803
HBV-specific T cell specificity and functionality can be influenced by stage of chronic HBV disease, antigen levels and age
Poster presentation
Presenter: An De Creus

2824
Hepatitis B virus genotype and some baseline characteristics, but not race, affect HBsAg kinetics during nucleos(t)ide analogue therapy
Poster presentation
Presenter: Rachel Wen-Juei Jeng

3044
10-year clinical outcomes in chronic hepatitis B patients treated with tenofovir in The Gambia, West Africa
Poster presentation
Presenter: Erwan Vo Quang

3053

Metabolic dysfunction-associated steatotic liver disease (MASLD) evaluation in HBeAg negative chronic hepatitis B patients: italian cross-sectional observational study

Poster presentation

Presenter: Livio Criscuolo

3106

Serological and nucleic acid testing laboratory screening rates for hepatitis delta virus among adult patients in the United States

Poster presentation

Presenter: Chong Kim

3208

Disease progression and persistent alanine aminotransferase elevation in HCV/HIV persons after DAA – related eradication: role of HBV and HDV co-infections

Poster presentation

Presenter: Roberto Rossotti

3237

Chronic hepatitis delta with normal ALT and hepatitis D viremia: unravelling its natural history

Poster presentation

Presenter: Muge Ozari Gulnar

3245

Compassionate use of REP 2165-Mg in chronic HBV/HDV patients with progressive liver disease and failure to previous pegIFN therapy

Poster presentation

Presenter: Andrew Vaillant

3297

HDV infection in Israel: epidemiology and co-morbidities

Poster presentation

Presenter: hisham sholy

3300

Early treatment of patients with indeterminate HBV viraemia does not improve retention in care and risks overtreating patients who may spontaneously clear HBsAg

Poster presentation

Presenter: Sharon Macleod

3301

The underestimated burden of hepatitis D among people living with chronic hepatitis B in the Gambia

Poster presentation

Presenter: Erwan Vo Quang

Viral Hepatitis B and D: Current therapies

51

Tenofovir-based antiviral therapy reduces long-term incidence of hepatocellular carcinoma in chronic hepatitis B patients

Poster presentation

Presenter: W. Ray Kim

213

Risk of hepatocellular carcinoma after curative treatment when switching from Tenofovir Disoproxil Fumarate or Entecavir to Tenofovir Alafenamide: a real-world multicenter cohort study

Poster presentation

Presenter: Hyunjae Shin

427

A national multicenter study on initial antiviral treatment preferences on chronic hepatitis B: Entecavir versus Tenofovir disoproxil fumarate

Poster presentation

Presenter: Tansu Yamazhan

442

HEllenic multicenter ReAl-life CLInical Study for bulevirtide therapy in chronic hepatitis D (HERACLIS_BLV_D)

Poster presentation

Presenter: Margarita Papatheodoridi

496

Efficacy and safety of tenofovir alafenamide fumarate in preventing HBV vertical transmission in high maternal viral load: a multi-centre, prospective cohort study

Poster presentation

Presenter: Xiaoping Tang

652

Changes in metabolic parameters after switching from tenofovir disoproxil fumarate to tenofovir alafenamide among chronic hepatitis B patients: a randomized, open-label controlled trial

Poster presentation

Presenter: Titinan Veerachit-O-larn

861

Progression and risk factors after treatment with tenofovir or entecavir for chronic hepatitis B based on a multistate modeling approach

Oral presentation

Presenter: Wan-Jung Wu

950

Improvement in liver histology is observed in most patients with chronic hepatitis delta after 48 weeks of bulevirtide monotherapy

Poster presentation

Presenter: Pietro Lampertico

972

Characterization of hepatitis D virus RNA and hepatitis B surface antigen kinetics during pegylated interferon-alpha monotherapy: The D-LIVR study

Poster presentation

Presenter: Ohad Etzion

1063

48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204

Oral presentation

Presenter: Tarik Asselah

1276

Undetectable hepatitis delta virus RNA at the end of treatment with bulevirtide and pegylated interferon alpha-2a is an important predictor of 48 weeks sustained virologic response in chronic hepatitis delta

Poster presentation

Presenter: Fabien Zoulim

1337

Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis

Oral presentation

Presenter: Young-Suk Lim

1342

DARING-B study: 5-year outcomes after nucleos(t)ide analogue (NA) cessation in Caucasian non-cirrhotic patients with HBeAg-negative chronic hepatitis B (CHBe-)

Poster presentation

Presenter: Margarita Papatheodoridi

1524

Hepatic flares after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B: results from the Nuc-Stop study

Poster presentation

Presenter: Marte Holmberg

1535

10-year results under tenofovir disoproxil fumarate and entecavir in chronic hepatitis B; HBV clearance rare, disease outcomes good

Poster presentation

Presenter: Zülal İstemihan

1560

Comparative efficacy of standard and low-dose peginterferon-alpha2a in chronic delta hepatitis: a retrospective controlled study

Poster presentation

Presenter: Asim Qurbanov

1643

Association between post-treatment ALT elevation and subsequent hepatitis B surface antigen seroclearance in chronic hepatitis B patients stopping nucleos(t)ide analogue therapy

Poster presentation

Presenter: Yao-Chun (Holden) Hsu

1674

Functional cure and prediction analysis of pegylated interferon alpha-2b in HBeAg negative chronic hepatitis B patients with normal ALT (Ice-breaking Project in China): an interim analysis update

Poster presentation

Presenter: Xiaoguang Dou

1769

Long-term virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy for up to 120 weeks: a retrospective multicenter european study (save-d)

Poster presentation

Presenter: Elisabetta Degasperi

1841

Improved HBV-RNA quantification by HBV-RNA reverse transcription droplet digital PCR

Poster presentation

Presenter: Bernhard Kleter

1864

Comparable outcomes between Besifovir and other antiviral therapies in hepatocellular carcinoma development among patients with chronic hepatitis B

Poster presentation

Presenter: Jae Seung Lee

1882

Demographic, virological and clinical features of patients with chronic hepatitis delta treated with bulevirtide: a multicenter italian study (d-shield)

Poster presentation

Presenter: Maria Paola Anolli

1993

Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort

Poster presentation

Presenter: Victor de Lédighen

2000

The composition of HBsAg along with HDV-RNA predicts virological response in chronic hepatitis delta patients treated with bulevirtide for 48 weeks

Poster presentation

Presenter: Stefano D'Anna

2046

Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis

Oral presentation

Presenter: Elisabetta Degasperri

2260

Tenofovir disoproxil fumarate and tenofovir alafenamide interruption in hepatitis B and human immunodeficiency virus co-infected individuals in the United States: monitoring practices and incidence of hepatitis B reactivation or hepatitis flare

Poster presentation

Presenter: Douglas T Dieterich

2441

Factors influencing HBsAg clearance in children with chronic hepatitis B undergoing antiviral therapy: significance of age at treatment onset and HBeAg titer dynamics

Poster presentation

Presenter: Byung-Ho Choe

2600

The large (LHBs) and middle (MHBs) hepatitis B surface antigen are associated with response to bulevirtide or PEG-IFNa treatment in patients with chronic hepatitis Delta (CHD)

Poster presentation

Presenter: Maria Pfefferkorn

2832

HBsAg loss in inactive chronic hepatitis B carriers is dependent on level of qHBsAg and interferon response: a randomised control trial

Poster presentation

Presenter: Seng Gee Lim

2849

Effectiveness and safety analysis of switching to tenofovir alafenamide after entecavir or tenofovir treatment

Poster presentation

Presenter: xuemei Jiang

Viral Hepatitis B and D: New therapies, unapproved therapies or strategies

166

Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)

Oral presentation

Presenter: Tarik Asselah

331

Adoptive immunotherapy using dendritic cells pulsed by hepatitis b vaccine and the induced t-cells mixture combined antiviral drugs in treatment naive patients with chronic hepatitis b - a multi-center clinical phase ii study

Poster presentation

Presenter: Yurong Gu

406

A double-blind, placebo-controlled, single-ascending dose phase I a study to evaluate the safety, tolerability, and pharmacokinetics of HT-101, an investigational small interfering ribonucleic acid targeting hepatitis B virus in Chinese healthy subjects

Poster presentation

Presenter: Shanzhong Zhang

505

Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone

Oral presentation

Presenter: Kosh Agarwal

592

Safety, tolerability, and hepatitis B surface antigen reduction of HT-101 in chronic hepatitis B patients: preliminary results from a phase I b study

Poster presentation

Presenter: Shanzhong Zhang

603

Extended treatment of HBeAg+ CHB subjects with the Capsid assembly modulator ALG-000184 with or without Entecavir is associated with reductions in viral markers and favorable anti-HBeAb trends

Poster presentation

Presenter: Man-Fung Yuen

749

Tobevirbart (VIR-3434), a monoclonal antibody, resistance analysis in participants with chronic HBV: Results from a Phase 1 single dose study

Poster presentation

Presenter: Andrea Cathcart

807

Preclinical profiling of ABI-6250, a novel orally bioavailable small-molecule therapeutic candidate for the treatment of chronic hepatitis D

Poster presentation

Presenter: Marc P. Windisch

842

A double-blind, placebo-controlled, single-ascending dose phase I a study to evaluate the safety, tolerability, and pharmacokinetics of HT-102, a neutralizing antibodies against the hepatitis B surface antigen in Chinese healthy volunteers

Poster presentation

Presenter: Shanzhong Zhang

895

Dosing with the Capsid Assembly Modulator ALG-000184 in Untreated HBeAg Negative CHB Subjects Results in Potent Antiviral Effects Including Suppression of HBV DNA/RNA and Declines in HBcrAg Levels

Poster presentation

Presenter: Kosh Agarwal

957

Pharmacokinetics and safety of the monoclonal antibody tobevibart (VIR-3434) administered as monotherapy or in combination with the small interfering RNA elebsiran (VIR-2218) in cirrhotic participants with mild hepatic impairment

Poster presentation

Presenter: Li Wang

977

Modeling dual antiviral activity of lonafarnib to explain hepatitis D virus RNA negativity 24 weeks after end of therapy despite RNA positivity at end of therapy: The D-LIVR study

Poster presentation

Presenter: Harel Dahari

1143

Promising preliminary data on preclinical efficacy with an innovative plasmid-launched live attenuated virus vaccine for chronic hepatitis B

Poster presentation

Presenter: Frederik Pauwels

1161

High-dimensional analysis of flow cytometry data reveals differences in post-treatment frequencies of naïve B cells, CD56dim natural killer cells, and terminally differentiated effector memory CD8+ T cells in responders versus non-responders to bepirovirs

Poster presentation

Presenter: Jennifer M. Singh

1192

Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: indirect evidence from B-together peripheral longitudinal biomarker analysis

Poster presentation

Presenter: Shilpy Joshi

1392

Antiviral efficacy of REP 2139-Mg and effects on HVPg in HDV/HBV coinfecting patients with cirrhosis and portal hypertension non-responding to previous bulevirtide treatment

Poster presentation

Presenter: Michael Schwarz

1480

Epidemiological data and clinical profiles of hepatitis B surface antigen levels in chronic hepatitis B: implications for novel drug development

Poster presentation

Presenter: Rex Wan-Hin Hui

1484

Rapid hepatitis B surface antigen reduction in chronic hepatitis B virus infection: preliminary results from a phase I b study evaluating multiple ascending doses of HT-102, a neutralizing antibodies against hepatitis B surface antigen in chronic hepatiti

Poster presentation

Presenter: Shanzhong Zhang

1618

Safety, tolerability, and pharmacokinetics of BJT-778, a monoclonal antibody for treatment of chronic hepatitis B and chronic hepatitis D, following single ascending doses in healthy volunteers

Poster presentation

Presenter: Edward J. Gane

1690

Long-term hepatitis B surface antigen response after finite treatment with siRNAs ARC-520 or JNJ-3989

Oral presentation

Presenter: Lung Yi Loey Mak

1894

Study on the role of dendritic cells in CHB patients treated with intermittent Interferon therapy

Poster presentation

Presenter: Minghui Li

2059

Characterization of BJT-778, an anti-HBsAg neutralizing monoclonal antibody for treatment of hepatitis B virus and hepatitis D virus infections

Poster presentation

Presenter: Hilario Ramos

2389

Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment

Poster presentation

Presenter: Man-Fung Yuen

2390

Association of baseline characteristics and plasma ALG-001075 to HBsAg responses in HBeAg+ CHB subjects following ALG-000184±ETV treatment

Poster presentation

Presenter: Kha Le

2512

A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos(t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B – Interim results of the OCTOPUS-1 study

Oral presentation

Presenter: Tarik Asselah

2521

Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver

Oral presentation

Presenter: Lena Allweiss

2565

Viral sequence analysis of chronic hepatitis B (CHB) patients treated with the silencing RNA (siRNA) JNJ-3989 in the REEF-1 and REEF-2 clinical studies

Poster presentation

Presenter: Thierry Verbinnen

2823

VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels

Poster presentation

Presenter: Dereck Tait

2841

Downregulation of soluble FASLG as a potential mechanism of enhanced immune-related clearance of infected hepatocytes induced by JNJ-73763989 in HBeAg-negative virologically suppressed chronic hepatitis B patients

Poster presentation

Presenter: Simon Verheijden

2935

Intrahepatic changes in immunologic and virologic markers during siRNA JNJ-73763989 (JNJ-3989) based treatment of chronic hepatitis B (CHB) patients: imaging mass cytometry (IMC) analyses from the INSIGHT study

Poster presentation

Presenter: Simon Verheijden

3123

Safety and efficacy of REP 2139-Mg in hepatitis D patients with advanced liver disease: an international compassionate use program

Oral presentation

Presenter: Christiane Stern

Viral Hepatitis C: Clinical aspects including follow up after SVR

131

Improvement of hepatitis C virus care cascade by In-hospital Reflex tEsting ALarm-C (REAL-C) model

Poster presentation

Presenter: Jonggi Choi

274

Long-term liver morbidity and mortality after HCV elimination by direct-acting antivirals in patients with chronic hepatitis C: results from a large-scale, multicenter cohort study

Oral presentation

Presenter: Eiichi Ogawa

275

Baseline gamma-glutamyl transpeptidase levels are associated with aggravation of esophagogastric varix after direct-acting antiviral therapy in cirrhotic patients with hepatitis C virus

Poster presentation

Presenter: Yuki Tahata

438

Individualized intervals for streamlined directly observed therapy in PWIDs - a unique approach to continue HCV microelimination throughout the COVID19 pandemic

Poster presentation

Presenter: Caroline Schwarz

440

Achieving HCV elimination in underserved populations - an austrian initiative for HCV care for homeless people without medical insurance

Poster presentation

Presenter: Caroline Schwarz

513

Sustained virological response after early discontinuation of HCV treatment

Poster presentation

Presenter: Robert Flisiak

668

Prediction of outcomes in patients with HCV compensated liver cirrhosis after SVR: results from 5-years of follow-up

Poster presentation

Presenter: Luisa Ranieri

737

The risk of hepatocellular carcinoma development in DAA treated vs untreated cirrhosis patients with chronic HCV infection: a propensity score analysis in the PITER cohort

Poster presentation

Presenter: Maria Giovanna Quaranta

935

Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR)

Oral presentation

Presenter: Pierre Nahon

1028

Liver fibrosis and steatosis in children after effective treatment of chronic hepatitis C using direct acting antivirals

Poster presentation

Presenter: Anna Dobrzeniecka

1104

Regression of hepatic fibrosis in patients with chronic hepatitis C treated with direct-acting antivirals (DAAs). A long-term, prospective, observational study

Poster presentation

Presenter: Christos Triantos

1191

Impact of hepatitis C treatment on mortality among liver cancer patients in Georgia - 2015-2022

Poster presentation

Presenter: Anna Khoperia

1217

Safety and efficacy of two pangenotypic direct acting antivirals (sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) for the treatment of hepatitis C in children

Poster presentation

Presenter: Ewa Talarek

1228

Incidence of hepatocellular carcinoma in patients with hepatitis C treated with direct-acting antiviral agents: results of a long-term prospective study period

Poster presentation

Presenter: Emanuela De Santis

1362

A new pattern for hepatitis C management in hospital: establishment and effectiveness verification

Poster presentation

Presenter: Siheng Zhu

1396

Analysis of a decentralized model interdisciplinary for the elimination of HCV in vulnerable population in the province of Huelva (Spain). To continue advancing in the elimination of hepatitis C, it is necessary to establish a clearly defined integrated c

Poster presentation

Presenter: Gema Romero

1473

Prognosis after sustained virologic response of chronic hepatitis C related cirrhosis patients treated with direct acting antiviral treatment; interim analysis of multicenter prospective observational study

Poster presentation

Presenter: Jeong Han Kim

1578

Long term liver-related events in patients with HCV-related liver disease and advanced fibrosis after sustained virological response with direct-acting antivirals

Poster presentation

Presenter: Jorge Barajas

1586

Predictive performance of HCC risk scores in chronic hepatitis C patients with advanced fibrosis after achieving SVR: real-world experience from a tertiary UK centre

Poster presentation

Presenter: Riham Soliman

1708

Burden of extrahepatic manifestations after HCV cure: assessing the effect of IFN versus DAA-induced SVR in a large population-based cohort in British Columbia, Canada

Poster presentation

Presenter: Dahn Jeong

1728

Renin-angiotensin inhibitor intake is associated with improved survival in patients with chronic hepatitis C viral infection following SVR – data from the german hepatitis C-registry (DHC-R)

Poster presentation

Presenter: Tammo Lambert Tergast

1768

Is hepatitis C screening based on risk factors enough in primary care setting?

Poster presentation

Presenter: Elena Vargas-Accarino

1912

Artificial intelligence model for predicting liver-related events in non-cirrhotic patients after successful treatment by direct-acting antivirals for chronic hepatitis C

Poster presentation

Presenter: Huapeng Lin

2073

Clinical interventions and use of resources for the management of adverse effects associated with multiple drug interactions in the hepatitis C population

Poster presentation

Presenter: Marinela Mendez

2109

Knowledge, perceptions and barriers to the diagnosis and treatment of hepatitis C among persons who inject drugs: findings from the Educate-Test-Treat (ETT) programme in Singapore

Poster presentation

Presenter: Shann Long

2205

Screening for chronic hepatitis C in pre-surgical patients

Poster presentation

Presenter: Mercedes Vergara

2216

Prognostic implications of liver stiffness impairment after HCV cure in cACLD patients

Poster presentation

Presenter: Monica Pons

2242

Long-term histological fibrosis evolution following sustained virological response after hepatitis C-recurrence in liver-transplanted patients

Poster presentation

Presenter: Tibo Lemmens

2271

Impact of hepatitis C cure on outcomes for patients undergoing curative therapy for hepatocellular carcinoma

Poster presentation

Presenter: Alex Wynne

2281

The prognostic influence of toll-like receptor 4 +3725G/C gene polymorphism on biochemical profile among chronic HCV hepatitis patients

Poster presentation

Presenter: Tetiana Bevz

2752

Evaluation of LiverRisk score as predictor of liver fibrosis and mortality in patients with HCV-related hepatitis treated with direct acting antivirals

Poster presentation

Presenter: Amalia Rita Caspanello

2894

Hepatitis C lost to follow-up rates in primary care practices in Belgium

Poster presentation

Presenter: Marie Coessens

2910

Lead-in cohort results from a phase 2 study of a novel 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection

Poster presentation

Presenter: Alina Jucov

2958

Metabolic factors predict significant liver fibrosis in people who use drugs (PWUD) and general population with HCV infection. Time to re-consider the follow-up strategy in chronic hepatitis C patients

Poster presentation

Presenter: Hariklia Kranidioti

3145

Higher cardiovascular burden in people living with HIV (PLWH) with metabolic syndrome and history of HCV infection

Poster presentation

Presenter: Alessia Siribelli

3229

Evaluation of liver fibrosis in patients with advanced chronic liver disease due to hcv after 6 years of sustained viral response. study with paired biopsies at 3 and 6 years

Poster presentation

Presenter: Lidia Canillas

3310

HCV patients achieving sustained virologic response after direct-acting antiviral therapy may still face adverse clinical outcomes: analysis of gene enrichment, marker expression, and clinical outcomes

Poster presentation

Presenter: Daniel Millian

Viral hepatitis C: Therapy and resistance

216

Effectiveness and safety of direct-acting antivirals in the treatment of elderly people infected with HCV

Poster presentation

Presenter: Michał Brzdęk

366

When glecaprevir/pibrentasvir ultra-short therapy is enough to eradicate HCV infection

Poster presentation

Presenter: ALBERTO GRASSI

423

Modeling suggests that undetectable HCV at week 2 of DAA therapy could identify patients for shorter treatment duration

Poster presentation

Presenter: Harel Dahari

477

Real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir for treatment-naïve patients from Taiwan nationwide HCV registry

Poster presentation

Presenter: Chung-Feng Huang

764

Use of proton pump inhibitors among German Hepatitis C patients treated with sofosbuvir/velpatasvir: Data from the German Hepatitis C-Registry (2016 - 2022)

Poster presentation

Presenter: Markus Cornberg

1156

Description of age, sex, and characteristics of hepatitis C patients in the SVR10K study: a real-world SOF/VEL analysis performed across five global regions

Poster presentation

Presenter: Soo Aleman

1987

Ravidasvir in combination with sofosbuvir for 12 or 24 weeks achieved high sustained virological response rates in genotype 3 chronic hepatitis C without or with compensated liver cirrhosis

Poster presentation

Presenter: Soek Siam Tan

2436

Hepatocellular carcinoma may be a viral reservoir during treatment of hepatitis C with direct-acting antivirals

Poster presentation

Presenter: Mário Jorge Silva

2534

Quality of etiotropic therapy efficacy of chronic hepatitis C patients in accordance of toll-like receptor 4 +3725G/C gene polymorphisms variety

Poster presentation

Presenter: Tetiana Bevz

2911

What happens to HCV incidence after WHO elimination goal is met? Agent-based modeling predicts sustained availability of direct-acting antivirals among people who inject drugs is required to prevent returning to pre-elimination levels

Oral presentation

Presenter: Harel Dahari

2936

Point of care hepatitis C screening and treatment among people who use drugs in new york city addiction centers: barriers and opportunities

Poster presentation

Presenter: Jessica Siguencia

3139

Impact of a simplified diagnosis-monitoring strategy on Glecaprevir/Pibrentasvir (G/P) treatment initiation and response in patients with chronic hepatitis C virus(HCV) infection receiving opioid substitute therapy in Israel – a real world evidence

Poster presentation

Presenter: Eli Zuckerman

3226

Validation of a modified pediatric formulation of Sofosbuvir and Daclatasvir in genotype-4 HCV-infected children weighing 17-35 Kg

Poster presentation

Presenter: Manal El-Sayed

Viral Hepatitis: Experimental and pathophysiology

124

IL-15 plus anti-PDL-1 restores CD8 T-cell response against core but not against polymerase in chronic hepatitis B with extreme exhaustion-associated factors

Poster presentation

Presenter: Henar Calvo Sánchez

127

Discovery of a pan-genotypic hepatitis E virus replication inhibitor

Poster presentation

Presenter: Xin Zhang

318

Absorption, distribution, metabolism, and excretion of [14C]-Bemnifosbuvir in the rats

Poster presentation

Presenter: Alex Vo

411

Targeting cellular cathepsins inhibits hepatitis E virus infection

Oral presentation

Presenter: Mara Klöhn

432

Impact of hepatitis C virus direct acting antivirals on hepatocellular carcinoma evolution

Poster presentation

Presenter: Stanislas Pol

480

Identification of IGF2BP1 as a novel host factor in regulating HBV RNA stability via N6-methyladenosine modification dependent manner

Poster presentation

Presenter: Xiangmei Chen

487

HBV promotes viral replication and autophagic secretion through HBx down-regulation of HDAC6 expression

Poster presentation

Presenter: Lili Wu

587

Low risk of drug-drug interactions for Ruzasvir based upon in vitro metabolism and transporter interaction studies

Poster presentation

Presenter: Alex Vo

604

T cells expressing HBV-specific chimeric antigen receptors harboring a Fab fragment control HBV infection in mice

Poster presentation

Presenter: Zhe Xie

612

Development of a replication-competent Vesicular Stomatitis Virus (VSV) vector for therapeutic hepatitis B vaccination

Poster presentation

Presenter: Jinpeng Su

741

Hepatitis B Spliced-generated Protein (HBSP): a key factor of viral escape

Poster presentation

Presenter: Pierre Bablon

797

Immune checkpoint proteins are associated with persistently elevated liver stiffness after successful HCV therapy in people with HIV

Poster presentation

Presenter: Rubén Martín-Escolano

809

The combination of TCR-redirected CD4⁺ and CD8⁺ T cells in T cell therapy of HBV infection enhances virus control in vivo by increasing IFN- γ and TNF- α secretion

Oral presentation

Presenter: Sophia Schreiber

850

Efficient and heritable elimination of HBV viral antigens in vivo by epigenome editing

Oral presentation

Presenter: Dai-tze Wu

857

Precision-cut liver slices as a pre-clinical model for the evaluation of host-targeting agents against hepatitis B virus and hepatitis delta virus infection

Oral presentation

Presenter: Armando Andres Roca Suarez

901

PRO-C3 determined active fibrogenesis is a predictor of liver-related outcomes in patients with chronic hepatitis C

Poster presentation

Presenter: Emilie Skovgaard

962

Use of capillary Samples for hepatitis B Virus Load Quantification Using Xpert (R) HBV

Poster presentation

Presenter: Gora LO

1013

Hepatitis B virus mutations associated with hepatocellular carcinomas are regulated by HLA genotype

Poster presentation

Presenter: Masaya Sugiyama

1038

Perturbed pathways of lipid metabolism in patients with chronic hepatitis B infection after cessation of long term nucleos(t)ide analogue

Poster presentation

Presenter: Lung Yi Loey Mak

1224

Novel epigenetic editing technology targets hepatitis B virus in vivo to deeply and durably repress viral markers

Oral presentation

Presenter: Yesseinia Anglero-Rodriguez

1235

Highly expressed CTLA4 on B cells defected BCR signal to inhibit the secretion of anti-HBs in CHB patients

Poster presentation

Presenter: Shengxia Yin

1283

HBV dominance is associated with a distinct inflammatory milieu in HBV/HCV coinfection
Poster presentation
Presenter: Carlos Oltmanns

1321
HEV replication and genomic diversification in the human kidney
Poster presentation
Presenter: André Gömer

1329
Detection of HBV-, HDV- and human mRNAs in archival FFPE tissues by spatial transcriptomics
Poster presentation
Presenter: Sangeetha Mahadevan

1338
Second generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs
Poster presentation
Presenter: Jin Hong

1395
Burden of acute hepatitis A in France - a 10-year nationwide study
Poster presentation
Presenter: Charlotte Mouliade

1408
Comprehensive analysis of CHB concurrent with NAFLD: a proteomics report based on clinical liver samples
Poster presentation
Presenter: Xin Tong

1414
E-selectin levels in patients with chronic hepatitis C
Poster presentation
Presenter: Petr Husa jr

1450
An mRNA vaccine exhibits anti-viral activity in mouse model of persistent hepatitis B infection
Poster presentation
Presenter: Aditi Deshpande

1454

Sequential administration of siRNA with an mRNA encoding clearance profile associated variants of HBsAg exhibits significant antiviral activity in AAV/HBV mouse model
Poster presentation
Presenter: Aditi Deshpande

1511
Proteomic analysis of plasma exosomes: a novel method to identify potential therapeutic targets for chronic hepatitis B
Poster presentation
Presenter: Meng Zhao

1529
Potent and sustainable HBsAg clearance by a liver-targeting PD-L1 siRNA in mice
Poster presentation
Presenter: Zhiwei Yang

1556
Hepatitis C virus specific CD8+ T cells of patients with acute and chronic HCV infection display high expression of CD96 and other co-inhibitory molecules
Poster presentation
Presenter: Maximilian Knapp

1561
Macrophage-augmented organoids recapitulate the complex pathophysiology of viral diseases affecting the liver and devise advanced treatment strategies
Poster presentation
Presenter: Kuan Liu

1661
Transcriptomics reveals the regulation mechanism of the Chinese herbal TiaoGanJianPiJieDu formula on inhibiting hepatitis B virus replication in mice
Poster presentation
Presenter: Ningyi Zhang

1761
ROS-dependent activation of JAK2/STAT3 pathway contributes to HBV-induced liver inflammation
Poster presentation
Presenter: Rui Song

1763
Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles
Poster presentation

Presenter: Yannick Debing

1780

The combination of therapeutic vaccination with siRNA-mediated silencing of HBV and PD-L1 effectively breaks HBV-specific immunotolerance in high-titer HBV carrier mice

Oral presentation

Presenter: Anna D. Kosinska

1784

Profile of miRNAs in chronic hepatitis D patients with or without viral replication

Poster presentation

Presenter: Maria Francesca Cortese

1813

HBV genotyping: grasping a new window of opportunity?

Poster presentation

Presenter: Marion Delphin

1836

Generation and characterization of hepatitis D virus specific antisera with respect to the recognized epitopes

Poster presentation

Presenter: Keerthihan Thiyagarajah

1838

The Lipidome in phenotyping hepatitis B infection ('LiPHe-B'): preliminary results from our pilot study

Poster presentation

Presenter: Marion Delphin

1840

Low diversity of the TCRbeta repertoire in patients with chronic hepatitis D

Poster presentation

Presenter: Maria Francesca Cortese

1871

Mapping HBV cccDNA and integrant transcriptomes in infected liver tissue identifies novel transcripts and variable patterns of HBs encoding mRNAs

Poster presentation

Presenter: James Harris

1996

Therapeutic vaccine (BR11-179) induced immune response associated with HBsAg reduction in a subset of chronic hepatitis B participants

Oral presentation

Presenter: Yun Ji

2010

Chronic hepatitis C virus infection induces HCC risk by perturbing the human liver circadian transcriptome and epigenome through deregulation of the deacetylase SIRT1

Oral presentation

Presenter: Atish Mukherji

2017

HBV and HBsAg strongly reshape the phenotype, function and metabolism of DCs according to patients' clinical stage

Poster presentation

Presenter: Zuzana Macek Jilkova

2018

Immune correlates of HDV clearance in chronic HDV infected patients

Poster presentation

Presenter: Arshi Khanam

2029

Hepatitis B virus seroepidemiology in the Vukuzazi population programme, KwaZulu Natal, South Africa

Poster presentation

Presenter: Motswedi Anderson

2041

Human intestinal enteroids as a new in vitro model to study hepatitis E virus

Poster presentation

Presenter: Nanci Santos-Ferreira

2045

Long-term sustained decline of anti-HCV neutralizing antibodies in HIV/HCV-coinfected patients after therapy-induced HCV clearance

Poster presentation

Presenter: Daniel Sepúlveda-Crespo

2065

Serum levels of IgA inform on the transcriptomic architecture of the liver and predict hepatocellular carcinoma in chronic viral hepatitis patients

Poster presentation

Presenter: Nicolaas Van Renne

2086

Hepatitis B virus-induced collagen VI expression by hepatocytes contributes to liver fibrosis by promoting stellate cell activation

Poster presentation

Presenter: Zakaria Boulahtouf

2094

Differences in the intrahepatic expression of immune checkpoint molecules on T cells and natural killer cells in chronic HBV patients

Poster presentation

Presenter: Zuzana Macek Jilkova

2142

Transcriptomic analysis and high-throughput hepatitis B virus integration sequencing of HepaD38 cells

Poster presentation

Presenter: Cristina Musolino

2158

Using retrieval augmented generation to increase large language models accuracy: a proof-of-concept pipeline on european hepatitis C virus (HCV) guidelines

Poster presentation

Presenter: Mauro Giuffrè

2188

The Chinese herbal TiaoGanJianPiJieDu formula exerts an inhibition effect on hepatitis B virus replication by regulating hepatic CCL2-CCR2 signaling pathway and inducing immune-inflammatory response

Poster presentation

Presenter: Ningyi Zhang

2214

Hepatitis B virus particles in serum contain minus strand DNA and degraded pregenomic RNA of variable and inverse lengths

Poster presentation

Presenter: Gustaf Rydell

2217

Ethanol exposure exacerbates HBV-infection pathogenesis: possible mechanisms and treatment targets

Poster presentation

Presenter: Natalia Osna

2266

Mathematical modeling of hepatitis B and D viral kinetics during coinfection in humanized mice suggests differences in their infectivity

Poster presentation

Presenter: Harel Dahari

2405

Rapid establishment of enterically-transmitted hepatitis viruses animal model by using lipid nanoparticle-based viral RNA delivery system

Poster presentation

Presenter: Tianxu Liu

2412

Differential expression and sequence variants of sodium taurocholate cotransporting polypeptide (NTCP) do not affect HDV inhibition by Bulevirtide (BLV)

Poster presentation

Presenter: Roberto Mateo

2432

No amino acid substitution in HBV PreS1, HDAg, or NTCP associated with suboptimal response to bulevirtide in combination with pegylated interferon alfa-2a treatment in participants with chronic hepatitis delta: results from MYR204 a phase 2b study

Poster presentation

Presenter: Yang Liu

2464

Immune profiling of HBsAg-specific B cells in CHB patients with HBsAg loss

Poster presentation

Presenter: Yifei Guo

2468

Metabolic alteration linked to antiviral treatment response in 3D in-vitro model system of hepatitis B virus infection

Poster presentation

Presenter: Abhishak GUPTA

2470

Study on the correlation between HLA-DR+CD38+CD8+ T cell changes and efficacy in the treatment of hepatitis B virus with interferon

Poster presentation

Presenter: Yanjie Lin

2507

CRISPR-Cas13b-mediated suppression of hepatitis B surface antigen – pre-clinical investigations of a new therapeutic approach

Poster presentation
Presenter: Laura McCoullough

2571
Rapid analysis of HBV-specific T cell secretomes reveals distinct antiviral immune profiles among chronic HBV patients
Poster presentation
Presenter: Nina Le Bert

2717
PegIFN α treatment in NUC-suppressed HBV/HDV-infected mice with high numbers of HDV-monoinfected cells reduces HDV infection below the limit of quantification
Poster presentation
Presenter: Annika Volmari

2732
Combination treatment of a TLR7/8 dual agonist with an antisense oligonucleotide bepirovirsen and entecavir leads to additive HBsAg decline in the AAV-HBV mouse model
Poster presentation
Presenter: Ke Qiu

2756
Hepatocellular carcinoma development post hepatitis C virus cure is associated with distinct changes in the dynamics of the soluble inflammatory milieu
Poster presentation
Presenter: Moana Witte

2757
Establishment of a highly effective in vitro model for HBV genotype E infection
Poster presentation
Presenter: Rodrigue Kamga Wouambo

2790
Characterization of intrahepatic immune microenvironment in liver biopsies across different phases of untreated HBeAg-negative patients
Poster presentation
Presenter: Maria Stella Franzè

2791
Bemnifosbuvir is a potent HCV NS5B inhibitor with a favorable antiviral profile and high resistance barrier
Poster presentation
Presenter: Qi Huang

2869

Vitamin D supplementation accelerated reduction of HBsAg levels in patients with chronic hepatitis B requiring treatment and in inactive carrier phase

Poster presentation

Presenter: Thitaporn Roongrawee

2931

Prevalence of hepatitis C virus infection in a nursing home: a frequently overlooked submerged population

Poster presentation

Presenter: Paolo Gallo

2955

Association between occult hepatitis B virus infection and parenchymal renal cell carcinoma

Poster presentation

Presenter: Daniele Lombardo

2960

Nonclinical phenotypic evaluation of clinically identified baseline and treatment-emergent hepatitis B Virus variants that contain single nucleotide polymorphisms in the bepirovirsen binding site

Poster presentation

Presenter: Christine Livingston

3020

Molecular and functional analysis of a hepatitis B virus genotype C infection in a vaccinated individual

Poster presentation

Presenter: Daniel Candotti

3023

Whole-genome hepatitis B virus sequencing at low viral loads from serum and dried blood spot using a multiplexed tiled amplicon approach

Poster presentation

Presenter: Sheila Lumley

3039

Hepatitis B core related antigen in South Africa and the United Kingdom - does one size fit all?

Poster presentation

Presenter: Louise Downs

3088

Intrahepatic sodium taurocholate co-transporting polypeptide gene transcript and membrane-localized protein expression changes in chronic hepatitis D patients following 48 weeks of treatment with Bulevirtide

Poster presentation

Presenter: Wildaliz Nieves

3175

Investigation of HBV cccDNA Methylation by Bisulfite sequencing for therapeutic targeting in liver biopsies from hepatitis B patients

Poster presentation

Presenter: Purnima Tyagi